var title_f41_8_42112="Unstable fracture pattern of the shaft of the distal phalanx";
var content_f41_8_42112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unstable fracture pattern of the shaft of the distal phalanx: Transverse basal fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A transverse epiphyseal fracture at the base of the distal phalanx in children (Seymour's fracture) is an unstable fracture. These fractures are often associated with a transverse laceration of the nail bed that can get caught within the fracture and prevent reduction. These fractures require open reduction of the fracture and pinning, followed by nail bed repair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42112=[""].join("\n");
var outline_f41_8_42112=null;
var title_f41_8_42113="Enlargement of the great auricular nerve in leprosy";
var content_f41_8_42113=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enlargement of the great auricular nerve in leprosy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 409px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gorbach SL, Bartlett JG, Blacklow NR. Infectious Diseases, 3rd Ed. Philadelphia, Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42113=[""].join("\n");
var outline_f41_8_42113=null;
var title_f41_8_42114="Suicide trends adol females";
var content_f41_8_42114=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Suicide trends among adolescent females United States, 1990-2004",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 558px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) Yearly suicide rates per 100,000 population for females aged 10 to 14 years, by method, National Vital Statistics System, United States 1990-2004. Panel B) Yearly suicide rates per 100,000 population for females aged 15 to 19 years, by method, National Vital Statistics System, United States 1990-2004.",
"    <div class=\"footnotes\">",
"     * Per 100,000 population.",
"     <br>",
"      &dagger; Standardized Pearson residual &gt;2.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention (CDC). Suicide trends among youths and young adults aged 10-24 years-United States. MMWR Morb Mortal Wkly Rep 2007; 56:905.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42114=[""].join("\n");
var outline_f41_8_42114=null;
var title_f41_8_42115="Sonogram of placenta accreta";
var content_f41_8_42115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sonogram of placenta accreta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 529px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) Placenta previa. Sagittal transabdominal scan shows the placenta (P) centered over the cervix (C). There is a normal hypoechoic area between the placenta and the bladder. Panel B) Placenta accreta. Oblique sagittal transvaginal scan shows the placenta (P) centered over the cervix (C). Note how the placenta invades the myometrium, with loss of the hypoechoic layer of myometrium (arrow), which can be seen in the above panel where the previa is not complicated by accreta.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42115=[""].join("\n");
var outline_f41_8_42115=null;
var title_f41_8_42116="Ankle valgus";
var content_f41_8_42116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Valgus foot deformity in a child with myelomeningocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 539px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Drs. Vineeta Swaroop and Luciano Dias.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42116=[""].join("\n");
var outline_f41_8_42116=null;
var title_f41_8_42117="Lichen simplex chronicus2";
var content_f41_8_42117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar lichen simplex chronicus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42117=[""].join("\n");
var outline_f41_8_42117=null;
var title_f41_8_42118="Acetaminophen, codeine, and doxylamine: Drug information";
var content_f41_8_42118=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen, codeine, and doxylamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/19/25909?source=see_link\">",
"    see \"Acetaminophen, codeine, and doxylamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14854542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Warns of Codeine Use in Children After Tonsillectomy and/or Adenoidectomy",
"     </span>",
"     <span class=\"collapsible-date\">",
"      August 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA has issued a Drug Safety Communication after reviewing reports of children who developed serious adverse effects, including death, after receiving codeine in the usual dosage range for pain relief following tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome. Three deaths occurred in children that had evidence of a genetic variation (&ldquo;ultrarapid metabolizers&rdquo;) which results in faster and more complete conversion of codeine to morphine, possibly leading to overdose or death. The estimated incidence of this genetic variation is ~1-7 per 100 people, but may be higher in some ethnic groups.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare professionals should be aware of the risks associated with the administration of codeine or codeine-containing drugs in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnea and should use the lowest effective dose for the least amount of time on an as-needed basis. Parents and caregivers who observe signs of overdose in a child such as unusual sleepiness, confusion, or difficult or noisy breathing should stop codeine administration and seek medical attention immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mersyndol&reg; With Codeine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F854819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Miscellaneous;",
"     </li>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Ethanolamine Derivative;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F854846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: 1-2 tablets every 4 hours as needed; total dose should not exceed 12 tablets in a 24-hour period",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F854845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F855264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F855265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Use with caution. Limited, low-dose therapy usually well tolerated in hepatic disease/cirrhosis. However, cases of hepatotoxicity at daily acetaminophen dosages &lt;4 g/day have been reported. Avoid chronic use in hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: Dosage adjustment of codeine is probably necessary in hepatic insufficiency; no specific guidelines available.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F8119608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mersyndol&reg; With Codeine: Acetaminophen 325 mg, codeine 8 mg, and doxylamine 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11216590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F854814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CDSA-1",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F854820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of headache, cold symptoms, neuralgia, and muscular aches/pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5118569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F854829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F854824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetaminophen, codeine, doxylamine, or any component of the formulation; significant respiratory depression (in unmonitored settings); acute or severe bronchial asthma; hypercapnia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F854825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Acetaminophen may cause severe hepatic toxicity on acute overdose; in addition, chronic daily dosing in adults has resulted in liver damage in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene-derivative opioid agonists (hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension/hypotension and tachycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with known G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal motility disorders: Use with caution in patients with gastrointestinal motility disorders; avoid in paralytic ileus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with angle-closure glaucoma and/or increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Use with caution in postoperative patients following thoracotomy or laparotomy due to suppression of cough.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage limit: Limit total acetaminophen dose to &lt;4 g/day.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F854835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F854834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatostatin Analogs: May decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F854838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F854821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F854823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F854847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of pain, respiratory and mental status, blood pressure, bowel function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Chemist's Own Dolased Day/Night Pain Relief (AU);",
"     </li>",
"     <li>",
"      Fiorinal (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F854841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acetaminophen inhibits the synthesis of prostaglandins in the central nervous system and peripherally blocks pain impulse generation; produces antipyresis from inhibition of hypothalamic heat-regulating center. Codeine binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; causes cough supression by direct central action in the medulla; produces generalized CNS depression. Doxylamine competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells; blocks chemoreceptor trigger zone, diminishes vestibular stimulation, and depresses labyrinthine function through its central anticholinergic activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F854842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/8/42118/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/8/42118/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/8/42118/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/8/42118/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/8/42118/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/8/42118/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/8/42118/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, \"Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),\"",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, \"The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,\"",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/8/42118/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8776 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-201.65.114.212-30F76E55B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42118=[""].join("\n");
var outline_f41_8_42118=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14854542\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854816\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854819\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854846\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854845\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855264\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855265\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119608\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11216590\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854814\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854820\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5118569\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854829\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854824\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854825\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854835\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854834\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854838\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854821\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854823\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854847\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869445\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854841\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854842\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8776\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8776|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/19/25909?source=related_link\">",
"      Acetaminophen, codeine, and doxylamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_8_42119="Perforating folliculitis - hand";
var content_f41_8_42119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62671%7EDERM%2F72434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62671%7EDERM%2F72434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perforating folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxRSrt8w28ccUm6LYIlADfxP60gG793jLc5xTlj3jfKDsBwBnvXA2eylYQGGNioywxwfekfYqIpj5J5pSqKo8sFpS3yqKaqS+cXY8j17/SlcHqOQiUbFTavf1qWZVRANu3PQdTUqRuAVK7S3OaTy1CtJl5JMgKKlSYcuhEwYIFCEMece1CDcFZdoP8K4+771NHEUOGYtI55X0qZwxK/KEBOOtHPcaiRRRud3lRgjHzO3SlZUZgV+cj7zdMfSp4oSwMrEMinKpn734UOWfEcMa7mPIxwKXOyrIZBGZ5iLiXy4+wUZwKeREjA2+yRl7kYA9/eoxDJAWaY4UHBAbg+1WHuYFhYG3QucAYHSjUEMWSaRyHLSEj7zHGB7VC4hxgNz3J7VLIHjXMq7N3boSKglkdhnYFUDA54/Gi7HoRyln2BVAx02jBNNnPyhZpdq5+4e/1pxl3sQsq4xy/TH0qOXYoPIc9jnJq0+5ACQbtibQOoYUwsScrnP8AeJz+QoLlSVwy56jHOKieX+Fd231A5/CtVqJlgFUZfPTb3AA5b6024nkGDKhWLsimoVLjO9QWB53H5hRgkFgCVIxk07Et6EscoZgZMbP5VIGdl2/djPQ9sVBGA+0ImPVmNSAMv3QMjPzGi41oicHdkbmYdAQaYGKkHOSD0qsZey5J/vDtT4wqMdzArjtVJWBss7m3ggYB75pskoAyjbjSxzleUO3A7jNRGMA8D3oTEGGIHv2pzk52ouXPAUCngM7BFXJboB2ro9C0XL75CMtyWb+EetaJGcpJIseD/C32udZ74ZAwcZ4HtXrWmWNvaRCOKJFVfavPdMfUJbW1VbaNo7W9BM/miMSqAcAg9BXd6dfPdWcM7w+WJMnbnOOfWtHFrVnI5tmyu3yxs5XPIArK1rULpJbe20fEl3HOq3CbP3ZQ8bWfopzVqBznKEgg8VjeJtCF+kEuno6XT3SvcETFVdB1JHQmnBRvqD1WhYuL6/tfEk1xf2kEiwlYYbaC7UlC3VgByfxrsUVQ5U5yK5Xw7pEWhalqNxbTAwXeCsRXLwn/AHj1FdJBIp9+eDRN32JV+peUbsnPH0qG+uksEjke3luN77emEX/eOOBUsB5z/DVxE3oy75FV1KnY+3gjBxSXmBw+n313b6drLR63ppVZCII5pCWRmP8AAcdPrW74YL+UNPuobiS5TMsl2kyyozEdCe1XE8LaF/ZslgbFlgfkyBsyg+u41sx26xwwwoXaONAi5OCQO5x3rSUk1oKxUNqXBLjPuaoXFs6MeCPTnit/yD0CkqecdcU4WmNuxQ/14xWZR5r4l0m7WxuptKnv/NndfMt1YGNj69M8Vdt/Cd4NYsb65kGoQbVS6SWTDIMdcdwK7lYmhc7UKk9RnrTJSBgR9RnqORV87sS0mLCsUSeUJUCLwqquBikkXZ8wfJ9M1CsmCCWznt3FPfZjO44/OoGUtXto9RhQMqu8eWVJCdkgA6NjmuC2addxaUtvpt1aXhdwxtMEyEdCoPXFehN5a5EeSTwc/wAjVa6sLeeCBJYUj+zt5kTQ4Uo31q4ysBm6e98bLzNUj23ecAlQGZe24djTpLggAdvTFXbuNnbe4ZmbJJNUWjKqQynPvWbeo0WIJUB/eAAHjOKxPEV3G6XdhqNxb2FoyDZLcwsyzD/ZI6EVf/d4IMm0+hFZ+rwS6jZrbJchY85ct/EPQVUJWG43KN7aRzro0Ntr9jfQonmLHI+xRj+En/Guv06ddQslmMZhfJUxMc4x3B7isCDRrGDVdP1KD7OjWq+XLbmP5bhf73pmuqjvY7twnnxqBwBt2jH4VU5J7EJWKTKrMVwF46gULabUaRhwozgc5FahsgfmVUYf30ORUUu+FvuAhf71QtCnqfHkAlROMjd1IpxjLzfKCIgOp9angnaFHjUbnlGPXApo8xpFRAeO3pXnSZ6Y91ii2yQ/d6AHqTTTAzLv+779hUphzKP4sfoae07xgER5btu7VndvYdiImPyhkuzg/M2cAD0p8bNNLuRWTHEaqOg9TSQIFVvMhLyAjaM8CrO1nZnldE9QvHFK9hkKQ8jYHMzZyewFPjCifCBXKjHzdKlQBm+TCx9yT1qYwxqgaRiqDnIHWlzDSIpbeUAM4WNGPQd6ZI5Rgts4bHBYDGDUqL5pLzuRGOgJqSeSNIEMUSZQcBlpcwFCWFjH5lw+GY/KDg596jDqrdGkOeD7+1SPLt8x2TdM/BJHA+lVyXDL5YYNjCgdfrWiYrj5+HP2jc8pGcscYqAgMS0pUDjC5/nSvmLduTfJ1LtySah+TeGYM8nYdqcbieoks6iERQIrbjyxpvmTAhEMagHOVGT+dTmMeTmRljP6t7AVUyGDJAhHq57CtErmbdiwVIheXzcEttLM3zMfYelRIGH+rYRjux61XQI0w2kbhxuPNSFxuAfEg3fdHU1aQc1xytIWIUnDdSOpp6p8xBkyy9EPQU05+YgKmffNBnj+QKmcHqRgmnd3sGg9mCKDgMw5AHAFV5ppHLZzg9h0pk0jTHGAFI6DioS5JwSQtWomcpE8bgkE8euTT0ZTxu3Y+7VUuAi/MM0qykBiAOauxHPbc0YduzJOWHHHWke7JYQwqWkJAIHWq9vaXN0B5QZOfmPtXXeG/Dvl3bTQgsj4BB5x75oUEtWTKo3oifSNKOU+TLHkmu903RY2tisoIVxgn0FWdF0cRKG43Zrpobc4wo6ckCqTM27nDXHhee4vL2IXU620Aia1edshyOoI9B0rqYiREqsiKwUZA4A+laLQYAwWxnjPOKqzxsWUnAAq3JvcjYjU4APHtg08SZHOB+OaRUGeh/OmxhAWD5HekBei/hPQnn6VbgzgfeY+x4qlAYwRt3EEY5FXER0BK7cY7mgp6kzXKxfeUirdrrESY3uOR0xmsa5fIDA7ie23pWbcq+QRu4ouLl0O7h1OInaBxVo3sSgYX65PWvMlv54PlJP59KtQazKi5Z8gDvzTTQrM9MF2pGYo2XI6FsmpRMrDqwOOa4O21tWKY+Ukd+1bNvq06x5hmyn0HWgDbuGjUgxh37nAqEtHJ8ygqR1X1/Gs5dTeRtrudx64FHnjflMk9yRQI0vLkkUlbdY1H+z1pqyGLG+ON17AjvVFJ3P3S+38cCpvtAwFdckdCKBF6WAMoYIikjOM1E1shg3bSM/rRbMWYEsuemGPNWJFYwqApxnqBxQNamXNBzx0rPuYpMEgpz061uuwRMYO4+tV5kWXJC4A7DpSGtDnJ02heAeOtVZN+0rkY9Dxity6twTgqcdiKoTWaMpDKcD1pFJmezkcdB9f1pUn2euaknsD95Bx6VUktpEGWRtvqKC9GaVnqckZwHZB7HrV/wDtkSr+/wBxI7iuZIVfvZzTDPjIUkH0NFxOCPn4DY5C/IuOT1pUcj93H9719qAQSSoAJXB+tCLgncwHvXnSPQuWUi8pN5kG4DJApI3zx5e+Vz8pbtUSkp+8ds9gpNKrEsxJyF9f6VNhosughIPmZbOW29qhT97nfkKTwOu6nfeYNI4iTHQnrV1Zg0aZ2DPoOlK1hrcI98UWSPmHQHpUclxJPKfNAdv7qjgU2QjexY7uccDimPuQBVJQdcDrUjZJIowplHlKoyFXvUEpldS5J8ocAE4poGWyVY+pY1HLLEyZ5LZwF7VVibiSySgPI7g7vlVSOFFVZZGUBYwyuD8z57Us29QXZwWI43c/lQYJFtlmZxgccnv9K0irENkLuV2gOGJ52k9velMjP8kTE56uRgCmb+pG3B6nvVeRjIQFJ2Z7nrVRIbJZWVWIU+Y5HJJ4FQzs03G/L9gOlSAKrbF25/iYngCpFKxjzAm8E4x0GK0VidWQxxs3G0bR36VJHKFXABXnqBStiV97rsHYdqJsYIZjnvjgCmtWFrEUkgOQjHGc8jmomO4jbgL79RSMQB0GPSod+VIDKTmrUTOUgdiV2g5XPHrSPId3J4FRu+MnjA9KiDNJ8q4z61qkkZORN5nzAIufQZrV0zT2lZWlGec4pNKs4xtLYYkcn0rrNNgB2jHy9qCVruW9G0reFGMLXomg6esSL/OsTSfLiC5XKnvXU2N7EFO05x74pWG5aaG7Z2yhgp4B5rQSJUY7fwNZFtqEW9VLqM85zWrFIHAIJb0x3qrEsfLGCOh96z72BQrArmtM4C471UuULISBzQCMY/ulO7GPaoC65+Vhj3rQkiG3cqEH1IxmqE8Kvhl2Hrgqc/XFAiaGQjBXJz6Vp24H3j1xyM1i2rAfJ8+R36Vc1GV4tJlMN4un3OP3Mzru3N/dxjvTSbdir2NlYFlQ9SBz9BUU9iTzjC9q4/VL/XNZ8N2V09m9vELkR3DwsF8wg4xjtXT2muLd3s1rJYzWrQIN25xIuPYj+VVKHKrk3ZVvtNXGXypI4xzmufubV4WITcU6nNdnO+YgY2VlPXB61n3ahx8ybUPoc1na5omcFc66tjfxw3PyI/AkDZwfQitfR9fjnkmWJmby2AYnp+FZHivRnsrS8vLKVneWRW8kxBuSex7Cso2+owanE9yERZQMvGmNjY6ECtXaxLV2euafqEUsY2q27uc81qB3dfkyePSuC0uchlDPzjqK6WxvzGMM0pOMADpWd7icbGqizueJG6EkD0FQ6TqFveWQu7W5Wa23FWfkbCOuRWLruu3lpCrafHJ5m7DOqB9g7nFedrqsEVvrRe/vIJJG6RJsRs+o7VrCN0S0e46bq1lf7/s8/nrG+DIq8A+lakUw27SSB1A7V5F4P1G8hitbONfMsdu8yCMpsJ+vWvQ9NulkcRuwAweT0qZKwkrGzN5OwESMZc/dxxj61VdlU8oTUyTxlSvkqQf4gSawL3XzaXF9sie4s0YeVKI/ljOcMrHtila+wzTZi3zbAU9c4qvL+8Un5eKuXayeZHIJAxZAysDlSKoyhipaVxzSGVWBL7c5PpTHhb8PrUzFcbV5Y8Vhya5Da+IprC7WNbbyvMgu1JO491bHShJvYL2Ls9msiZY4ZeKz57Eq2RipND1o6ybt1hiWBG2xLu+dsdW+lXJHboNpGcEEdKTVtGXc+Z0RycBgAOcmmlRu3MMj0FTuvyjsMdPWpQoCDtnoCK82TPRsVWjAzIxzxz6io4ZwjYVCWx1YcAetW5FVzwcE9feqksbqnDDB55HanHUTRIkDOEaQ7ml+bHoK00tAIkZFKsOT3qlp5/0tS7fLkD6V0muyR27HyImggZNy7ud/0quS+o0+VmA0kxmxkMD0PalBbcQDub19TVWV8IuSAcfdPrUKuWUhWxz8zdqiUBuRZmnCxgfM0rEj8PaqkjFAAfvuOp/hFNQBCfLbbnq3XAqOUjcRFjPq3NUomTYsuCv7xvMYdAOAv1pvlM434UKP4mPH4CmMu1sgcDkk9zUU0jyvvbBHRR0AqkhOWg2TdjOAcnj3qWOC3VgHYu3Vtv8ADTUBY53bj3x6elSEFl2LtRe+Bz9BT8mJCEqMkL8pOF3H+dPZWxulcYHQDoKN3koqrAAf7zjLVTuJic529fxqo6g5KI+RvMkOSSDzknA/CoZHGSoPy9uc5qFpWcc4x2pkj85I5HatYxZi5hJIcnJx9KhaX5e3NQyTYOf6VVZy+VDYX1FaRRhKXYlM4ORnpxnFXLWdIyMc8dcVQSLKD5Tz3rUtIhgYAIz196pyshRi5PU0bOWaT5guE9cVvWz3UcKvG6j03cflVLS0bpsyoPHH9K1JQoTliSDgjoR7VhKq+h206Mbaiw6pqETHyr9z7HGBWhbeIrhCv2ra/qycZrKZIiSQuPcntRHFG7bgxbjgEZFZ+1kaOlHsdVD4j2xb0kGRztPBrrPCHi6DUGeLJ3qQAzHr9BXlkkfmcFBuz93tTbWM291HLbM8EikZA5WtoVU9GYToPofSNrdLJyCox7ValdRFI8kgjjVS7MeAAOteVaB4sWIKL0siPwHI4P4139neRXlm3ypNA4KsByGHpWqsc8ouO5zOptqs+o6xPp8gi02WwMiC8O0Kem+P1zU3hyR106306W3hItoFP2mG48wFjzhsdCfSll8MWd5f6mbpTDbyRrBZxxMW8odSx5/StywtVtdItbN5kmlhjCM6pt3kfxY9a0lKNrIhJtlIRbHbPXPBq29jDdm3lee7hmi+aKSFgNnY9eP/ANVMYBJTg8Y7irSOXixuHy8gE1lezNLdDiLXSbvUtM1eG5vbu3DXBFsJ2JRmByWYfrW7pUs1po8VtcxW0M653+QABIR/F6/nVq7EsiYaT5e3tWLNbSEjaxPuKcqjktRRir3NA6iELN5i8+gqI6mHLb9271HesuW3mi+YkN7HqKgAkbPzDPrWd2W4o2ftIkGDIvPGKo3cca5IbdVKRvLHO7d60kMod8YJzVCSsa+nwqyiRQfl6kVeE+V2o3PrjpWfbRTQkMnAPap3dc4bAP1ov0C1xZyy8qxbPX2NZK2FjFbyW32cvHJy3mNknNaHm7Mqo3Dviql07OCVIQ/qKLsaRZ02VbO1jt4mYxpkKG7D0rotNviPuEYPBzXFRzSxscnIrTsrltwII2+tNMTiehWV0wCjLEVHqNjcy3UR0XKG6jcXUf3o3b3U8Z96ytMulCgEnPauhspV4UNyefxq07MyasP0G2xpafdV3Ylogu3yj0KgenGfxplxHkkcYU4rVjkd8hyMjgleM1BMAwYEjcRxx1oYHOanaC4tJIFuGiMnCug5U1xKXuoQ6petp1tZzm3gMTsIiol9sf3utejzWu4cKW9RWdLp+3cyDyucnaMZoTsVZPc4zw3ALuysb+URQyLuwI49jk9w1dEJCQMfxdan+zCMHC7W9arsCCAF2+9RJ3dzSNj58YKYhtH7zrzSNyq/NyBkn0FEcgBJJ6jiqxlKuQSDzXnNHe5Eip5km5V2qR360sqsdwXGyovOAz/nNOE5KsoxnHJPQUJCvcYJZNgAQIuep6mnTXtxcGMSTu6xqEUN/CPQVHtJdfmLegNMlYoQBt5HNXfoQ2McnBLHCnjPc/SljUlETdgA8D296YoUEOxzxnnmklkBDF87RxgfxH60xXQ8oXVmDKsAOGY/xfT1qOFS5OwbU7uR1FML4Zd+OhxnogqOR2lKqW/d0cpLkEkiNLlV8xF5IHGahO+STc4CRk8CntJGn+v52jhV4/Cow/nFcLgn7o7AVaWhFyyAuADhQeir1p7ymIcbUwOOOTUG5YSS7YKjAUcnHrVK4uNxBOCTwF9KSjfcpzsPnn35ZnZ29T0FVSxz79fY0E5yT37UxycdcAVskc8pXF3HaQBxnHNQSNk5Y9KWVu/BJ7jpVWTLHrx3q0ZtXGOxlJ54FPgjY7eSVzSpHkDHHv2rTsrEuAzMcHtjgmnzWKjTuCwiMKCeKtRLuYGM7G6kEcGrctmFwIxt9SecVCIl8xvMmOegwMA1DkmbRptFy1mZN32jzA2PlKjgVbSYS/IWBJHJPBrOTaT5cflt+JBFPx5a/O24sf4l5H41nZM6Iu25dDMUZBn5ex71PY3RVNrHbtPAxWXKx8txkeYno3UVNbO6MirypGCr9ce1TyFqRqxSDeVcgZOemc/jVxYw6l14HTg1lxI4KArtZTwT0I96vwlk+ReoPHpUS7GiZdEBVUVskDtnirFjNe2RLWl1Lb/7jH+VMhcjCyAbj6VoRRrltzAc1PM47FOKluatv4s1WLZ9sW3uVx1KbG/MVt2fjG1kI86G5hbHQfvAa5ZUAOcZJGORkVJEJQComKoeCFAGapV5LcylhoPWx3MGtWd0+IblS3oflI/OtWO3lkUSCNmX+8OR+leXSIBg7jwfTk1fsJLm32m1u7q2briOQhfyrT6wuqMng+sWehLEXbbtBbvmmyWnl88Ka5u38Wa1ANl0treIBkedEA/uNy1p2/i61ukButNuIWHUwuHX9a0jWpy6mLw9SPQdcWy7yQc46k96oXFmGJMaoB0zWymoaddqfs94u8D7ko8sj8+DVDWbyLTLaCZ5AwnlEUezDByfQjitEubYw1i7MwZ7R14xu9+1P05Arl5NoRBz6VtXMW0lScSA4K4qgYh5rQDGD1z2oehSZWv9TjcHymCj0JrPW8bpuyTWd4ksb601OCKyjiuUlByg4ZT9awtImvBM0dyTJKXIYL/yzx2NVy31BSR3UN2SoTBU1PPEu0kyDdjpXPpJKg5qdbmXg7T7E1KRRbdTuHPy1NB8jA7ht9KpPNhC8qkInLEVatTFIiuGJDDKsD1p26iub+nXGMMACPRj0ro7CfJwO/IIrjbXKuMAYz1Nb9lcBSuSGx3HFCbJaR19vOAnJIOfzqzE6O+WYgk9xWJZyCRcjrx1NakE2WAZdv0qjMvtIpBMbD5eM4xmqMvllGc4Ld1Iq0fLcADeo9zmoJIlMjhS3ljoQMZoAypVDZwDtHrUJgTHGPXFa8kICklsd+RVWRVyoI5x1FJopHyhIcbRu61FKRgqMjHGfWlkcklsEkDj3pfuRozceua5ZRZ2uVxkR2/ezkjqakjIDCNuf4ifWoGmJDbfvY6+1EbEZcHhRjnuahoSlYsXUsSFFVscFm9RVQsrsTtPAJ5/pUW7ceoyQefemuxMbMSSoOB71XKRKVxxOThjx7fypGkIZdp56BRzimq5AHACD8/rTVOY1PRWz06/WnYlsVizFi4MjEjk85qOWRVxhgMDBOeFqT5j5UcIYuwx6Y9aryRqg2Egy7ug9feqSRPMNClgJME5PTu1SAuZSvCBfvH+lQ/aHErqHO4dgKc8E8cAmYqFY8ljkk1IcyRDOwWRih3L6darNKdxPHXpQzNzg/LntT3RRsIAxj5j71aVmZuREzEE9cnnFDM7LnOcU2aZYwdo5HYdaYyXNyV3Abe2K0RnzkTbmc5PFTRQ7mGOV71at9Mu5Gwke8Y7UTRTWhBmjkiH+0uBQ5GkdCeG2DYGMVqW4KLGM8ZrKt9QSMkEF89NpzVhNQRy2xdpPUMcVnJNnRCUUbPmJlpHXJzwM1HHbxs42NtzznNV4pPPiXys7xwRirVvpUsg3XLlR/drF3idEbSFdAsq/alidCOJRj5fqKZcxiMBo2WS3fqV5A96ty6XZRkLtaZXXGA5/pUcWhkOogeaKL+6W4qlJbsTTvoZ8ZxIqkebG2drr2PvV23tdymPBB9MYH1rXt9ISEElSN3A2jGRV9LLadqoSR13dqmVQqFMzbaHKDYxIIAKnoRWnFauIduCSo5HerPlEMAEBCjaBjtV1I98ICqg5xnPNYymzoUSpHADEq55X7uf61IFMmSBuUkbgR0P1q6kKIA2GYtkEEYpkTnzy0Y6k4GOKi99yx0UkjbdijaDj2FWxHk4JI9BimKqhNqqMscnPTNSpuPysfm9OpP0pPyDRjlRcAMhY+o7VZMYCgDY30HSqkquqZjyqjqD3q1aZcjaRnHIPUUXYWQgJRj8m70GaV5nXh4wqn06CpXAiKncrsfvDoB+NGQyGRgwXoDt70XCxVlwwCzJlSMLzxVdrVGaFZBuihcSLEzHbu9eK2EXIG9sZ9s1FOBlTId3O1V7mtIVZQd0zOVOMt0S6bd2sMcwmllSSRywUksqL2AJ5pGnhNzuicewJqlJbqZGyrKg5Kj/ABpn2dZIycBecAVqsVLqjneDi9mXtRtpf7Kmlt724eRrhGESxDduJx98c4FbJ8DQWdxcvYzTGOTDNDIN21sckN9a5yJpreUfZpZEKgZIbGD9Kux6/rcYVF1W4wc44H610fWk46oweDnF6MkudJeAkPHwOjVnPbMr4zg+hrUPijUpUVbtLO52jndDtJ/EVVfVLWXmS0eJyf8AlnJkflQqkXsJ4eouhz+vx/Z7cTmV3H3fKUE5z9O9UYLl7OSyjivHWFF8ySJhgpnt9K6x5YZFZkDhcde4rKmgie4SfhnTvjqD2PrW6qxtYydOW9jVtrsSKrIQUbkYPBrXsZWAU5+X+76VzcJXIAGxeuBxirtpc+W3Umoug5XbY7izuo8KXjAx71uQ3mUUAYUnt1NcPbX0EMYe6cKAcc8k1XPiC5gu9U2W9xc2axBoH2EeS/o3sauKctjOSPQGvUQ5XPPr1FW4NQQjb69eetctoF59r06EzzrNdYzMuCCmegIrdjhHLLtIx0xQ9NBaGizbkJIDHHSoZUZmzLxjp2xWddakLEpvQyZbCoOrewrlTrWuQaRqKta3BH2rZbXDqP3aE/dI9qpRuLY+d0ByFB6jHNMmV5WAP3R2qUAlCcYxgcUwqWfC4BHHNcsjrasRpkqC3G5vwxTD8xDbhtzwuaJN6gAAHaM01I96g5wxqSBJDnOAAvQe9MlGUUKT5Y461PKmNqx4IbJ+lRohdlReQBliP7ooSJ0Guh2AMcbyNx7Ko7Ux2BOQMkHp7U6bLSDf8xHY9KbvCyShQMk7apIlvUT7WYXY52ySEKPQCqRfdKxG7AbAx61NdKkBEjvl+CAf51UnuXkCMTjDFsgd6aRDlYlKOuXJAyeveoZpGlbG48dKjecgszfMSO5qt5zBRg8+tNITlcstIkJIABJ6VG8hC4QbnP6UtnZvcsCMk56muj0/QmYqAOnelKpGG5UKM57HMRxFskHBOAdwz+Va9vbGPbh93c5rq4tDXAAABHqKmj0lATnH0ArN4pPY6Fgmt2Zmh3qW8v76NuOpUZFekaV4m8LLbqupx3bnptS28zj6k4rkF00FyuNoHc96sJp6rIuCoTByD1z9Kj29+hosOup3o8aeCrNsWOk6lPjG54rGNNo/E81i+K/FOm63by2ll4TtzFjAu79h5gH95VXofqaw44CNwTAz/e6/hUzIqIpGGI4IHUUnXk/ItYeK1/U5+x0pYYtyIY89x3NacenggEhjkc7j0rQKqcL9+Qn7w54p0cSscLzk8bgc1m5Xepso2KyWiAeXCgXIycDJFTrCAFUSbh05HIqcWm/5XDjH3tueTVmO3MYIVeCPm3g8fiKV0XFFQJ837pmZiOGb7tWLeLzFzKuSBgYPU1a8hC2UEZKnloyR+hqxBbAuSzZGMhnHT8qllJWRBHErRF3iK5Gd5FLHaRlg4xgDpj71aAiRQi4QsT1GSQPpSxhIRllDRuTgEZA/KobZVijHBgl3VpgOoZtoz/WhI/MUELtVc5HQitLfGTlCF7DPA/DNRGNWZiZWQ5289CKXMVYpyCRlI2hmAyCBxj396WyKp8yKQ3Tn1q+UKIMOv+yCeg98UqoiM7NJ8x4ASP730NUpICI7icyAhzxgd/pUrwoU8xwVccMp4P4miAStIUK7QR1PXFPjRZSPuDjIUk/rSk+ohsEKiMtJkM3AXsAKsbsYGCCOm7oKVEB+abktwg7fiKUjyIpXEauyjHznqT3ApXKvcruNqlehb360z5ZpljjyNowcVG0RFyYpXyY1+bJySfapLUMUCRpkMSCT2+lU46hsPlMUaM0kWQDggtn+VV2hXyAVJJJ4UVMFVv3SKxDsFUZ4z70+5iVVaSTHyvsCg85pklYRqJpWkUjjgk8VAjGNY5cKSxzitB4/tEuwjbHH1x/EaqmPMcRUgv5hUD+6KtrQRDMvy5bhmORjp9KXdgF2ABT0FXCp372CHZ1XNMaJZJCX4VvmAzTsDK3KyKWbarc0gCxMQxyucqccmpkh3F+CUA6Go0jZ5lRjgx8rjv7UWECxlSXbkH9KRo8t/snnNTOubj90Oo3MGPSmElkynKE5H+yaTb7hyociquPtAZlzkENT0urpHk+zzzBJBh/mOWA7GoFb5ymGCN1JHenRkxqJVbDAjbnuO9JTkuonTi+hZh1K/jnaVbl1lYBdwGMgdqml1rWGcI2oTrt54IGarSFyh2geWeDn+E+1I6fuGChSQMlieQKPazva5KowWyGSXd5cSKZLqRypyCW6H1FMlluHDI1zM6Z3YLk8+tP3gLtjRt3UEdxSbyELMcAHHTmjnk+pahFLY8jUDY+G6/4VCJOSBjO3OfSrs9tJBkMu1hxyOtUSrBgp4HT8K7Wjy3Ia7ZYk7sMuMUhcZxnAx1FOjy2C3J/pSW/zGSNsDAzk0rC5gnjO1VjyxkHB9KuLbxtABHJsdox948kDrUFv8qPuBwD949h7UisqWbg4YYJRm64J9aqxm2QFkbKuAFUblYDv/Wq0+8XWWUqFAIXHWp2dAkgHKZCjHas6WV1lBkYtGWA3Z5xTtZkXuS3ssUqN8oIXgnHrWc03lAH16in3GGVthJweT2rNlb5jjIP1qkrsh7CzSb3JAwT2HatDSdOku5QO1VtPtZJ5kVR1Pp1r0rRNLWGEHGCBkketZ1qqhojehS5ndiaHocKqqn7x547V00FhCsW0sFI9upptpblE8xATgZK1eSWMxbv4W4Oe1ee23qeqopKyKqwLu2suG/hfPBp8cKxvlwYm9eqmrSzQrGYpQCx+62elRtcoGCSAqh4BPSpt1K0HGeP7sqRg/wB4c1HNEHYgbOed3cU9goX+Ej1AzUQjSOTicRk8jJyCPSqVxaAkEkWSHOw8cYOfpS/Z1JAE67MZ5X5jT1RvNUJIMk8d1q2tti4KzMiP6McKfoad31AqxRRqdsds0jEYABwfrUkdudwJLxkH/VkYNaSRwKmVR45T9115FPkWORQbhmlA646/lTtcRXjzE674UUYxmT+eRUhjUtsLJISeu35fzqVYLbZuQu8bH7qSYZfqDUkRgZdrJGyepOCMetFrDVisLOWMqzBQu0gjnFPWO2Zhl33AdE2kGp4mDMVjPy5+6G/rSSxIqqJX37ufmG4D2qbdSxqxyxAtIvyk7evlnH1pJHh2t5Yk2AY253Y+h70sflpvYFcR8D5TtJ9hTXEZZSuXx8xOzjP0otcrTqIPId988sjjGQg+XB96ehVn3MjzJ3w33aVLkoAAWIxnGzGacTIdzxhhk8nIHNTyjE+WIYwqAt0pwuGRm2OvmNkDI3fp2piKcxN8pkOT0zUqqzMVRiHbgMAAfegNCu4ZYyqhjno3f3q3G+I4iYGSBeXLEDd6D1psgEsbAZaQnGW7KKkQKmwEqyxnAzyWoEyZQ5kby4Y1kddwCsSVH1quYzKSxTdK3CZPC0WxMtwEJ27mPPQKBVld0squ+4KW2DpnA9PatFqiHoUIrcIJwAu77pPp9KjnRfKiiCsw25wp5FWwnzgA/KXOcnGTSSECSQoQCowaat1He5WlkMLxKsYOwbwO/wCNNhfzBEcjLMSSexp5I8ttpLStwDjpTyuZQzbAkQ+YDpmkx6DbcMobeQZGclR2NQvB5WZCQWDcgU95GCoSPl3HmiUgArGPlz0PahPTUVtSuSxgJ2EbyTu60FiJ48YbA71LcffdSD0H0qKUeZMgLhdp5OOapMGge7KscqORzUdtKS7yDG4jcOemKbsWVtoIIJyWFOtSouXRBkbSo/Gi4rC+aWuFlk58wgEelPU+RNKjjZGTgjHvUZgfzBGpzIOSewolV7idGZhiRe/r71LdyrWImfafLLZJ+YEd/SpEaTIJQAPwB6U3O5N20Ar8hIHQ0OVJiLHqOQp6GkIlWQbtgG0jgqe9NW4MfG0Fi2fpn1qAO4MrhQcAcnqKmfaMsitksCDSGSiXcX4+Y8jB6e1AeOWREjyx/iz2PrRG6NP8o+Z1Oc/3x/iKjjKRssoIPmZAA7fWq9BOxY1bSLbVozHLGodRhXUY2151r2gXWltsmjJiY4WUDg17LZ2xMYPPJq09jDNEYrhFkjPZq9JxueLzWPnV4z5fyjABwSaiYAHzNuQoxxXrPiP4fpJvl0R+MZNvIev0Nee6po11YyvHcQSRt2JU8j0qPh3HvsY0chjWMSITnOzn+dU2V2t5Ac/LnIz+gq7NEAEYDIXkgmoZWYR4OdrDKuP60XE13KCFVhBQsIzlitVJXbOCBsHIBNXZVVYmZsBd2FHes65kzuCDdTRDRTlmyW25AbqKntbMjEk3A6gdc1a0vTDKxlmGQDxW1JZBW4UADr7USl0QQj1ZP4btSJDMUy2ODjpXY2mzyGCsDzyRWVpIjjs3YnDuQPwrSsHxE44+dh2rjqXbPRopJWNWJpEhd1baQMYPpUKeau7fhkYZ4qVm+XDg89KdA6mNdrfMhwc9hWdjdakMaqeQSVH3Qas2YaWJ5GtpJIUHzKByB61Y0u0a6kL+UfL3DaOm4+p9q6QWSW+1muo/OIKFQOMVpCDlqVa25ykMKxpujyQ33WA5/EVJ5BusxOF8zqpI/SuwtNLjijUhozbsSBIezVmXUEaW5YFAe3y96cqbS1Ejn41SOX97GQynDAcEVZNxOoCOBLbdt38NZ7kXE7rKjmToGRsE1ZjhuI1ba5Zf7kq9fxrOxSaJWAjRfkki/uNGcj8qVLiQZCSrIc/Mj/Kx+lNFpceXw/lqf4GOQPoaVLfOElZEkHK+YNoPtmhNxQ73JIZl+0MzsUcdmGT+daIaEwKqRIWHLOh3A/UVmjd9wxxtt7hvmX/Gpd8Ib95hm/hwCp/SlJtit0J7bdI2IwCvPyxHDD8KtyQyM21XdSGAAkHSs/5NhLqpC4I3DDD8RQ10cr5V0xXOcTDP60Mo1XEqIWcI6qcDa2Mn6Gqruxc+Ur8L8wJ6E1Ve7unUea67fpmnXDeUFaUtlzkuvHH4VIydpDkb42KgY9xUrZZSwdkCr90r1qnFJ8++MJMemN3NTec+ZFdWAx3FA7imSUhcOm5Y+cDHFNckICo24AzjqTTfMIViEwSw27qQTobjMnY5YDuaTsMspNiRgrEqibTlenHNSRsYcPCAFZDjcKrwvGUmPPXnHep53iYHC7SI8c9qSXVCZOgTEcifMgi5575pSCrqh2ZH3WHH1qpA21Io/uvuweeMVZjl3XOwLxnaDVX7E2HuyrcbdoZVYkY6ZpIfLlMqSyqm/wCYAjqKV4U2uVJ3ebge9RmHbcHyR8pXkdaYO1rBKixy/ZwUO1s8HjFUSP8Aj6bOMcexq+g2szMuIycfNVaSNzDIq5YF8nIqkh3IpmEsQjiyWxwB61GqssQLtlycH2NTyIUQLGUC98D5h9akEYEjlTuUYOD0NN6krQhO/wC0OGf+Goh80jyEED7uT3rRlRGmkk8vbgAgA1WncBGZlAG4EA96S00Hcoj/AFTeZwAMAetFrKI7mOVRgHjioLqQmR5Gbav92mxyMY0fgKDketU0Jl2PcL0jJbgnHvUUpVF/iByGHoPWop5t14paQ7u+KtBMLIhGV5OfUVD0HcQKyBlDFvl3qQM8+9AG+AF4+rZBA5zVnCJcYhHyqBwfcVABgupONhz9akCJABcOWG5WGDT0XZH87HaPl9/apG2rI2Pulsg+hqAgu5DnduJ6fpQMkX/j2lidQ7R4Yt3/AAqLy3SRvlIzggGoxkY3Ofn64NLO5LE7sMQAvemnZisd5p7vJaRO/wArOoYjHSq2p6mLRjFGYhckBl847QPp71aXG0demPwqKSCGSQSSRJI+QQxHIx0r17o8AWyupLmDzZIRDzgJk547k1LOUkQLcJEyHjEoBGfxpWYs2ckn3qnqNkb63WEyeSN4ZnC5OPalu9RmHLY+G79GYWlqMTNBhRtLOOuMdR71wnxK07T9Kt4Rp1qkL5AkxnvXolnpNwl4Li5mijkhfZAI4x/qx0yR3PeuW+JunPdoHVchk9P4qzqWjsXC73PGL3Mjkkng9DUMSBpVJHGeQKuTISMuCpBwRnvUdvjzRng56VFxdTpLYxJGm0KB6ntTLoeZK2OhOcjoar2UsROxjl89K2JLSSS0eaIZVODSTszXdaGZFIYwV5rQtdSdLbYBwp44rKOWTdu74OKcF/cgqxyTyvpSlBPVlwqNaHTfafMsxJuPmA8jPSrFhIs10jI3Trg9a5fBKcSkEjlat2N19lbdFncV71k422OiE23qeqaZMkemyuwdWxkHGFIHUVBo/i4teTJCsYjTHzsgKkk9OetY9hqZk02KGRvMAypT0B7isaeznhvFEDo8LHhgRtUe9ErpXRpO7Z6zJfQ+QrMqiK8DK8YPCOD1Arnb5o1iJySOjbaoWV6tvpsStIZWVsqx7+tZ1/rSOHj3iMM3OPWiTvBX3NEtC0rqWKRoMryPXFTGeYgMjBu2GPSsuO78wASTQ4UZBOQatQysSCqRN/uv1P0NYNF2sWJHlKlnjkWP+ILgj8KqTmQpsdphEeR5i4FXEaaQ7orQEqeQrinSz7YXzHcwZ6ow3J+PpS23BMri0kCkx7XKYzsO7PuKGJYlJovtB4wBw496sKYHiP7lIpMbVmQkY/KoSS2EkmnRgfkc8g/jVLUCUwbj8wll5wQ52un4d6c8e/cBJkAY2sMMPwoMjjP74zxn5tsnIH0PalmKu5ZQFzjKuN2Poe9INRn2d7cOmBISN2QeCKejhZVIOCg5VlODTY8h3jG/J4AHKn8KlkOVfzFMbdGjcEBh9aQXYjurMv2iKJhjIwMEflUkbOS6W8rInQBuQahXZlWVisB4HGSv1qyvlmPErAOWypHGR6ilYor3MMiwR+adrF+oOaiiQiReOSc5HoK0HheGeJtwkQfNtYc1VWCVXlbYAwySAaXKFxyyBYGznJfn1NAeQ3Erbt28DjGR0oEnzRLIVHOSehFSnCvcMHGUyMY6UWY1IfE8Uqw/Ntk3k9OKmgGblW38o3PoRWeGCJEG29DzmpbNgj4J3BgfmU5ppCZcDgxly7gmUnaPTNPUoJI8hw2SRmqaXQazJHGGxjHNQNcyK+PNLYPHvVpXEaaTDyzuRZMH+I8A1L9ozAyEkN12e9Y1tIvlOj7hkEnNWGlBg+aUheMEDn86q1ibFycwh1CAhjgllHP0pJV2yPKpPI4Udqar+WjsCrkrng4JpBKo/eFX5A4J6VOwybaplLnJfb0z0qtMC0DMxOQenalXIYuWBLDjtVWaRiih8bt/ABo1ewWIp40m5KhMjGaqum9mRegGBV68YtOMgBTgnB6VB5YWdCx+R6Gwadik8RXbgbmPGT2rSaNo1hZWJB4b0Bqu+0XDxnO1eSRUcbPsBZmA3Um7jWxdE3zOWGd+V+lRGYNFyPmH8WegqFpwZG/ujgA96gkkLPsAAAHJPpSsOxeDAliQNpI/OmTuASAu1Sd1UBPsAHLZNWhIRIWOGUYIpWYnoNd1dAMYye1KSu9CuSuPmJ7GoZSwZvl5zkY7UySRwAgPynkgjqaqMe4z0rPpwKa3A6ZNRXN3b2vl/a5DEsjbVYrkZ9Kbp15BqVt59rnbuZCGPzZBxyO1es0fPkoLqd2MirEbCRMg5qPZkgfj61h/2pLb3g89oFtxJ5bZYK7ejbfSizGdAyfSqV/aR3cDQzKGB6exq8CGxg8HpUVy8VvBPcXDYht4mmkPTCqCT/KpavoCk7ni/wASPCzaXANQWS3W3c7SN4Dlv93qa80kuVV2CAZJANdXruo3Guak+oXh8ySYkoD/AMs0PRQPpWM1hCpcuuQeRWLajobcjepkvqLKQUwCOhzWhYeKZraMxON0R6rUctpAf+WQBx09arSWEZJ2rj2qk4vclqa2ZYl1xSzeWu1WOcAdK14SJbWOaDocbjmsGPTkWQF/XgVu6TEsUbwvgDOV9qG10CKk9y3C8j52gMR3bipmiuFYFtint/hV17OQbJJLdpYOpeLt9aMl4/KhuIjHnO2U4xWcmdEC1p08sHzyjGeOmRV2a6gKByCAT6daw5bW+gAYx74eu6N8ipItzYQCZGxkB14H41KdtDoUtDXm1aSaUFY43VVCAkYCiqVy0U+d9uyt6r0aie1vI40D27LEepXnJplv9ozuXd8pwQeKzk2aJvoSwpwBFMQeytUgluFwCANp4OKkeXcAJAhzxkjpRFEckwY3dwG4P51KSK5miwL3K5mtsserqcc06LVXTeI7klG6xyHrUCZU7gjAdCFPNOdoXcNJArD+LaMEilyIfOXhqcLqrKywydDgfKfqKkg1jDeXL8nOAQfl/Cs5bazkkKxHKHs42kfjUUtjF1idwucEEdDRyoOa5ttdofmRQVzgFDjI9xUqXFu+Ml4pPcZU/wCFc9Dbc4E5RhwQTx+FWJdMvFTfHIWj9AelHKNTNl5tz+YBu2nkKxGRUovJFLOkuWA4SZd361zqw3qNulZtnQsvrUn2mU/60FgOAwHNDiWpI6pbpWjDSQrH8uGaPkHPqKjLoqARFZIgOjc4Fcubpyd0UuMcH1qZ9RycPy+MbkHJpcgHRm5KzquQIweNx4qWO6SSOXdkSMeMjnP19KwBOeR99cflRFP+7YLncpxg1PJYejOjuFiuER3TL55HQjHeqrI4kWQSMUmxwRyAKzIrpgxbcQ2OmetTLfMLdNoyy8EGgVie6Hz4OG2Z7daitMYcOeccEdqgkuCJC7cZHK0W8375tv3aV2OxY8wiGUEjAIIqAXCb2BO1SetVnuGBlIIbnGKgeVWO7IHbFWmHKaaTDzGG/fweTUkM4WLaSWJ6isiJ/mGzOTU8bjKlmwc4NJhymxDcsd2TgDoR3qQXTsUy2Bjnn+dZUMjICNwZc8Y7UqyGPeDzkVNw5TTkuy7AAqCPXvUAfDbzj5TnHrWRPMXxjIIo80gbiM+vNVqx8pf+0li24kJ1PrSm4EcSsxDH+EVnh98fOAo61HkyHg8A0WFoX4ZHe6fYOvWrKOdsm4AJnNUgWiJkA5OAOO1WG/fKYlIx1FLlE+wSD5lkwAewPpTFYZkV1ABXJ5qZLc3SKmdrj7ue+KhSHKyMR8g6k/yp20FcjEqKB8uVxjOP5URyZHzdBUUqgIN+Qc5X2FRsm07lyF7/AFp2QmyxcXAlLbBtKKMZ71A8rSABgOBk47UrNxv9eMYqPeEcEMBkcmqasCZ6lrGnT3loTZti7j5h3AFQc9TmmaTo89pdXc93Kk0sp3JIuBjP3gR9elXLa7SZOCPpmrsaqT1yfrXp8ztY8SyITD6jp79apXWm2d1ceddQiSURGEH0XOf51rNGyDOOPeoTPCHCeZEznkbWBzS1E0ii25ZYgADCRgsTyDjgVm+KJ4v7H1Sw/eNNd2UkUYVc/eB6mtyURsuFByOef6UyezhuxF56BlTGNpwR+NRJNrQStfU+abXIjJPbCnPbsaZIVUFcZH8xWp4m0mTQfEWo6VMpwkheJj/HEx3K361jMcrjb0PWuVKzOzmutCORVIGByOee3tUYiBODyT3xVh0JwB0PJxUiL+7G0ZP86oEkMtLUs5GMnHWrqQFJFXOADgcZzVuzACjaBgrn6e1SkbsnoW7elIdjS0t5Io0KudkmQy5xzUWoWcM4IlUozHAkXjBpLUgWZUDJhbd74q9LJGpMdx/q5F3delJt2KjExPs95pxYo6yRnjAPX8KSK/lKeXDMyf7D1qxRPLEYlG7ncre1MOjCZQ0wBIPJPWldM0UShFfzREBZJQ/p2q6btZziSJ45zzvHQ/hU8WiqpbEx2/3XFXFtWs4GWd4Z4McKwwQPY1MrFpMqwJK4JSISJ1LKPmH4VPDA0wbZInmY4zwfxp8ENuqxywylDnKsHPyn0NawuLOXEU7BZEGVkQd6nWxdmZ9tEgX96G8zODtGRt/xqRbKJ5CscoLY+UkYFWSsSlmk+638SUiSARbf7p4Zev41N2UojVgjdXEqxh1HGO9Ry2cisxhZRuHTswq007EhiiuSBkY6ilWRWwV3Rt2XGc0rsOUxrzT1IVgpiJGeeVP41HAb2BsJIdpHHORW6suJMxSKWxyhGMfnUF2wQ4njGG/ixjFXcFG5lyX2oWp3GIbjypHIamy6kJZFkmthBJ/EVHyt/hV4YEeEbegP3GPP4UsjFiAy/Jxg+lUmLl1Ksd1AXP7veCDuB4psjwumF5UYwwHIq8jxDYwWOQgnIYdagCQMrFAqynkDGMilfqNplXYzScMCePmWpDld4cEODke9MuVAZCDt9CDg0hUlmzJvB5z6UIaYuQ0mMkPjAB6VPb7wChG4kevSqKllIYncp4GaljkaOUckUuUdy+7b4mUgMQR1pFKIwK8D0qm0h8zIPzDt6ileVnVQrY7EelJ6DTJbobX3DkE4NQIGDlQQT1wfSoppOiu2M881FG2WZQ6sQcg96kq5cXHmfKcYpxb5yEOV65IqMyLs2yAYHIIqF7omMbOR602guXi5Cjjjuc01n4ODz2z3rOW7G7lgR/d9alFz94DpU2HctB/7x+Y9aHRSpXcQ1UUuGBPO6pYZC8uX79KtKyE3csBGwUOMGp4tgDIQcr3FV0dSxcnGOMU8zLtB7dxS6aCLzu+EO5QqjjNSwOI2JY7XYcfSshrgA7g/y9hmoRNJOrSsGCjoc1cVoQ2kdLHMIh+7OXBBFQzXSiKYPgknIUetYttqgRTtPX5ad5o2FjyT603EFZlgFyq7znnKinvNuZ9zcYxwO9UXOYA4k5DYIzzUUUhZjjlT3qXEd0aDSAbe/qOxqrcgvKRJ9w9CKaxIXkYAx+NQE7nOCV7Y9aWtgPSY2upr+O3sbYlud8jghVHt610sMNzbGMyyo2OGAPOPWpdP054rIRpLtldQsj4598e9aNrpdtAoVULMeC7nJ/OvVPDe9iPfFcRMgYMpGMA9aqS6XY7iTajAGAoYhR+HrWTqEDW16t9ol/ESWxJaynAf12H1rpiRLEsiDCkZK+lJq24iiYUQAKoCjoB2pJZUtLd3Y4TGTxkj3xVnALkAc1IbWXbkoQQeM0vUbsedfE7SF1/wyNTsDFPfaYDJhBh5Yf4lx146ivFQUEeQ2QRke+a+pLhJEk82VY8ngmTA3D0PtXifjPwJfWV7LNoUBudNLF1jjKu8QP8ACR3Gc1lOPVFwlbQ4+Dyygzjvz65pwQKVwcqOM4qpqVtf6Zhr2znt1b7pkjIFVFvmMW4Bio79qlLuVz2Ogt2jVQMjbjFWI8PE67sNkYNcpHqkZfByuPStO01Hb94bgePWh0xqqb9jIgmYORg/L9asApLuST768ZFZCyRspMRBJ9KkguMPvHHykNzw1Zyps3jNHSafc/6P5JC4jOAQKdHcZEqMAc9DXNR3r5kEbEZIJ96el3skYuRlhzUezkbKomdA903mKB94DqOlLJfNsEciBxjvXNvftwFwDT/t0jcbh0pOm+pSqI2YoFdXKQsFY846VI9ljZmTGBwBWMuoXETExg7SMHFKt7PuUru2Z7+vvSUGVzdTUS5ntpEAIaM5HNWEvbeRgQfKfGCM8E1z80lyzkHg9ePSkDPtbeh3jiqUO4e0Oid2JzHIoJO4YNRGd1DryHzz71z8MkjSqm4RhRwSaUSzRk5Zue9Hs7MPaG6bmQcOoYdsnmmyXjPF87MQOMGsmKacvnhqRZZQzISdufxqlCwe0NEXbjCgDae3WpBcsI88kqSCD0rL2yBiflIXvSHzlkYmMkNyQD1quS+4+dGl9rjcHyzskA5Vv6VFJOQ4YZbacGsxyTNwMEHODUhmIUsIyM8UcmonULZvCyFX4x0P9KEu/THK8kVmEk5AytKjgDLA7h79aOS2hPtLF4yDd8mSp/hPY0+O75Yc4qjvGN3Q03zRt6Dd3NL2dxe0NIyAsp3c+hp8bbs5+XHPXrWT5vygBulKZiEDZz71LplqoaRIkfbnPHymq0hII2uM98VWS4IcNx8vAo2vcSllGAD82KPZ2K57oka5Z+S3A460qzKsbAEkt0pP7PZ2YxEgYzg1NFp+9uWbOO9NrsPmZDuG4MvJHapFc/McgDHFPm0qe1wSv3+R3JqEgrlWBU9weKTS2FexIshEg57Yq6koEYDEE9fpWYpwPvEr6VKg43DgjrmpcUPmLctydhwoBHP1qBbknhj1qOTnPYetQMw6en60KFxcw+eU889P4e1QnUJShRSQDTZCNvyqcn1qNkCkMQCPatUkkZuVyzC67PnOKt+b+6B3d/zrMUkyFsYHX8KlBkOGGMA0ONxqRoxOpB3EK1OilCEngDGBiqXmMeuBxTo5BnYWAyvWpsFycTvljuyrevSljkYsN54BzyO9RQDejLuyo5xUqMDCdx56CpasNM+lY0AHAz705oo5UMcy70PUZP8ASnIMZp4HHIPFegeMY0Xh21WLZLLM480yiPGEQ57VY1Oay0uzNzcyrbQ5wgB5cjso7mtAZ79BXGfEmIT6hoWMFYYZm2/7RYc/XFTUk1G5dOCnJJnN+JvG146kWg+x2zcLtHzv7k9q4yfXZSPmuJ2kbqzSMa3PFVqZ9PcoPnj5UVwJWRWUSoR6Z71wOUm73PRjGMdC7dXC3LFpHkbnklyc1VNshYvC80eeMq5H9arhmVuM46c0rTOFZVJAHc0JyBtFXUhK6iKa+vJk/uSSllH4Gs82iyx7BuKL2zgVoQRmS4CtkhutPaMBYyvBJO5fTmr5miFCLRhjR1YMd5XFPjga3wu44HetpUGw7Vzj5jTXhDE7jz6VcZsxlST2M9dyEMoZe+R0q7BM04wQAfXPWoHt5YzmM5GPunnNEUhViHTbxwR0q07mbTjuXSTjYAqjpnPNReXI/wA2MgjrmpEkLAElMnuT1qwqBmAMeMdxTaaVy4tPcgjjOANrsKsW9sZjtCspPAFTIgdtqk4PH3sGrgto48Dznjfj73NQ2apdjd0TQGlt2+z3ARlXJ34yW9OaoXekNDIxlnIOcMoHT3rQtLt9P2yMEkyOM/zrP1LVEuElWVjk9CvrSSb2NL8quQraQIcytLt/2sCpPs0GT868DON/asVpg/LsScY5PFOYIuCknBHIJo9m92HMmbY8mPjzflI6Mmf5VGLlDgbIWZfwyKyBvfID8dqcY5WAY4+tJRXVlc5flngP/LEq/faelVvtJbIIx6Ejmn21qSmZHxnkEc1bW3hSPnJPfn9aNEBn5O5thOT2AxmlMczAfvDx74q64gUqQ27HQjiomlgbI3FT2p3fQPUqyySE4kO7HTjNJ94fMT/hTvNXBBKkH17VD5oHTk9xTTfUl6AMZzuG0nHIqNw27GMHNObAbcVOc+tPdcwF1OQDz7VauybjVVSAW4xTCpy2QMHpiiEnzWDNnNIVcS7MgA8gk0A7EbKBywNKih/lyR6ZqSQEjIPPoaqNl2DbgOemKrVrViZcmtgjtsbjAPHPNXLMNviZVAA6nHWoLddxAAKhh3rStwFhI5JXuKlK5rA1LOAy7mUKSOSKvfZEMYwOcYrDmW4e0DWnysD82OuKopFJGFlglka6UfMCxqXOKdjdN9DWurdlk2vvVl9+RWZPAzO2BnPGTW7FfLcwxLdf6xflyR+lU7khAdpHXGaUkrXQJ3WpltasgLt9wdh2pske6MyDI56VYv2aGGLILb+d3rVYXBMZBQNz96s7djFuxGG2ptcYOfSkCpyx65qN5S752EKTTZCWYAjH0NNIVyYRZYYPXnpUhtwgBOSPQVDCQpHzNn1q0sgVwTuIxzmk2NFeaPAGBz6VLHDtQFhzjgU8yFjuCkr2pWmY9Ru9qV+gIrJGWcuMZHanGFHDBfkPoe9PiKncwOG64HakkLZzjPvVK+wSZGfkTAJUUxmZcCT7v86cW2oSAxpAjNlsHgd6pITkfUdu4lQSIdyt0NSNxgHI9xSLtZz5eFXqAOABRHJHN5ioyt5bbWwe/pXWeUHRiMD8ao65p66lp3k7QsqMJI3HbHb8atyL/d61H5nzYPFJq+jHF2aaPNr+3+/DNhX5BzxmuI1HTWBMUqldrZjkHY17jq2iWuqJmWEFwMZ715rrekPaagYbRLiGIxkgToW3MD/L3rFUux0qtfc4F7OQMd44J5wOhrPnhCJh1buM5rvf7K1E2ySXFoyMeSoGQa57VtPZIZi0bKRhiNp/Ss7aj5r6nODKIGTjaR3pXcC5RjnG7P4GnPFuOYjkj7wqORM9DtxweOtJq5akTxkL5iDkcgj0FCMpdMYORg1ErHI4IYjBpyKVY4XilylcxKYxsIx86tnPqPSkmtlbJ6AjOKm84F0cY6dqXzVIx3JPB7VSTE9TPWExvt4PpnuKkhzv+UlV9BU5O3AYD5elM3xEj5trfpWkW+pk0iZSZGXIBPr3pGdy21yTn8ajUBWxnjtjtQ7MCecHrnFW0g5raFt9YvzbG2NyJIkGFV4wxUegPWqOHlf5iQMZ606NwwOC2e520rKW6Z57ip5ktikr9QSEhcknHtUsaqAW2FvXIqKFlAx+8Y9AccVOZJBzG5VvRh2pblJWJUlyijblvpilEoAw/wB0nOB2qi0kiSbt+4mja+7JwCffpRyormZaeYqu4NtA4AqKS9dUCknp1FQPjPzMQeRgdKhcgrjmqUVYHJlnzN2S2Tx61AxYFQxOKeCDAIxkNjLcUipuJDZI6U9EJ3YisduCeRSRSsW2kAZqQRKBtwQfr1pfKCrkjLHmldBrYQuRIATuI6VIjjkMSdx6CosD5WAy2fyqVRGMGVMrnpSv2DoIssav8owR0PqKlldHcMEOajbyyx8vj8KeZlDlRk+9IdwAY5BUEE5BpkcPmSeWo+cnC05LgrMrAE4HQ0kpeSNnXsecdafK0K6RpzW0umpClyMucnFS28ySBggwwAJHqKylnZPLdHLSpyN5zz6VC91JJK0hKpIWzhRgU0mhqqkdRY38URCHBG4nPf6VbOpwMo2W6Buoyo5+tcfNfHK77dWK9SDg0Je27KXVp0lB+4RkY+tJwvuivbo6S5nRpC7FcjkY4rPuL5OXIO0nhSetQaSP7Su1gAPqWJ6D1rKvQYtQmQtv2uQpHTFDV9Buqajzmdck4QfdB7UpiBUfvAxPcVl+cQdrj5hUiTnIA4AFZ+zZLmi+se0bSchvbkUsgUEiORSe4YVRW5bnjk9PaomkZzhj+famoMOddC6DtAwgDDuOhpst3wR1B9qpgkJnOfoaYBx1zVKCTDnLKzMBtDEA+lS795+6Rg+tVDyBxyKkR+D15o5UHMTNKQ3BIB54pyzEsOSOw56VCsbHO0EkCrEduQoLkAEZp8liHUGOWyQ/J7Yq0zosGACWxSCKHYcPk0sLWzytF5o3r1B71Sh1IdQ93n1iKfSrpIpCZtoKKDgsQRkVL4Uhgjv7tohcGIR741myDG+cN9a8y1GR44VWNpBIx+Vl6rW7ot1fWVpHtneRm5bcetbc1lY5HuerFgx7ZIycVUuYGIzGRn0rmbXxKyRg3SEE/KSo4Faena8k1w1rcxsjyzBYDj+EjPJ+oNQBqWlwpbZJkNnHzcflVxkA3SKBvZdpbqcen0qtLEkykNjPTPcfjTY53tCFn+eEcBwOR9aB+ZFqEdvb2c93ckx28KeY5/oK8Z8R65ear5ipsgtB0RFG4/U13nxdvJGtNDt7eUpbzLIWKniRge/4YrgUgju7V8ErcLw2e9edVrtz9mtD2MPgbYdYiSvc4G6geOUTW5IlX8vxqB72JW/fKU+vT6VqXSmN3THPQ1Tnt43jHmIPcntShVa+IidLm2KE19bx5ZJN6A5461RudazhosOxPSrc2lwl3+XHIwAanttIiUmTYBjpxXQqseqOd0ZXtczI9RvM7xCwX6damm1goFaS2dT7V0VvZRswDHn9KS605BIN6hj16cVmq6bs0afV2lozKstTjuF+bhT2PJU1cKJIu5ArDNMudOWKTzYQoPcdjUdvFnmLIIOTitFK+qMnFrRk08JDfuhtbHAFQq06k7l3Z9G5FTAzbz5jtgd6eYQcDLZPNXF9yXHsVzJldrBgR2z/ADqzbqhIVYsE9yeKVEycMNwx3p0agPhec8CrdmOOhOC0YIfA46VCyrIAAWTHOe1PkZkGOGHoaiDMRgHFQaXG+UM7AQWPQ1E5OMEYYHBp7jafmyT7U0tluRnPWqQDSAM7z16e1NXGB0JzyTQ8eep/D0p4Q7cckVWyJuKhJOOhNS7cseOM81Ht2jdnIPrUglChckbvp0pehV0NaEhmYHIH6UvTGQT680yQkHLMQD6U1N7Z2hse9GrJUiySsbtjGSMYxUWTkb1BHYZpHkIkG7rjGKjKuxOFKnt707C5i0TE1v8AdIkHIx6VBI4DBkHJ9KfAVh+9Jtbvmmq7bgqYwemaLahdiZMmHtyN6H5gRUTmTzi33WPUdOaQr5chG7DAdRRLMhjG8s7/AN41Rm0AkZpsybQB19zTJRufKnB+lN3ENlkAU9M96aZ25ICqPUUxWLYD7SQc5GKqmNg/3eKrPLK+7DN7YqS20/ULhtsQlIPI9qV7D6alyKSeCUSWzMhcYbHekaLZKScFs8+9WE8N6kVBaQ/QvU8Phmct802PpQgVluyoqeYxZzwabtUfeJAFbMfhxA3zTSE+1XYdGt1UBkMnu9AnUOaG0kZY5PoKUR7uFJP4V2Eel24biFM1r2OnouAsSD8KBc5w9roeoXIHk25IPfGKkPh+/hJEsQz9a9Pig2R7nPTpise9j3OTxkmhC52cOujXC8HAH1qxBpDBvm5HcCum8gn0p622RyKYnNmCLJl4HTFI2nh8Egk11MOnu3QcVdg0UtjIxTuK6OGfTAxIUYbt9azn8OXkl+kpjZ8Dll4zXsVh4eVznbmt+20OGIZYL+VHM0S7M5gWke7dgHb070siiC3L4LHooHetG3tvMzg57ZBrRg02MOrzZbHQY4FOxNzOtoMqmVO4gZrai0uOeIDO1s8H3qeOJVxsUCrEQxntSEV0t761Bw3nRj8xU0d6nCyfIfRxir8EvTOSfrTb1bZoy10qLGBgsaVh3MnWNFstZs/InUiNWLoUP3Se4rh7/wAHatpExltgl/aAZzGcSY9xW7dXOoaffaubG3uZrW2eMW6FeJN2MhvQjNbmn64kvFxG8Tqdrbh91vxrKphoyabWp14fHVaMHTT919DxHU7GG4mnCr5ch6owwy1zc8TQs0chIXuTX0nqmhaTrsTrPEN5HEsZw36V5/rnwr1MgvpVzDdoOiykq30rCdF9DSOJXU8jZSWyQQR2qeJyEI2nPvXS6p4M1/TogbrSLrC9XiXeB+VYYt9sjI+Vfb9x/lYfgahruWqqeqEt5FCsrkq/UH3qa4uvMjDYViDyQegqCSIuh2ja2MYPeqzIwUryQcDjtU+z7mvOifftyVBJOcAjioBEZFBQmMj+IGnYfHOducULE3K4+Tsc1rFW1RjNoSEyM22VwJD0P8JpyFlLLNlPfFDKoYq6EqeeP6VIXEoCS/vF6Bq2TuZCgZ+Y4HoexpuMMeQMHjHNR7WiyBJ8h4HemooCgZYknk+taJXJuSzsX2kkDtnFRj5T94GlYADJyU/lTCAnz5OKFAfMKwIPOCe1Nj4NKmXAy3IqRYt7/JkDvTsx3GFRvC++frSqAGIHP41M20kYAz0o8sQg5cMx/hHanYhyK7q2R8vU4AHNI0LhxlTvPQVKhcMXDAdhipXgf5WlkG7sKewt9yvIgRF81sn0qIEnJANWlijZz5jA46AdqQMsbnaQQP1pO5SsimSxfLDn6VYYSC33jgg4A70/ZJK58uLIPT2p8VpNGcspJPbrikMzxl8tIMsfXpUk0hfamApH8VaCadNJ9xWLH0X+tXbbw8zcygsT1FILo58Rsd2zB9WPpTo4jgZAPua65fDskrLvdYox2UZrYtPDejF49+oByXEZXGCCfaizexLqRieffYmZ1DIWPYCrsOizSFSyYX+Ve22fhHTbcbFjDMOMnipn8PW4HyxAfhRZrcXtr7Hj1lpSW7fc3n3Fa9vGQoAGFBrvZ/DyclY8e4FVf7EwxIXpwRinqQ533OaWDc3Tj6VKLJieBxXTJpg2j5cCrKWAH8I6UybrocmunFu1WE0hjg4rq0swB939KtR2q7QSPwoQmzmINGJbkACr8WmCNecE10MQgWeOJtoeQ4RScFj7Ut1ABJwMfhTYkc1dQlUwB+FZMlqzMSQK62S2y3zCmfYhnhf0qbFXOWjsSWHer9rppJztroYNPyc4GPpWhDZogyVyaLCuYttpoGOO1acFmoIz+tX9oQfdAwM1HPdQQWMt28i/Z41LMynI4ppX2JuD7oU2Qr8/WsXUdK1m/kjNvdfZ1BJYNn5vTOK6KykSWFJVxudQ+09QD0zVzcCuP6U1oNNo5zyIgoOwD6U+NMDAkZaRTxUyE59K9NxT6HzUa046pioZVGA6Nj14o33gmiZY08kZL4PJpxAPenKMZ9PaodCDN446qiaOYgjcSv1FY+u3Upu5LEL9qtjGJ22dQB1/Gtk45KMQO+aUBWHKLjHZcE1H1aO9zVZi/tIzND0+a5gt777TMLSf50SY5Lr2Bx06V0X2BJAxbAx2I7VTRAgHlAp2wp4FWYp5ocYkVx3Dr1rOWHl0OqGPpPfQztUsbextGuMMsoYARq20tn0qpZ6jeNcpb26SvcY3fZ5B84X+99K6hNTPmbp7WJ8fdKfw/TPSrSX+nPJ50sEsVwF2eaUycemR2rP2Uo7o6I4inPaRQs5NUSNXmjaFz1XI5FUtX0jStXQ/2zpEE7/89EUK4/EV0sctlNxFcxvux95sfzp72p/h2lOxVuPzrJxfVG0Wuh4l4l+HtogLaVf+RzlUulJA/GuSTwDrTzsI5NOdTjOLgD8QK+lnsIi48yCJmA6uucVA2n2/mGUW1tvPBYRjcahwia+0kj58X4c687AItsf+2oA/Wnt8NNcGAwsk9D54/KvepbCAn5reLHTpiqUmkWr8CLb9KnkSF7ST3PCrr4ca0o4ktAevyyZrNn+H+vLjCxMT6V7lqnhl7lQtrdpbBeWLKST9O1c83hvUV1h7Q3E0diIg6XQBy7emO1aKCE5s8Xv9FvdJZV1GJhk4wnJ/KprXREv8rZXaeen3om4Ir3SPw1AqjzZWuJAc+Y65OR9axfEXhuFZprgyW8SSlWeVY/nTHpinZAqkjxe7029sZClzBIp/vAZFVAnHoPQ17LcX2mYCQefdheDmPGawLvTNJutUXfBPHp7qWmVuGVh6UJDdQ8/jgZgQq5J6VPFZyt8iqTnrXeaN4JgvbxSt5JFbyJ5lvGmGwAejZ710B8FJAT85IHpQ9BqaPObXw5eTp5kcS4IwPm6VpWXgq7lChUO/oTXpGlaDBAwy5zXQrbrEAEOakTm1seP6h4Fv9NtTPLCrRd2U5NUrTw/A+C8Eh9eTXuUYBJDAEHqDUTaZboS8calTzjuDTsyedvc8pi8K2rgCO2P0JNTx+DkBGy1XP0r1D7FbSrgLh/UcEVGjNbHypwv+y4FIOZnn8fhKTI/cqB6Yq9b+EDwdgUE9MV6ACu0Y5+tOY8DsKAuzjYPCKqvLgfSrtv4YtUxuw2K6L5eev1FRsOeM4oFcz4dGsE4MQJ9D0rmbrQ5Yry5uLTSnGlW4aR1lwrscclT1IrtGR+oOKjInzncG4xhvSrjLlFYw/Cou5dKhublt0dwgaJSclQOOa20JAwcUoEiRhFWNEXoq9KaqNxuP4Ckx2C4hNxC0auY2cYDj+H3rkdNnb/hJJ44LpWaC3YTea37uVh059a7iMADqNw9e1VZLK2a3mjFvCqyghyqgE560J23EY/h25e9ty2otEJ5GJiVRjK+1bawRgdBWfpGkW2nWscRRJXgYmGQk5VT2rUDLnJ79aJeQETxoeCMn2rG19AbB7VVf7TL/AKjyzg7h6VvZBJ54qtqFlbXcebiESNGCyYYgg/hSi9R+RxCjVWvdD1a9MJaAvCC8oGXBxyO2K66xuzqVl9pMbRyo5UgnIb3Fcunhe4fRHSWUpded50cZOV69DXaWQY2sKuoV1QBlHAB71c2uhKIopYRdolwVUMhfJ6cdqbot5Bq1g95aowi81o13Dk470y/sopwBKu4DnFZ+iWkyXEVna+dbxwuWkDMCrR+w9aElYbOgUADikz71O8Q/h6daiMZCHAzUAVb+6a1h8xIzMxO0KB2PrXGW1paeZq1i11cyIyGRLaEEqPY+gziu62upzg5FQWlkltNPLCuJZzmRz1b/AOtVxlyiMzwpsNobwIY5JEELKxJPynqc10KMz4xTBbszc9/arSRrGB61LBHPRt255qZMYzUEfQHFTpyAPSvVPm+UeOMcU9eQaaOg61Io7UEtDx1PvT1HX2poGOcU8cnAoFYAQMYyT9KmUkcjqB3FRqCMk8VJzjnmgLDg2Rj+lKOvGRSJxyacvzE9qZSiDqHHzBSPcZojXyyTGWX02sRTsAd6d2FFk90aJyjsyaPUbyIDFyzn/poA1WU1afaTJBbv9AVNUDyc0o54NQ6UH0NY4mtH7RdbUEfBe3kU/wCywYUkd1bnlpAv++CMVSAGfpQ2RyDms5YWL2Nlj5x+JXNNTHMuYpEbPoc1HLG8Y2fNjspPFZhQc5VTn/ZxSHfjAeRcdCG4H4Vi8K11NoZlF/ErBrV1b6ZZm7vd4hWRY32rypPQ/SsHV7uK4uBb2yF4GOVm/hcjqK3rpnuIHiuwl1E4wyypwfyrBfQ1iuYpLGRYIYzxbliV56kZ6VLoStY2WNpN7lmWxiZuIkU4xkDBrNvdFjnXbuYOenGa2lfnE6OnOcjkUGeFf9X8ue9ZShKO6OiNWEtmY2g+Hv7OkeSa8fc/3VVRhRWyzvbkecmY+m9f5mkFxG3G7NPjlySAeowfpUM1Sb2HCOORdyBW9waQFVuza7v3yp5nlnqF9fpVW4tjkmzuDBJ2UdM/SuettQvbLXLrUdVikWWK2NsrSrhZQOQcjtVxipIl6HZJGxb7uPrU6qcY4z9ax/DOpS31rJNfXkMs7/MsKf8ALNf61uBlJPr2ocbOwk7kE0APOMH1FVLm3Z49hIYe9aS4Oc4pCuSOAc1AznVnubA4lVpIB3xkitCCeOaLfEwYZ5wckfhV9k4OMA+h5qhNpUDOJoWe2nHRo/uk+4p2AkBwOPxppLH1qpOb6zUG5t/tCDgS25zx7j1qwkisMqdwNIB+7jr196Y0pHBP6U7twBjpTSmQc9aYEL3Kg549801byNjwenXmpns1dScde2KzrnT2HKD6jvQBoCZWORUiuuOvNc86TR9d2BTRdSIO+RQB0nU8mmmMjnGTWJFqsijnqKtx6tG5G9iPeiwzR2kYPal6561B9shIAD5zSpcxHPzA0gHMNx5p6fKMCoDcRjJGDimCVnyRwtAi7jeORzUKpslEgA3LxnPamRzbScn8alVwwzigC7FOjjsD6VOEUjIx+FZ2wNzgZp4DoOGOKALflgk87fwpoj+bnkfSoPNlxyAaVLh152n8KYFvbgHHSonOKYtyWOcce1KZQSMjvSA8+h8beGmXB1RFPvxVuHxd4dZcrq9qf+BivmchD2yTTfLUtnAr2+WJ4DgfVUPiLQpMeXq9mTjgGQCr8OoaZNxDqNm5/wCuq8frXyQIkx90ZqRYogfuAfQ4p+zT2J5UfX0RikJ8u5tm+kgq0tvI3KtGynurivjtECHcryA+ocirkFxdRsvl314vH8E7D+tHsl3F7qPrw2cuOUNNMUiqAUbHXpXypFrutQhfK1vU1wccXDGtC38aeKrYkReIb8Z9WDD69KPYvoxXifTHzAjdkH6UBsYHevnm3+JfjKE/LrbOB/z0hVqvQfF7xjG43XGnTD0ktP8AA0exl0Fddz3tWBPOM+tKDyRzx6V4lH8aPE4w09jo0o7/ACOuf1q5H8aL8gC48OWL/wDXO4Zf5ij2Mw07nsmfQ/hQMMepB9K8rg+NFnjNx4Zuww7xXKkfqK0YPjF4bdR52laxC3+yiv8AyNTySW6K07nohBGcgmjsetcPF8WvBUmPNm1W3/66Wp/pmrtv8TfA8rbRr5iJ6ebayD8+KWvYXK2jqwOO+KQgcVhx+NvB8gynifTuezuV/mK0bfWdEuQDBr2ksD0/0pOf1oJcH2LQFRmPpxU8Hk3IxbXllMR18u4U/wBamWyuG+4iv/uuDRdE8j7Ga8eT05FQyR5+ta7WVzn/AFLComsrgE5haluTaS2MZrcZ+4p/SoWhXB+Vww6FWxitiS3lzzGwx9ary27A8ow/CpdOL3RpGtVhs2ZbeahzFKwHowzUVzJLPbtFcxxTqQV298VpPEeAVP4CoXjA9az9jA2jj68d3c5uPT107EmlRS25QYw3zCtCz8UpC6RapG8L5xvC/Kfr6VoiMEjGRjrg4qCeJZF2vhl9DzR7CL6mqzGa+KJu2dxHdor27JIjdCprK8Q62kWj3q6eZhfJwjqhKhs/dz0rFGnyW0vnaZI0EgHGDwfwqpeXmoPeW4ml+xQ+ZvleMEo5B4JSoeF6o6KWYRno1ZnTXHiiCCOxt1tLi51KaJS0CqVw3ckmt8IQo3rhsDIz90+lcRpsuo+I7zULu6jtpLyNhDFcecYygHIYev412tvuFtEsxDzquJGXoWrlqLldjvhLmVxdxDHacc/wnBqBreF85TbIf414/SpyN2MEVHhsttGazLM64V7bJbLJn7wpFuI9jMxwoGSc0s9+kOr2WnTDE94rNGSODiq93aIJf3DpHMw+5u3AnuCKdgMW+1W7bW9PudHjnktp3EDxMMLIQc5U+tR2F1f2Ot67eahasQzqqwmZSYVJyOO5+lQ6vYyyX9iwb7CsMhdymcN9B0zVzT9HWDxGupwzLd2kxAk8/l0IHUVpeNrC1OgMIlQHbgMobB7ZqrNpyP0BB9q1PMUtuByD604hS2RxWQzldQ0eWSJlgm8lzxuK7sVyMFjqjanOsYLQxjBlbIVm9q9VK5yMAk9zVeaJW+XIwO2KpSaC55xpbalulS6VomQ4zjIYe1aazzKclvwrqZbGJhhVNVZdJXoAPxFJyuNGEt9KrHp+FTJqxUfMGq3PpWDjHFU5NNA5YECi4aDxrAJ5yo9alTWwG2g5ArMmslx8maiWyIPRqLhodFHriZBGR7VYGux7e9YUNjvAAyTVoaNMUZlR8euDRcNDXGtRABnYAe9Z/wDwlFyLu7i+xmWFYz5cqjAyR3ot/Dl667/LIUjgscZq5H4fuFA3OpX0VsinfyAh8NancHTrK1nt3eQKTJOTwMnoa31kTbziqCaK0agtJIAemKtRaZ8nVjj1NJu4j5A2jfjt6UKBt/GiivaR4j3FPc1IOPxooqkZyFHFSLyVPtRRWhDHEkHr04qT/ln1PNFFPqZMf0xxQRgjHeiiqJFJwcDGM1Ko+YjJxRRQSKGIUkVMjEpyaKKbAB1+vWjJXgdPpRRRFgMVVLHKqfqKZJa28hUvBET/ALgoopjTaI/slurjbEq/7vH8qkji8uRTFJPGfVJnH9aKK0SVi1J9y9Heaiv3NX1VB6LdyD+tWYNa1225g8Q6yhHpdsf50UVDiktjRNtlhPGHiqPIXxPq2B6zA/0po+InjCLn/hIb18HHz7D/AOy0UVMYq+xrNaET/F/xrA5RdWDAf3oIz/SkHxo8ZlvnvLV/961T/CiisaiVxqK5di7a/GnxUxxIumSY/vWo/oRV6L4w+IZB89rpJPr9nYf+zUUUU0jGSRqad8TtXumRZbLS8E4+WFh/7NW+fFl0UbNlYEEDqjn/ANmoopySTM0kULnxBc24+0WsVvA+BxGG2n8Ca63QPFd7Lbxs8NqSw5+Vv/iqKK4sTFX2PTwDfKdjZX5ucCSCDpnIU/403VJf+JZdlEVGVchlzkUUVwxSsepPYxrTQrWe5sbqR7gzLA0qt5hOGxnIz0qj4AtYpvt+pXCma8Z2XfIc4Ge1FFbSS5TJNnWSWVvIqo8YKnqMmuW8QWEOn7JrTfGxPIDcflRRWDSNURaJqE87FZCCPbiujRlALbFJxnnP+NFFFkAkM/mYJijB9s/41Vvrs2yZSGIn1bP+NFFZ2DqZy65MWfNtbEL0GG/+KqndeK7qIOVtLHjsUb/4qiirSRRz+p/EPUrWEmKx0zPqYnP/ALNXG6h8W9dEpjFnpIUc/wCob/4qiitoRXYUtjKm+MXiReI4dLjz3W25/U1Qb4weLHY7bizTj+G1T+tFFacsexldgnxW8XyABdUEQbg+XAi/0ps3jbxTcSfvfEGoHHo4H8hRRW0IxtsTJuxQn1/WZ3Hn6vqEmefmnaprbXdXtk3QapeofQSnFFFaTiuxjTk+bctn4keKNOjSKDUnYcnMgDGoR8UfFokLf2mx56FRiiiuSUV2OyL1P//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules with central hyperkeratosis were present on the extremities of this woman with perforating folliculitis and renal failure. Perforating folliculitis most often occurs in the setting of renal failure or diabetes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Patrick Keehan, D.O. and Greg Hosler, MD, PhD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perforating folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules with central hyperkeratosis were present on the extremities of this woman with perforating folliculitis and renal failure. Perforating folliculitis most often occurs in the setting of renal failure or diabetes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Patrick Keehan, D.O. and Greg Hosler, MD, PhD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42119=[""].join("\n");
var outline_f41_8_42119=null;
var title_f41_8_42120="Diagnosis and assessment of distal forearm fractures in children";
var content_f41_8_42120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and assessment of distal forearm fractures in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/8/42120/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/8/42120/contributors\">",
"     Jennifer Wang, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/8/42120/contributors\">",
"     Paula Schweich, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/8/42120/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/8/42120/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/8/42120/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/8/42120/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/8/42120/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2133687\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood forearm fractures are very common and typically occur after a fall on an outstretched hand. Early assessment should focus on identifying an open fracture, neurovascular compromise,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    associated injuries. The correct radiographic diagnosis at the time of injury is essential to proper care.",
"   </p>",
"   <p>",
"    Initial care of nondisplaced fractures consists of pain control, splinting, and measures aimed at reducing swelling. Nondisplaced distal forearm fractures other than complete fractures of the distal radius and ulna can then be referred for scheduled evaluation and further management by an orthopedist with pediatric expertise.",
"   </p>",
"   <p>",
"    Closed reduction is adequate treatment for many displaced forearm fractures and is often accomplished under sedation in the emergency department. Prompt orthopedic consultation is indicated for an important subset of these fractures to ensure the best outcome. Early orthopedic follow-up for potentially unstable fractures is essential to avoid long-term complications.",
"   </p>",
"   <p>",
"    The diagnosis of distal forearm fractures in children will be reviewed here. Management, fracture reduction, and casting of distal forearm fractures and the care of pediatric midshaft forearm fractures is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14569?source=see_link\">",
"       \"Initial management of distal forearm fractures in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31368?source=see_link\">",
"       \"Closed reduction and casting of distal forearm fractures in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11609?source=see_link\">",
"       \"Midshaft forearm fractures in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2133694\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forearm fractures are among the most common fractures in children, representing 40 to 50 percent of all childhood fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The distal third of the forearm, involving the radius",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ulna, is the most common location, accounting for about 75 percent of forearm fractures and 20 to 25 percent of all pediatric fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This high incidence can be explained by increased body mass in relation to an overall decreased bone mineral content during growth and development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/2\">",
"     2",
"    </a>",
"    ]. Most of these fractures will occur in children older than five years (peak age 10 to 14).",
"   </p>",
"   <p>",
"    The type of fracture varies by age (see",
"    <a class=\"local\" href=\"#H732412\">",
"     'Specific fractures'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Torus (buckle) and greenstick fractures occur most frequently in children younger than 10 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/1-3,5\">",
"       1-3,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Physeal separations (ie, fractures involving the growth plate) are more likely in patients older than 10 years.",
"     </li>",
"     <li>",
"      Complete fractures occur most commonly in adolescents in the midst of a growth spurt.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The location of fractures has also been noted to advance distally with an increase in age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2133701\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bones, muscles, ligaments, and tendons all work together in stabilizing the forearm. An interosseous membrane connects the radius and ulna, and the radius rotates around the ulna during supination and pronation of the forearm (",
"    <a class=\"graphic graphic_figure graphicRef78612 \" href=\"mobipreview.htm?23/13/23760\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef64025 \" href=\"mobipreview.htm?36/52/37698\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/1,3,5-7\">",
"     1,3,5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two areas where the radius and ulna meet, at the elbow and the wrist, are called the radioulnar articulations. The distal radial-ulnar joint (DRUJ) is stabilized by the triangular fibrocartilage complex (TFCC) (",
"    <a class=\"graphic graphic_figure graphicRef63443 \" href=\"mobipreview.htm?15/39/15986\">",
"     figure 3",
"    </a>",
"    ). Because of the interosseous membrane and these articulations, any disruption or distal fracture of one bone is usually accompanied by fracture to the other (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53716 \" href=\"mobipreview.htm?43/28/44480\">",
"     image 1",
"    </a>",
"    ) and may cause a tear in the TFCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/1,5,7\">",
"     1,5,7",
"    </a>",
"    ]. Thus, if only one bone appears to be fractured, the clinician should check the proximal and distal joints for injury to the other bone or the joint.",
"   </p>",
"   <p>",
"    The articular surface of both the radius and ulna is initially formed by the epiphysis, which is separated from the metaphysis by the physis or the cartilaginous growth plate (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"mobipreview.htm?26/18/26918\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/8\">",
"     8",
"    </a>",
"    ]. The physeal area, where longitudinal growth occurs, is firmly connected to the metaphysis by periosteum, and is difficult to separate by injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/5\">",
"     5",
"    </a>",
"    ]. The distal radial and ulnar physes account for 75 to 80 percent of forearm growth and almost half of upper extremity growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The porous nature of bones in children makes them more flexible than in adults, and thus, they are able to tolerate more bending and deformation before a fracture occurs. The periosteum around the bones in children is thick and strong and provides some mechanical stability after fracture. It is less readily torn than periosteum in adults, but when it is torn, a fracture becomes displaced. Rapid growth in children and abundant blood supply to the distal radius and ulna permits excellent healing and remodeling of forearm fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/5,6,10\">",
"     5,6,10",
"    </a>",
"    ]. The site of the injury and age of the child determine to what extent the deformity can remodel. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fractures near the growth plate remodel best in the plane of motion of the joint (flexion and extension).",
"     </li>",
"     <li>",
"      Small deformities from fractures without reduction or after incomplete reduction are corrected by growth of the physis and periosteum. Bone is resorbed on the convex side and formed on the concave side [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/5,10\">",
"       5,10",
"      </a>",
"      ]. Even malaligned physeal fractures may have excellent results over time, especially in young children (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70353 \" href=\"mobipreview.htm?11/6/11365\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H729812\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fall onto an outstretched hand (FOOSH) accounts for most forearm fractures in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/2,5,6,11,12\">",
"     2,5,6,11,12",
"    </a>",
"    ]. When falling, a child usually braces against the fall with the arm while extending the wrist. This arm position puts maximum axial force onto the forearm.",
"   </p>",
"   <p>",
"    Common high-risk activities include snowboarding, skateboarding, skimboarding, soccer goalkeeping, and horseback riding, although any activity that results in a fall with sufficient force can cause a distal forearm fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. Wrist guards have been shown to reduce the risk of fracture associated with snowboarding by 71 percent (95% CI: 13-90 percent) and are also recommended for inline skating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most forearm fractures result from falls on an outstretched arm and are not associated with multiple trauma. However, children who fall from a height greater than three times their standing height or sustain a distal forearm fracture as a result of another major trauma mechanism (",
"    <a class=\"graphic graphic_table graphicRef57293 \" href=\"mobipreview.htm?0/42/684\">",
"     table 1",
"    </a>",
"    ) are at risk for multiple trauma and warrant a complete physical examination and appropriate ancillary studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40119?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the initially stable child with blunt or penetrating injury\", section on 'Approach to blunt trauma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H8#H8\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Initial approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2136323\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child with a distal forearm fracture typically has a history of a fall on an outstretched hand with swelling, bony pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deformity of the distal forearm. (See",
"    <a class=\"local\" href=\"#H729812\">",
"     'Mechanism of injury'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2133715\">",
"     'Physical examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2136315\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of nondisplaced Salter I physeal (growth plate) fractures, plain radiographs of the forearm provide the diagnosis and should be obtained in children with bony tenderness or deformity. (See",
"    <a class=\"local\" href=\"#H730609\">",
"     'Radiographic assessment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732244\">",
"    <span class=\"h2\">",
"     Nondisplaced Salter I fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a nondisplaced Salter I physeal fracture of the distal radius or ulna (",
"    <a class=\"graphic graphic_figure graphicRef54582 \" href=\"mobipreview.htm?20/55/21361\">",
"     figure 5",
"    </a>",
"    ) usually have normal plain radiographs at initial presentation. However, bony tenderness is present over the physis in these patients and helps to differentiate this injury from a bruise or ligamentous strain or sprain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/18\">",
"     18",
"    </a>",
"    ]. Other radiographic findings that may be present soon after injury include a volar fat pad on the lateral view and epiphyseal widening on stress views. However, stress views are painful for the patient and usually unnecessary. Plain radiographs obtained at least seven days after injury will show healing bone in children with nondisplaced Salter I fractures and also provides a definitive diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H730609\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;When obtaining radiographs in the child with a suspected distal forearm fracture, the necessary films should be taken with minimal movement of the extremity. In patients with an obvious deformity or where high suspicion for a displaced fracture exists, analgesia (eg, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    0.1 to 0.15",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum single dose: 10 mg) and splinting is advisable prior to obtaining radiographs. Otherwise, a sling typically provides adequate support of nondisplaced fractures and allows for radiographs to be obtained more easily. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14569?source=see_link&amp;anchor=H21#H21\">",
"     \"Initial management of distal forearm fractures in children\", section on 'Analgesia and immobilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Radiographic views &ndash;",
"      </strong>",
"      All patients with suspected forearm fractures need a true anteroposterior (AP) and lateral view of the injured forearm that includes the wrist and distal humerus. A good AP view of the forearm should have minimal superimposition of the radial tuberosity (located at the proximal radius) over the proximal ulna, and similar radiographic density for the proximal and distal forearm (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60234 \" href=\"mobipreview.htm?30/1/30750\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef66832 \" href=\"mobipreview.htm?34/27/35249\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/19\">",
"       19",
"      </a>",
"      ]. A true lateral view of the forearm has superimposition of the radial head upon the ulnar coronoid process at the proximal end, superimposition of the radius and ulna at the distal end, a view of the soft tissues around both bones, and an elbow position that is 90 degrees of flexion (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65236 \" href=\"mobipreview.htm?25/32/26126\">",
"       image 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/19\">",
"       19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If there is concern about a wrist",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elbow fracture or dislocation based upon physical findings",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      initial forearm radiographs, the clinician should order separate wrist",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elbow radiographs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Classification",
"      </strong>",
"      &ndash; Additional radiographic findings and examples of each type of distal forearm fracture are described below by fracture type. (See",
"      <a class=\"local\" href=\"#H732412\">",
"       'Specific fractures'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      When describing and documenting a distal forearm fracture, the key elements include whether the fracture is open or closed; the presence of physeal involvement, angulation, displacement; and the presence of bony rotation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A closed fracture has no connection between the fracture site and any adjacent skin wounds whereas an open (compound) fracture has obvious bony protrusion through the skin or a contiguous open wound. (See",
"      <a class=\"local\" href=\"#H2133715\">",
"       'Physical examination'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Physeal fractures are commonly described by using the Salter-Harris classification system and indicating whether the radius, ulna, or both bones are injured (",
"      <a class=\"graphic graphic_figure graphicRef54582 \" href=\"mobipreview.htm?20/55/21361\">",
"       figure 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20104?source=see_link&amp;anchor=H15#H15\">",
"       \"General principles of fracture management: Fracture patterns and description in children\", section on 'Physeal fracture description'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Distal metaphyseal fractures of the radius",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ulna are described as torus (or buckle), greenstick, or complete fractures based upon the radiographic findings. (See",
"      <a class=\"local\" href=\"#H732412\">",
"       'Specific fractures'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Fracture displacement is defined on the lateral view by the displacement of the distal fragment (dorsal or volar).",
"     </li>",
"     <li>",
"      The angulation is described by the direction of the apex of the deformity (dorsal or volar) and the degree of angulation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67542 \" href=\"mobipreview.htm?26/59/27583\">",
"       image 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69020 \" href=\"mobipreview.htm?0/61/978\">",
"       image 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Most displacements are also rotated. Rotation of the fracture is judged by a break in the smooth curve of the bone, or change in the diameter of the bone or width of the cortex of the two fragments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If there is displacement or angulation on the AP view, descriptions are similar, but in the radial or ulnar direction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43941?source=see_link&amp;anchor=H3#H3\">",
"       \"General principles of fracture management: Bone healing and fracture description\", section on 'Fracture description'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20104?source=see_link&amp;anchor=H2#H2\">",
"       \"General principles of fracture management: Fracture patterns and description in children\", section on 'Fracture description in children'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732412\">",
"    <span class=\"h2\">",
"     Specific fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different types of fractures may be seen in children with distal forearm injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H730724\">",
"    <span class=\"h3\">",
"     Physeal fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physeal separations or fractures occur across the growth plate of the bone. Until fused, the physes (growth plates) are a site of relative weakness and are therefore prone to fracture. When there is a fracture at the physis, it usually occurs between the calcified and uncalcified layers of cartilage corresponding to the hypertrophic zone (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"mobipreview.htm?26/18/26918\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20104?source=see_link&amp;anchor=H8#H8\">",
"     \"General principles of fracture management: Fracture patterns and description in children\", section on 'Physeal (growth plate)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physeal injuries of the distal radius are the most common sites of growth plate injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/20\">",
"     20",
"    </a>",
"    ]. Ulnar physeal injuries are much less common and typically occur in conjunction with radial fractures. When there is injury to the radial or ulnar physis, circulation typically remains unaffected, and growth is usually not disturbed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Salter-Harris system is the most commonly used classification scheme for describing these fractures (",
"    <a class=\"graphic graphic_figure graphicRef54582 \" href=\"mobipreview.htm?20/55/21361\">",
"     figure 5",
"    </a>",
"    ). The Salter-Harris levels progress from type I to type V. Salter-Harris types I and II comprise the majority of distal physeal forearm injuries (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79636 \" href=\"mobipreview.htm?13/48/14080\">",
"     image 7",
"    </a>",
"    ). The higher levels (type III or higher) correspond to an increased need for surgical intervention and a greater risk for growth arrest after fracture healing (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76017 \" href=\"mobipreview.htm?31/58/32672\">",
"     image 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61682 \" href=\"mobipreview.htm?31/18/32035\">",
"     image 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20104?source=see_link&amp;anchor=H15#H15\">",
"     \"General principles of fracture management: Fracture patterns and description in children\", section on 'Physeal fracture description'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14569?source=see_link&amp;anchor=H24#H24\">",
"     \"Initial management of distal forearm fractures in children\", section on 'Physeal fracture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In infants and very young children, who have minimal or no ossification of the epiphysis, the fracture may be difficult to appreciate on plain radiographs. In this situation, it may be necessary to get multiple radiographic views, comparison views of the other side, or rarely, other imaging (eg, computed tomography or magnetic resonance imaging). Discussion with a pediatric radiologist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an orthopedic surgeon is advisable to guide the diagnostic approach in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732624\">",
"    <span class=\"h4\">",
"     Bone bruise",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of children with presumed nondisplaced Salter-Harris distal forearm fractures may have normal acute and follow-up radiographs, and if obtained, normal computed tomography of the forearm, but exhibit persistent bony pain despite immobilization for four to five weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/21\">",
"     21",
"    </a>",
"    ]. Magnetic resonance imaging with fat suppression may detect microfractures, termed &ldquo;bone bruises&rdquo; in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H730731\">",
"    <span class=\"h3\">",
"     Torus (buckle) fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A buckle fracture occurs at the distal metaphysis, where the bone is most porous, usually in younger children (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67725 \" href=\"mobipreview.htm?38/52/39744\">",
"     image 10",
"    </a>",
"    ). This injury is caused by buckling of the cortex due to compression failure. On clinical presentation there is tenderness over the bone, but other symptoms (eg, swelling, decreased range of motion) may be minimal and not highly suggestive of a fracture.",
"   </p>",
"   <p>",
"    The most common buckle fracture involves the dorsal surface of the distal radius (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67725 \" href=\"mobipreview.htm?38/52/39744\">",
"     image 10",
"    </a>",
"    ), but may involve both bones (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81117 \" href=\"mobipreview.htm?26/56/27520\">",
"     image 11",
"    </a>",
"    ). It is important to look at all views for a disruption of the smooth contour of the metaphysis, since the buckle may be very subtle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58284 \" href=\"mobipreview.htm?17/60/18368\">",
"     image 12",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H730738\">",
"    <span class=\"h3\">",
"     Greenstick fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A greenstick fracture is a complete fracture of the tension side of the cortex of the radius or ulna and a plastic deformation, or buckling, of the compression side. On radiograph, the fracture will be seen as a complete disruption on one side of the bone with a buckle on the opposite side (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80128 \" href=\"mobipreview.htm?29/44/30400\">",
"     image 13",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69866 \" href=\"mobipreview.htm?31/45/32478\">",
"     image 14",
"    </a>",
"    ). Commonly a complete or buckle fracture of one bone accompanies a greenstick fracture of the other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H730745\">",
"    <span class=\"h3\">",
"     Complete fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fracture is considered complete when it passes through both cortices of the distal metaphysis (distal third) of the radius",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ulna, often with displacement (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67542 \" href=\"mobipreview.htm?26/59/27583\">",
"     image 5",
"    </a>",
"    ). They are usually caused by a high energy fall onto the hand with the wrist in a pronated and extended position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/1,22\">",
"     1,22",
"    </a>",
"    ]. These fractures do not affect the growth plate. If the fracture extends completely through the distal radius and ulna, the extension of the hand during these falls gives a characteristic deformity to these fractures sometimes referred to as the dinner fork deformity (",
"    <a class=\"graphic graphic_figure graphicRef66531 \" href=\"mobipreview.htm?8/5/8273\">",
"     figure 6",
"    </a>",
"    ). A fall on a flexed hand results in the opposite deformity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69020 \" href=\"mobipreview.htm?0/61/978\">",
"     image 6",
"    </a>",
"    ). Slight variations in mechanism can produce different injuries.",
"   </p>",
"   <p>",
"    Because children's bones are more flexible than those of adults, these pediatric fractures are rarely comminuted. The bony segments assume the position that is dictated by the muscle forces exerted on the bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. In particular, the brachioradialis muscle exerts a volar deforming force with the hand in pronation (",
"    <a class=\"graphic graphic_figure graphicRef55089 \" href=\"mobipreview.htm?14/46/15072\">",
"     figure 7",
"    </a>",
"    ) and with total bony displacement, shortening of the forearm with overlapping fracture fragments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H730752\">",
"    <span class=\"h3\">",
"     Ulnar styloid fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;This fracture a distal avulsion fracture at the site of the triangular fibrocartilage complex (TFCC) or the ulnocarpal ligament attachment (",
"    <a class=\"graphic graphic_figure graphicRef63443 \" href=\"mobipreview.htm?15/39/15986\">",
"     figure 3",
"    </a>",
"    ). It typically occurs in conjunction with a radial fracture. In most instances, fracture care is determined by the type of radial fracture with one exception; a displaced fracture that occurs at the base of the ulnar styloid may indicate a disruption of the TFCC and may warrant surgical intervention (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57244 \" href=\"mobipreview.htm?8/0/8194\">",
"     image 15",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H730759\">",
"    <span class=\"h3\">",
"     Galeazzi fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Galeazzi fracture is a fracture of the distal third of the radius along with dislocation of the distal radioulnar joint or ulnar physeal separation (Galeazzi-equivalent fracture) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54885 \" href=\"mobipreview.htm?35/49/36627\">",
"     image 16",
"    </a>",
"    ). This injury typically occurs after a fall onto an outstretched hand, and is very rare in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H730766\">",
"    <span class=\"h2\">",
"     Associated fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forearm fractures are associated with supracondylar fractures in up to 5 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/25\">",
"     25",
"    </a>",
"    ]. The combination of supracondylar and forearm fractures is termed the \"floating elbow\" and increases the possibility of compartment syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/26\">",
"     26",
"    </a>",
"    ]. For this reason, anteroposterior and lateral radiographs of the forearm should include the distal humerus in all patients with forearm fractures.",
"   </p>",
"   <p>",
"    Proximal humerus, clavicle, wrist, and hand fractures may also occur with a distal forearm fracture. Deformity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bony tenderness during physical examination dictate appropriate radiographic assessment of these areas in selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2133715\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with distal forearm fractures usually have a history of a fall on an outstretched arm with swelling, bony pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deformity accompanied by limited range of motion of the hand, wrist, and forearm. In most instances, plain radiographs provide the diagnosis. (See",
"    <a class=\"local\" href=\"#H2136323\">",
"     'Clinical features'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2136315\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who have sustained major trauma (",
"    <a class=\"graphic graphic_table graphicRef57293 \" href=\"mobipreview.htm?0/42/684\">",
"     table 1",
"    </a>",
"    ) are at risk for multiple trauma and warrant a complete physical examination and appropriate ancillary studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40119?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the initially stable child with blunt or penetrating injury\", section on 'Approach to blunt trauma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H8#H8\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Initial approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once other injuries are excluded, the examination can focus on the forearm. In a patient with severe pain, analgesia (eg, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    0.1 to 0.15",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum single dose: 10 mg) prior to examination is usually necessary to facilitate the child's cooperation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Inspection and palpation",
"      </strong>",
"      &ndash; The clinician should examine the arm from the clavicle down, noting the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Obvious deformity",
"      </strong>",
"      &ndash; The arm may be difficult to examine if there is severe deformity or if the child is already splinted. A dorsal deformity may represent a physeal fracture (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79636 \" href=\"mobipreview.htm?13/48/14080\">",
"       image 7",
"      </a>",
"      ) or a displaced metaphyseal or diaphyseal fracture resulting from a fall on an extended hand (eg, \"dinner fork\" or \"bayonet\" deformity) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67542 \" href=\"mobipreview.htm?26/59/27583\">",
"       image 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef66531 \" href=\"mobipreview.htm?8/5/8273\">",
"       figure 6",
"      </a>",
"      ). A fall on a flexed hand results in a volar deformity (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69020 \" href=\"mobipreview.htm?0/61/978\">",
"       image 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Neurovascular status",
"      </strong>",
"      &ndash; A complete neurovascular evaluation includes an assessment of radial and brachial pulses and the motor and sensory function of the median, radial, and ulnar nerves (",
"      <a class=\"graphic graphic_table graphicRef53902 \" href=\"mobipreview.htm?24/11/24763\">",
"       table 2",
"      </a>",
"      ). Patients with a normal initial neurovascular examination warrant regular repeated evaluation, especially immediately following fracture manipulation or movement of the affected extremity.",
"      <br/>",
"      <br/>",
"      Although nerve injuries may rarely be associated with long-term sequelae, the majority are neurapraxias, such as, temporary loss of nerve function (especially motor function) without anatomical nerve disruption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Blood vessel injuries are rare with distal forearm fractures, but occur more commonly with supracondylar fractures that may accompany a forearm fracture. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25961?source=see_link&amp;anchor=H6#H6\">",
"       \"Evaluation and management of supracondylar fractures in children\", section on 'Vascular anatomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Open wounds",
"      </strong>",
"      &ndash; Careful inspection of the entire forearm is necessary to detect an open fracture. Signs of an open fracture may be subtle because the bone often pokes through the skin and then retracts, leaving only a small puncture wound (",
"      <a class=\"graphic graphic_picture graphicRef63726 \" href=\"mobipreview.htm?38/62/39906\">",
"       picture 2",
"      </a>",
"      ). In contrast to an abrasion or puncture from the outside of the arm overlying the fracture site, a small puncture resulting from an open fracture tends to ooze blood. If no active bleeding is noted, the clinician should attempt to express blood through the wound site as circumferential pressure will bring blood to the surface from a small open fracture.",
"     </li>",
"     <li>",
"      <strong>",
"       Presence and location of tenderness or swelling",
"      </strong>",
"      &ndash; When there is no obvious deformity, tenderness over the distal radius or ulna",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      decreased grip strength indicates an increased likelihood of a fracture being present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/27\">",
"       27",
"      </a>",
"      ]. In particular, nondisplaced Salter I physeal fractures may be very subtle on examination because of a relatively intact range of motion (",
"      <a class=\"graphic graphic_figure graphicRef54582 \" href=\"mobipreview.htm?20/55/21361\">",
"       figure 5",
"      </a>",
"      ). However, the clinician will find localized tenderness over the distal physis in these patients. (See",
"      <a class=\"local\" href=\"#H732244\">",
"       'Nondisplaced Salter I fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Injury to the joint above and below the injured area",
"      </strong>",
"      &ndash; Careful evaluation of the elbow and wrist is warranted in patients with a suspected distal forearm fracture because of the occasional association of forearm fractures with supracondylar elbow and scaphoid wrist fractures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/22,25,26,28\">",
"       22,25,26,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Range of motion of all joints in the affected arm",
"      </strong>",
"      &ndash; The clinician should not perform passive range of motion in patients with a suspected fracture. The patient should perform active range of motion of all joints that can safely be moved without exacerbating the injury (eg, supination, pronation, flexion, and extension or the elbow; abduction, adduction, internal and external rotation of the shoulder).",
"     </li>",
"     <li>",
"      <strong>",
"       Associated injuries &ndash;",
"      </strong>",
"      When there is an isolated fracture evident in the radius or ulna, the clinician should check the joints above and below the fracture site for other injuries. Supracondylar fractures occasionally complicate forearm fractures in children. Patients with a forearm fracture and a supracondylar elbow fracture (\"floating elbow\") are at increased risk of an acute compartment syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Thus, the elbow warrants careful inspection for swelling",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deformity and palpation for bony tenderness. Forearm radiographs should routinely include the distal humerus in children with forearm fractures. (See",
"      <a class=\"local\" href=\"#H730609\">",
"       'Radiographic assessment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In addition, hand, wrist, shoulder, and clavicle injuries may occur and any deformity, swelling, or bony tenderness in these areas warrants radiographic investigation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Motor examination &ndash;",
"      </strong>",
"      Assessment of neurologic status is particularly important as nerve deficits, especially median nerve injury, are found in up to 8 percent of patients with deformed distal forearm fractures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42120/abstract/7\">",
"       7",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The following tests establish motor function of the major nerves while minimizing extremity movements:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      \"OK\" sign (alternatively, ask the patient to pinch your hand): anterior interosseous nerve (branch of median nerve) and posterior interosseous nerve (branch of radial nerve) (",
"      <a class=\"graphic graphic_picture graphicRef52203 \" href=\"mobipreview.htm?25/33/26142\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Finger spread against resistance or holding a piece of paper firmly between the middle and ring fingers: ulnar nerve (",
"      <a class=\"graphic graphic_figure graphicRef75179 \" href=\"mobipreview.htm?23/56/24463\">",
"       figure 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thumb's up sign: radial nerve (",
"      <a class=\"graphic graphic_figure graphicRef51625 \" href=\"mobipreview.htm?14/7/14463\">",
"       figure 9",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Sensory examination &ndash;",
"      </strong>",
"      The clinician should perform testing using light touch. The patient&rsquo;s thumb web space and pointer and pinky fingers are lightly stroked on the affected and unaffected sides, and the patient is asked if there is a difference in sensation.",
"      <br/>",
"      <br/>",
"      In children over five years of age, two point is an alternative means to assess sensory function. Using a folded paper clip, the clinician assesses the ability to recognize two points, 5 mm apart, applied simultaneously to the skin as distinct from a single point in the following areas on the hand:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Dorsal web space of the thumb",
"      </strong>",
"      &ndash; Innervated by the radial nerve",
"     </li>",
"     <li>",
"      <strong>",
"       Index (pointer) finger",
"      </strong>",
"      &ndash; Innervated by the median nerve",
"     </li>",
"     <li>",
"      <strong>",
"       Pinky (or little finger)",
"      </strong>",
"      &ndash; Innervated by the ulnar nerve",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/20/7491?source=see_link\">",
"       \"Patient information: Common wrist injuries (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2135672\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distal forearm fractures are among the most common fractures in children. The type and location of fracture varies by age with torus (buckle) and greenstick fractures most frequently occurring in children under 10 years of age, physeal (growth plate) fractures more likely in patients over 10 years of age, and complete fractures most common in adolescents. Older children tend to have more distal fracture location when compared to younger children. (See",
"      <a class=\"local\" href=\"#H2133694\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The child with a distal forearm fracture typically has a history of a fall on an outstretched hand with swelling, bony pain, and deformity. With the exception of nondisplaced Salter I physeal (growth plate) fractures or physeal microfractures (or &ldquo;bone bruises&rdquo;), plain radiographs of the forearm (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60234 \" href=\"mobipreview.htm?30/1/30750\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef66832 \" href=\"mobipreview.htm?34/27/35249\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65236 \" href=\"mobipreview.htm?25/32/26126\">",
"       image 4",
"      </a>",
"      ) provide the diagnosis. (See",
"      <a class=\"local\" href=\"#H2136323\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H730609\">",
"       'Radiographic assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with a nondisplaced Salter I physeal fracture of the distal radius or ulna (",
"      <a class=\"graphic graphic_figure graphicRef54582 \" href=\"mobipreview.htm?20/55/21361\">",
"       figure 5",
"      </a>",
"      ) usually have normal anteroposterior and lateral plain radiographs at initial presentation. However, bony tenderness is present over the physis in these patients, and this finding helps to differentiate this injury from a bruise or ligamentous strain or sprain. Plain radiographs obtained at least seven days after injury usually will show healing bone in children with nondisplaced Salter I fractures and also provides a definitive diagnosis. However, microfractures or a &ldquo;bone bruise&rdquo; of the physis may only be apparent upon magnetic resonance imaging with fat suppression. (See",
"      <a class=\"local\" href=\"#H732244\">",
"       'Nondisplaced Salter I fracture'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H732624\">",
"       'Bone bruise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with an obvious deformity or high suspicion for a displaced fracture, analgesia (eg, intravenous",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      0.1",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      maximum single dose: 10 mg) and splinting is advisable prior to obtaining radiographs. Otherwise, a sling typically provides adequate support of nondisplaced fractures and allows for radiographs to be obtained more easily. Adequate analgesia also facilitates a better assessment of sensory and motor function during physical examination. (See",
"      <a class=\"local\" href=\"#H730609\">",
"       'Radiographic assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2133715\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific types of distal forearm fractures include physeal fractures (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79636 \" href=\"mobipreview.htm?13/48/14080\">",
"       image 7",
"      </a>",
"      ), torus (buckle) fractures (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67725 \" href=\"mobipreview.htm?38/52/39744\">",
"       image 10",
"      </a>",
"      ), greenstick fractures (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69866 \" href=\"mobipreview.htm?31/45/32478\">",
"       image 14",
"      </a>",
"      ), complete fractures (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67542 \" href=\"mobipreview.htm?26/59/27583\">",
"       image 5",
"      </a>",
"      ), and ulnar styloid fractures (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57244 \" href=\"mobipreview.htm?8/0/8194\">",
"       image 15",
"      </a>",
"      ). Forearm fractures are associated with supracondylar fractures in up to 5 percent of cases. The combination of supracondylar and forearm fractures is termed the \"floating elbow\" and increases the possibility of compartment syndrome. For this reason, anteroposterior and lateral radiographs of the forearm should include the distal humerus in all patients with forearm fractures. (See",
"      <a class=\"local\" href=\"#H732412\">",
"       'Specific fractures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H730766\">",
"       'Associated fractures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical examination of children with distal forearm fractures should focus on the presence of open wounds near the fracture site, careful neurovascular assessment, and identification of any injury to the wrist or elbow joints. Because of the anatomy of the interosseous membrane and the radioulnar articulations, any disruption or distal fracture of one bone is usually accompanied by fracture to the other (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53716 \" href=\"mobipreview.htm?43/28/44480\">",
"       image 1",
"      </a>",
"      ) and may cause a tear in the TFCC (",
"      <a class=\"graphic graphic_figure graphicRef63443 \" href=\"mobipreview.htm?15/39/15986\">",
"       figure 3",
"      </a>",
"      ). Thus, if only one bone appears to be fractured, the clinician should check the proximal and distal joints for injury to the other bone or the joint. (See",
"      <a class=\"local\" href=\"#H2133701\">",
"       'Pertinent anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2133715\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of distal forearm fractures in children is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14569?source=see_link\">",
"       \"Initial management of distal forearm fractures in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31368?source=see_link\">",
"       \"Closed reduction and casting of distal forearm fractures in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Price CT, Flynn JM. Management of fractures. In: Lovell and Winter's Pediatric Orthopaedics, 6th, Morrissey RT, Weinstein SL.  (Eds), Lippincott, Philadelphia 2006. p.1463.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/2\">",
"      Rodr&iacute;guez-Merch&aacute;n EC. Pediatric fractures of the forearm. Clin Orthop Relat Res 2005; :65.",
"     </a>",
"    </li>",
"    <li>",
"     Pizzutillo PD. Pediatric orthopaedics. In: Essentials of Musculoskeletal Care, 3rd, Griffin YL.  (Ed), American Academy of Orthopaedic Surgeons, Rosemont 2005. p.863.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/4\">",
"      Abraham A, Handoll HH, Khan T. Interventions for treating wrist fractures in children. Cochrane Database Syst Rev 2008; :CD004576.",
"     </a>",
"    </li>",
"    <li>",
"     Rang M, Stearns P, Chambers H. Radius and Ulna. In: Rang's Children's Fractures, 3rd, Rang M, Pring ME, Wenger DR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/6\">",
"      Noonan KJ, Price CT. Forearm and distal radius fractures in children. J Am Acad Orthop Surg 1998; 6:146.",
"     </a>",
"    </li>",
"    <li>",
"     Waters PM, Bae DS. Fractures of the distal radius and ulna. In: Rockwood and Wilkin's Fractures in Children, 7th, Beaty JH, Kasser JR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.292.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/8\">",
"      Slongo T, Audig&eacute; L, Schlickewei W, et al. Development and validation of the AO pediatric comprehensive classification of long bone fractures by the Pediatric Expert Group of the AO Foundation in collaboration with AO Clinical Investigation and Documentation and the International Association for Pediatric Traumatology. J Pediatr Orthop 2006; 26:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/9\">",
"      Ogden JA, Beall JK, Conlogue GJ, Light TR. Radiology of postnatal skeletal development. IV. Distal radius and ulna. Skeletal Radiol 1981; 6:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/10\">",
"      Berg EE. Pediatric distal double bone forearm fracture remodeling. Orthop Nurs 2005; 24:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/11\">",
"      Do TT, Strub WM, Foad SL, et al. Reduction versus remodeling in pediatric distal forearm fractures: a preliminary cost analysis. J Pediatr Orthop B 2003; 12:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/12\">",
"      Merriman D, Carmichael K, Battle SC. Skimboard injuries. J Trauma 2008; 65:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/13\">",
"      Matsumoto K, Sumi H, Sumi Y, Shimizu K. Wrist fractures from snowboarding: a prospective study for 3 seasons from 1998 to 2001. Clin J Sport Med 2004; 14:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/14\">",
"      Kyle SB, Nance ML, Rutherford GW Jr, Winston FK. Skateboard-associated injuries: participation-based estimates and injury characteristics. J Trauma 2002; 53:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/15\">",
"      Boyd KT, Brownson P, Hunter JB. Distal radial fractures in young goalkeepers: a case for an appropriately sized soccer ball. Br J Sports Med 2001; 35:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/16\">",
"      Kocher MS, Waters PM, Micheli LJ. Upper extremity injuries in the paediatric athlete. Sports Med 2000; 30:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/17\">",
"      Russell K, Hagel B, Francescutti LH. The effect of wrist guards on wrist and arm injuries among snowboarders: a systematic review. Clin J Sport Med 2007; 17:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/18\">",
"      Musharafieh RS, Macari G. Salter-Harris I fractures of the distal radius misdiagnosed as wrist sprain. J Emerg Med 2000; 19:265.",
"     </a>",
"    </li>",
"    <li>",
"     Forearm. In: Merrill's Atlas of Radiographic Positions and Radiologic Procedures, Ballinger PW, Frank ED.  (Eds), Mosby, St. Louis 2003. Vol 10th, p.140.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/20\">",
"      Carson S, Woolridge DP, Colletti J, Kilgore K. Pediatric upper extremity injuries. Pediatr Clin North Am 2006; 53:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/21\">",
"      Sferopoulos NK. Bone bruising of the distal forearm and wrist in children. Injury 2009; 40:631.",
"     </a>",
"    </li>",
"    <li>",
"     Flynn JM, Skaggs DL, Waters PM. Staying out of trouble while treating hand, wrist, and forearm injury. In: Staying Out of Trouble in Pediatric Orthopaedics, Skaggs DL, Flynn JM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.85.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/23\">",
"      Abid A, Accadbled F, Kany J, et al. Ulnar styloid fracture in children: a retrospective study of 46 cases. J Pediatr Orthop B 2008; 17:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/24\">",
"      Kim JK, Koh YD, Do NH. Should an ulnar styloid fracture be fixed following volar plate fixation of a distal radial fracture? J Bone Joint Surg Am 2010; 92:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/25\">",
"      Roposch A, Reis M, Molina M, et al. Supracondylar fractures of the humerus associated with ipsilateral forearm fractures in children: a report of forty-seven cases. J Pediatr Orthop 2001; 21:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/26\">",
"      Templeton PA, Graham HK. The 'floating elbow' in children. Simultaneous supracondylar fractures of the humerus and of the forearm in the same upper limb. J Bone Joint Surg Br 1995; 77:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/27\">",
"      Pershad J, Monroe K, King W, et al. Can clinical parameters predict fractures in acute pediatric wrist injuries? Acad Emerg Med 2000; 7:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42120/abstract/28\">",
"      Hove LM. Simultaneous scaphoid and distal radial fractures. J Hand Surg Br 1994; 19:384.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16712 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-543E46505B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42120=[""].join("\n");
var outline_f41_8_42120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2135672\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2133687\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2133694\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2133701\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H729812\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2136323\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2136315\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H732244\">",
"      Nondisplaced Salter I fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H730609\">",
"      RADIOGRAPHIC ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H732412\">",
"      Specific fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H730724\">",
"      - Physeal fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H732624\">",
"      Bone bruise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H730731\">",
"      - Torus (buckle) fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H730738\">",
"      - Greenstick fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H730745\">",
"      - Complete fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H730752\">",
"      - Ulnar styloid fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H730759\">",
"      - Galeazzi fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H730766\">",
"      Associated fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2133715\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2135672\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/16712\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16712|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/28/44480\" title=\"diagnostic image 1\">",
"      Forearm fx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/6/11365\" title=\"diagnostic image 2\">",
"      Displaced fx remodeling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/1/30750\" title=\"diagnostic image 3\">",
"      AP forearm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/32/26126\" title=\"diagnostic image 4\">",
"      Lateral forearm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?26/59/27583\" title=\"diagnostic image 5\">",
"      Colles fracture child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/61/978\" title=\"diagnostic image 6\">",
"      Volar displaced fx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/48/14080\" title=\"diagnostic image 7\">",
"      Displaced Salter II fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/58/32672\" title=\"diagnostic image 8\">",
"      Salter III radius fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/18/32035\" title=\"diagnostic image 9\">",
"      Salter IV radius fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/52/39744\" title=\"diagnostic image 10\">",
"      Buckle fracture radius",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?26/56/27520\" title=\"diagnostic image 11\">",
"      Buckle fracture radius ulna",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/60/18368\" title=\"diagnostic image 12\">",
"      Subtle buckle fx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/44/30400\" title=\"diagnostic image 13\">",
"      Greenstick fracture radius",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/45/32478\" title=\"diagnostic image 14\">",
"      Greenstick fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/0/8194\" title=\"diagnostic image 15\">",
"      Ulnar styloid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/49/36627\" title=\"diagnostic image 16\">",
"      Pediatric Galeazzi fracture and dislocation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16712|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/13/23760\" title=\"figure 1\">",
"      Forearm anatomy 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/52/37698\" title=\"figure 2\">",
"      Radius ulna anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/39/15986\" title=\"figure 3\">",
"      Anatomy of the triangular fibrocartilage complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/18/26918\" title=\"figure 4\">",
"      Growth plate anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/55/21361\" title=\"figure 5\">",
"      Salter-Harris classification system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/5/8273\" title=\"figure 6\">",
"      Dorsal displaced fx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/46/15072\" title=\"figure 7\">",
"      Muscle displacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/56/24463\" title=\"figure 8\">",
"      Ulnar nerve test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/7/14463\" title=\"figure 9\">",
"      Thumbs up sign",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16712|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/27/35249\" title=\"picture 1\">",
"      AP forearm technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/62/39906\" title=\"picture 2\">",
"      Open fx forearm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/33/26142\" title=\"picture 3\">",
"      OK sign to assess median nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16712|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/42/684\" title=\"table 1\">",
"      High risk trauma mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/11/24763\" title=\"table 2\">",
"      Elbow sensation strength",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40119?source=related_link\">",
"      Approach to the initially stable child with blunt or penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31368?source=related_link\">",
"      Closed reduction and casting of distal forearm fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25961?source=related_link\">",
"      Evaluation and management of supracondylar fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43941?source=related_link\">",
"      General principles of fracture management: Bone healing and fracture description",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20104?source=related_link\">",
"      General principles of fracture management: Fracture patterns and description in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14569?source=related_link\">",
"      Initial management of distal forearm fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11609?source=related_link\">",
"      Midshaft forearm fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/20/7491?source=related_link\">",
"      Patient information: Common wrist injuries (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_8_42121="Pathogenesis of inflammatory myopathies";
var content_f41_8_42121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of inflammatory myopathies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/8/42121/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/8/42121/contributors\">",
"     Steven A Greenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/8/42121/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/8/42121/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/8/42121/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/8/42121/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/8/42121/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/8/42121/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18308386\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inflammatory myopathies are a group of disorders sharing the common feature of immune-mediated muscle injury. Clinical and histopathological distinctions between these conditions suggest that different pathogenic processes underlie each of the inflammatory myopathies. The most common of these disorders include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dermatomyositis",
"     </li>",
"     <li>",
"      Overlap syndromes (with another systemic rheumatic disease)",
"     </li>",
"     <li>",
"      Inclusion body myositis",
"     </li>",
"     <li>",
"      Polymyositis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither environmental factors nor infectious causes have known roles in these disorders.",
"   </p>",
"   <p>",
"    Other subtypes of inflammatory myopathy include necrotizing myopathy, eosinophilic myositis, and granulomatous myositis. Many patients with inflammatory myopathies cannot be assigned to any category and may be classified as having non-specific myositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The precise mechanisms leading to tissue injury in the inflammatory myopathies are poorly defined in most cases.",
"   </p>",
"   <p>",
"    The pathogenesis of the inflammatory myopathies, including dermatomyositis, inclusion body myositis, polymyositis, and necrotizing myopathy, is reviewed here. The clinical manifestations, diagnosis, and treatment of the inflammatory myopathies, the pathogenesis of juvenile dermatomyositis and polymyositis, and overlap syndromes associated with systemic rheumatic diseases are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13065?source=see_link\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15735?source=see_link\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/30/28133?source=see_link\">",
"     \"Treatment and prognosis of inclusion body myositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42968?source=see_link\">",
"     \"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18308393\">",
"    <span class=\"h1\">",
"     DERMATOMYOSITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise pathogenic mechanisms responsible for DM are unknown, and several different models have been proposed. One model, which the author favors, focuses on a central role for type 1 interferons in causing capillary, myofiber, and keratinocyte injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. An alternative view centers on the hypothesis that DM myofiber injury results from an antibody and complement-mediated microangiopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. DM in some patients is a paraneoplastic syndrome, associated with cancer, through unknown mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38566?source=see_link\">",
"     \"Malignancy in dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is well-established that DM muscle pathology is characterized by injury to both capillaries and myofibers. Perifascicular myofibers, located at the boundaries between fascicles and perimysial connective tissue, appear preferentially targeted. Central questions regarding the pathogenesis of DM are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Through what mechanism are capillaries injured?",
"     </li>",
"     <li>",
"      What is the relationship of the capillary injury to perimysial perifascicular myofiber injury?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H206354349\">",
"    <span class=\"h2\">",
"     Type 1 interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is substantial evidence that the induction of type 1 interferon-inducible gene products, both transcripts and proteins, is highly and specifically associated with DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/3,4,8\">",
"     3,4,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD4-positive cells &mdash; Inflammatory cells highly expressing the CD4 protein are abundant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. Although the nature of these CD4+ cells is not fully understood, many of these are plasmacytoid dendritic cells (pDCs) (",
"      <a class=\"graphic graphic_picture graphicRef53554 \" href=\"mobipreview.htm?9/50/10023\">",
"       picture 1",
"      </a>",
"      ), immune cells that are proficient at producing type 1 interferons (interferons alpha and beta, and possibly omega) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Such pDCs have been called &ldquo;natural interferon-producing cells&rdquo; because of their capacity to produce over 1000 times the amount of interferon-alpha than other cell types [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type 1 interferon-inducible proteins &mdash; Among patients with DM, the type 1 interferon-inducible protein, myxovirus-resistance protein A (MxA), has been observed to be densely expressed on perifascicular myofibers and sometimes on all myofibers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/11\">",
"       11",
"      </a>",
"      ]. MxA expression in myofibers is specific to DM, and MxA is also overexpressed in the epidermis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/14\">",
"       14",
"      </a>",
"      ]. Other proteins that are overexpressed in DM myofibers can also be present in myofibers in other myopathies. These include neonatal myosin heavy chains, neural cell adhesion molecule, histidyl tRNA synthetase (Jo-1), STAT-1, MHC-class I, and alpha-B crystallin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/15-19\">",
"       15-19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-IFIH1 antibody &mdash; An antibody that recognizes the type 1 interferon-induced helicase C domain-containing protein 1 (IFIH1, also called MDA-5) appears to exhibit good sensitivity and very high specificity for amyopathic DM. Among 262 patients in Japan with a range of connective tissue diseases, anti-IFIH1 antibodies demonstrated 69 percent sensitivity and over 99 percent specificity for amyopathic dermatomyositis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/20\">",
"       20",
"      </a>",
"      ]. Significant anti-IFIH1 autoantibody levels were present in 22 of 32 patients with amyopathic dermatomyositis but were present only in 1 of 35 patients with classic DM and in 0 of 53 patients with PM.",
"      <br/>",
"      <br/>",
"      An association of anti-IFIH1 antibodies with amyopathic and clinically amyopathic DM (those without weakness but with some muscle enzyme elevation) was also seen in one series of 77 patients with DM in the US; however, the sensitivity and specificity for amyopathic disease were both lower than those in the Japanese study population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/21\">",
"       21",
"      </a>",
"      ]. This antibody is, thus, a potential biomarker of amyopathic DM, although additional research is needed to establish how it relates to disease pathogenesis, and further study in other populations and in larger numbers of patients will be needed to determine its clinical utility.",
"     </li>",
"     <li>",
"      Gene expression profiling &mdash; Large-scale profiling, using microarrays, of mRNA transcripts abundant in inflammatory myopathy muscle has shown very high levels of both immunoglobulin transcripts and many transcripts that are known to be induced by type 1 interferons (IFN), IFN alpha and IFN beta [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/11,22-24\">",
"       11,22-24",
"      </a>",
"      ]. Type 1 IFN-inducible transcripts are the single most upregulated pathway present in DM muscle, with approximately 90 percent of the highest differentially upregulated transcripts belonging within this class. The degree of upregulation of most of these transcripts is unique to DM among inflammatory myopathies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/8\">",
"       8",
"      </a>",
"      ]. For example, the transcript for ISG15 (IFN-stimulated gene 15) was 570-fold higher, and MxA was 280-fold higher in DM than in normal muscle, compared with approximately fivefold higher levels compared with normal for each in PM and IBM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Upregulation of these type 1 IFN-inducible transcripts is also present in blood, but this finding is not unique to DM. Such upregulation is present in both DM and PM and correlates with disease activity in individual patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tubuloreticular inclusions &mdash; Tubuloreticular inclusions that are identical to what have been called &ldquo;lupus inclusions&rdquo; are biomarkers for type 1 interferon exposure; a variety of cultured cell types, including human endothelial cells, develop tubuloreticular inclusions in vitro when exposed to interferon alpha or beta but not to type 2 interferon gamma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/26-30\">",
"       26-30",
"      </a>",
"      ]. The finding of tubuloreticular inclusions in muscle capillaries is highly specific for DM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]; such inclusions have been found, for example, in childhood DM in 76 to 98 percent of all intramuscular blood vessels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relying upon these and other observations, a model of the pathogenesis of DM resulting from the induction of type 1 interferon-inducible gene products can be constructed (",
"    <a class=\"graphic graphic_algorithm graphicRef54558 \" href=\"mobipreview.htm?40/10/41120\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/5\">",
"     5",
"    </a>",
"    ]. According to this model, type 1 interferon production by plasmacytoid dendritic cells (pDC) might occur through engagement of toll-like receptor 9 (TLR-9) and TLR-7, which ligate sequence-specific DNA or RNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/34\">",
"     34",
"    </a>",
"    ]. Autoantibodies bound to DNA or RNA in DM muscle may stimulate pDCs to secrete type 1 interferons, as is believed to occur in systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/35\">",
"     35",
"    </a>",
"    ]. Injury to myofibers in DM may occur because of the inappropriate and sustained production of type 1 interferon-inducible transcripts or proteins within myofibers through unknown effects.",
"   </p>",
"   <p>",
"    These markers of type 1 interferon activity, type 1 interferon-inducible gene transcripts and tubuloreticular inclusions, suggest disease driven by type 1 interferons. However, the detection of the transcripts encoding type 1 interferons themselves or the proteins interferon alpha or beta in DM muscle has not been impressive. The identity of factors driving the transcription of interferon-alpha or beta inducible genes in DM is, thus, unknown, and it is entirely possible, though speculative, that some molecules other than type 1 interferons are capable of inducing this pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18308436\">",
"    <span class=\"h2\">",
"     Autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoantibodies with affinities for various antigens, such as the aminoacyl tRNA synthetase, have been reported in dermatomyositis (DM) and other inflammatory myopathies, including polymyositis (PM), necrotizing myopathy, and overlap syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. The pathogenic role of any of these antibodies is uncertain and continues to be explored, although the detection of these antibodies may be useful clinically because of their association with particular clinical syndromes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-Jo-1 (anti-histidyl tRNA synthetase), one of a number of antibodies commonly termed &ldquo;myositis-specific autoantibodies&rdquo; (MSA), exhibits relative, but not absolute, specificity for PM and DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/36\">",
"     36",
"    </a>",
"    ]. Several series have documented a total of over 30 patients with anti-Jo-1 antibodies and interstitial lung disease but without myositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In one study, a positive association was shown between anti-Jo-1 antibody levels and disease activity in patients with inflammatory myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/41\">",
"     41",
"    </a>",
"    ]. The association was stronger in a small serial cohort than in the larger cross-sectional analysis, but a pathogenic role for the antibodies remains unproven. Evidence is also lacking for most of the antibodies that myositis-associated or -specific autoantibodies injure muscle. As an example, mouse models of myositis induced by immunization with histidyl tRNA synthetase are not dependent on the development of antibody responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/42\">",
"     42",
"    </a>",
"    ] and have been hypothesized to be mediated by innate immune mechanisms or by the action of histidyl tRNA synthetase as a chemokine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that capillaries are first injured by an antibody-directed attack on an endothelial antigen, and perifascicular atrophy occurs as a consequence of a lack of blood supply to these particular myofibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, a pathogenic autoantibody to a specific endothelial antigen has not been identified.",
"   </p>",
"   <p>",
"    Injury to endothelial cells could also begin by some other means, with activation of the complement cascade on the endothelial surface developing as a secondary phenomenon. In addition, perifascicular muscle fibers may be less rather than more vulnerable to ischemia than central muscle fibers, according to experimental models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. There is also a lack of evidence that such fibers are damaged by ischemia in DM, such as the presence of transcripts or proteins in these myofibers thought to be specifically induced by ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/45\">",
"     45",
"    </a>",
"    ]. Notably, microvascular complement deposition is nearly absent in fascicles containing perifascicular atrophy and is limited instead to other fascicles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18308464\">",
"    <span class=\"h1\">",
"     INCLUSION BODY MYOSITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with inclusion body myositis (IBM) exhibit distinctive clinical and pathological features, including inflammatory cells surrounding myofibers and rimmed vacuoles. However, the mechanisms of myofiber injury in IBM are poorly understood. Some myofibers appear to be injured by invading cytotoxic T cells, while others have no apparent cause for their morphological abnormalities and have been called degenerative. Several hypotheses have been developed to explain the pathophysiology of IBM, but no single well-supported theory explains all the features of this condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15735?source=see_link\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/30/28133?source=see_link\">",
"     \"Treatment and prognosis of inclusion body myositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A group of inherited muscle disorders sometimes referred to as inclusion body myopathies or hereditary inclusion body myopathies (&ldquo;h-IBM&rdquo;) has only superficial resemblance to this disease and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15735?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28307279\">",
"    <span class=\"h2\">",
"     IBM disease mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observations in patients have been of particular interest in the study of IBM disease mechanisms. Studies in animals have not provided information that can be readily generalized to human IBM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/47-60\">",
"     47-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28307286\">",
"    <span class=\"h3\">",
"     Role of adaptive immune responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is abundant evidence for an important role of adaptive (antigen-driven) immune responses in IBM, including infiltrates of intramuscular CD4+ T cells, cytotoxic CD8+ T cells, myeloid dendritic cells, and plasma cells deep within fascicles, surrounding (",
"    <a class=\"graphic graphic_picture graphicRef64343 \" href=\"mobipreview.htm?33/40/34437\">",
"     picture 2",
"    </a>",
"    ) and displacing (",
"    <a class=\"graphic graphic_picture graphicRef77138 \" href=\"mobipreview.htm?18/9/18581\">",
"     picture 3",
"    </a>",
"    ) myofibers and sometimes invading them (",
"    <a class=\"graphic graphic_picture graphicRef55160 \" href=\"mobipreview.htm?29/7/29812\">",
"     picture 4",
"    </a>",
"    ). The following observations support this view:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clonally restricted maturation of intramuscular T and B cells is shown by antigen receptor sequencing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/5,61,62\">",
"       5,61,62",
"      </a>",
"      ]. A genetic influence is suggested by findings of different major histocompatibility complex gene alleles associated with IBM in different populations, including alleles seen in other autoimmune diseases, such as DRB1*0301 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Further evidence of an important role for antigen-driven antibody production comes from microarray studies of gene expression within muscle biopsy samples showing that the most abundant transcripts in IBM muscle were derived from immunoglobulin genes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/22,23,61\">",
"       22,23,61",
"      </a>",
"      ]. These plasma cells show evidence of antigen-driven affinity maturation and clonal expansion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of myeloid dendritic cells, which are potent antigen-presenting cells, was also predicted by microarray analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/64\">",
"       64",
"      </a>",
"      ]. Myeloid DC in IBM and PM frequently surround and sometimes invade nonnecrotic muscle fibers (",
"      <a class=\"graphic graphic_picture graphicRef63868 \" href=\"mobipreview.htm?25/54/26470\">",
"       picture 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/65\">",
"       65",
"      </a>",
"      ]. They are also present within dense collections of inflammatory infiltrates displacing myofibers in their differentiated stellate morphology, suggesting that they may be locally activating T cells, a process generally occurring primarily in lymph nodes.",
"     </li>",
"     <li>",
"      The targets of this potentially antigen-driven response are largely unknown. One possible antigen, alphaB crystallin, has been identified in some patients with IBM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/66\">",
"       66",
"      </a>",
"      ]. Some myofibers are visibly invaded by T cells, suggesting one mechanism of myofiber injury, although many myofibers are simply displaced by T cells without apparent invasion, and many other myofibers are morphologically abnormal without neighboring immune system cells. In IBM, compared with polymyositis (PM), less frequent myofiber necrosis and more frequent invasion of nonnecrotic myofibers by mononuclear cells have been observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/67\">",
"       67",
"      </a>",
"      ]. One hypothesis to explain these findings is that soluble secreted molecules of the immune system play a role in IBM myofiber injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10454645\">",
"    <span class=\"h3\">",
"     Myofiber abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several abnormalities of myofibers seen on routine microscopy or under electron microscopy are characteristic of IBM. These include rimmed vacuoles, inclusion bodies, tubulofilaments, and congophilic material, but the role of these structures in pathogenesis is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18308492\">",
"    <span class=\"h3\">",
"     Nuclear degeneration and TDP-43 sarcoplasmic redistribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rimmed vacuoles are a distinguishing feature of IBM muscle. Such structures were hypothesized to arise from nuclear degradation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/69-73\">",
"     69-73",
"    </a>",
"    ]. The majority of rimmed vacuoles are lined with nuclear membrane proteins lamin",
"    <span class=\"nowrap\">",
"     A/C",
"    </span>",
"    and emerin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/68\">",
"     68",
"    </a>",
"    ] and with histone H1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/74\">",
"     74",
"    </a>",
"    ], suggesting they frequently derive from myonuclear breakdown. Studies have found a nucleic acid-binding protein lining vacuoles of some IBM myofibers, while failing to confirm claims of specific beta-amyloid precursor protein transcript abundance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/71\">",
"     71",
"    </a>",
"    ]. The discovery of the nucleic acid-binding protein TDP-43 in IBM non-nuclear sarcoplasm has advanced this line of inquiry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/75-78\">",
"     75-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities in the distribution of TDP-43 in IBM myofibers with fluorescent microscopy are present in about one-quarter of IBM myofibers, most of which appear morphologically normal or only minimally abnormal on parallel H&amp;E sections (",
"    <a class=\"graphic graphic_picture graphicRef62042 \" href=\"mobipreview.htm?1/28/1481\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/75\">",
"     75",
"    </a>",
"    ]. In these fibers, TDP-43 has redistributed from its normally nuclear location to the sarcoplasm (",
"    <a class=\"graphic graphic_picture graphicRef79771 \" href=\"mobipreview.htm?2/54/2918\">",
"     picture 7",
"    </a>",
"    ). Both the mechanisms and consequences of TDP-43 redistribution from myonuclei to sarcoplasm in a high percentage of IBM myofibers are uncertain. Abnormal accumulation of extra-nuclear TDP-43 may lead to a deleterious interaction with or sequestration of certain particular mRNA or microRNAs and may affect the translation of specific proteins in IBM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18308499\">",
"    <span class=\"h3\">",
"     Beta-amyloid (A-beta) mediated myofiber injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have examined a possible role for beta-amyloid precursor protein (beta-APP) in myofiber injury in IBM, but convincing evidence in support of this hypothesis is lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. This widely discussed theory suggests that beta-APP transcript is overproduced by myofibers in IBM, followed by overproduction of beta-APP protein, which is then cleaved to produce one of its fragments, beta-amyloid (A-beta), resulting through uncertain mechanisms in myofiber injury and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several notable limitations to the A-beta toxicity hypothesis, and it has been contradicted by a number of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/22,47,79,81-83\">",
"     22,47,79,81-83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A-beta protein has been identified in IBM muscle using immunohistochemical reagents that crossreact with beta-APP protein but not by Western blot, and it is nonspecifically present in regenerating myofibers in all muscle diseases, not only IBM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a lack of evidence that beta-APP transcript is specifically overproduced by IBM myofibers; it is similarly overproduced in regenerating muscle fibers in all muscle diseases studied, including polymyositis, dermatomyositis, amyotrophic lateral sclerosis, and Duchenne muscular dystrophy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/82,84\">",
"       82,84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Quantitative microarray studies showed no difference in beta-APP transcript abundance in IBM compared with polymyositis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/22\">",
"       22",
"      </a>",
"      ], and polymerase chain reaction (PCR)-based studies of beta-APP transcript in IBM muscle showed no difference between the transcript's abundance in IBM and polymyositis, with even greater amounts of beta-APP transcript in dermatomyositis than IBM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in the author&rsquo;s view, there are insufficient data to support the suggestion that beta-APP transcript overproduction is responsible for IBM in human patients. Although beta-APP transcript overproducing mice have been proposed as models of IBM, beta-APP transcript overproduction is a nonspecific occurrence seen in regenerating muscle fibers in all neuromuscular disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/47,79\">",
"     47,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18308506\">",
"    <span class=\"h3\">",
"     Tau protein and other molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of molecules in addition to beta amyloid have been reported to accumulate in IBM myofibers and are hypothesized to play a role in myofiber injury, including phosphorylated forms of the microtubule associated protein tau (MAPT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/85\">",
"     85",
"    </a>",
"    ]. However, evidence that tau is present in IBM myofibers is limited to its immunohistochemical detection by antibodies (&ldquo;tau&rdquo; immunoreactivity), and the most common antibody used to detect it, SMI-31, is primarily directed against a different protein, phosphorylated neurofilament H. Studies have shown that &ldquo;tau&rdquo; immunoreactivity is present in normal muscle myonuclei and that some or all of this immunoreactivity is due to the presence of neurofilament H [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/85\">",
"     85",
"    </a>",
"    ]. Numerous other molecules have also been reported to accumulate in IBM myofibers and have been suggested as having a role in IBM myofiber injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18308520\">",
"    <span class=\"h1\">",
"     POLYMYOSITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immune mechanisms involved in polymyositis (PM) appear similar to those responsible for inclusion body myositis (IBM); pathological and molecular findings are similar for these two diseases, despite the closer resemblance of the clinical phenotype of PM to DM.",
"   </p>",
"   <p>",
"    Challenges to understanding the pathogenesis of PM include the very heterogeneous nature of this group of patients and the difficulties among experts in agreeing upon diagnostic criteria. Patients diagnosed with PM in the past include many who are now classified as having overlap syndromes, inclusion body myositis, and necrotizing myopathy. In addition, some patients with muscular dystrophies related to dysferlin and calpain-3 mutations have been misdiagnosed with PM because of the presence of immune cells in muscle biopsies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18308464\">",
"     'Inclusion body myositis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18308534\">",
"     'Immune-mediated necrotizing myopathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Findings common to PM and IBM, which suggest similar mechanisms of injury, include the endomysial T cells surrounding and invading myofibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/67,86\">",
"     67,86",
"    </a>",
"    ], macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/9,86\">",
"     9,86",
"    </a>",
"    ], myeloid dendritic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/65\">",
"     65",
"    </a>",
"    ], and plasma cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/61\">",
"     61",
"    </a>",
"    ]. However, unlike those with IBM, patients with PM may exhibit circulating autoantibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/37,38\">",
"     37,38",
"    </a>",
"    ] or high expression in blood, but not in muscle, of type 1 interferon-inducible transcripts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with PM can generally be distinguished from patients with DM based upon several immunohistologic features. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fascicular inflammatory cell infiltrate invading individual muscle fibers (",
"      <a class=\"graphic graphic_picture graphicRef69212 \" href=\"mobipreview.htm?0/43/696\">",
"       picture 8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/87\">",
"       87",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diffuse muscle fiber injury throughout the fascicle, with variable muscle fiber size, and a lack of vasculopathy or immune complex deposition",
"     </li>",
"     <li>",
"      Myofiber injury by CD8+ cytotoxic T lymphocytes that surround and invade myofibers. In some patients, the inflammatory infiltrate can involve nonnecrotic muscle fibers.",
"     </li>",
"     <li>",
"      Enhanced expression of class I major histocompatibility complex antigens by the muscle fibers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/88\">",
"       88",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although perivascular, perimysial, or endomysial inflammation is typically present, these findings are nonspecific and can occur in muscular dystrophies, in metabolic myopathies following rhabdomyolysis, and, as noted above, in IBM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18308534\">",
"    <span class=\"h1\">",
"     IMMUNE-MEDIATED NECROTIZING MYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;This uncommon condition, which is sometimes confused with polymyositis, may occur in several settings, including as a paraneoplastic disorder or in association with the use of certain drugs, including statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/90\">",
"     90",
"    </a>",
"    ]. In the small number of patients on statins who develop this syndrome, myositis that develops in association with use of these medications persists despite drug discontinuation, unlike the more typical statin-related myopathy that resolves after drug discontinuation. The condition can respond to immunosuppressive therapies, supporting the view that this condition is immune-mediated, despite the lack of substantial immune cell invasion of muscle. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with autoimmune necrotizing myopathy, which is sometimes classified with PM, scattered necrotic muscle fibers are present. Necrotizing myopathy is sometimes associated with anti-SRP antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. The small amounts of immune cells that are present in muscle appear to be macrophages that are invading myofibers secondary to necrosis of these myofibers. There is no evidence of invasion of myofibers that appear otherwise morphologically normal, and inflammatory cells are not present in perivascular or endomysial locations, unlike in dermatomyositis, polymyositis, or inclusion body myositis. Unlike those with DM, these patients do not exhibit perifascicular atrophy. Sometimes inflammatory cells are found around small blood vessels, and thickened basement membranes are seen. One hypothesis is that circulating soluble molecules may injure myofibers, but little is known regarding the mechanisms underlying this entity. Statins upregulate 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), and anti-HMGCR autoantibodies have been found in patients with statin-associated necrotizing myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18308562\">",
"    <span class=\"h1\">",
"     DRUG ASSOCIATED MYOSITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several drugs appear to contribute to the development of inflammatory myopathy, including statins (discussed above), interferon-alpha, interferon-beta, tumor necrosis factor inhibitors, L-tryptophan, and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/90,94-106\">",
"     90,94-106",
"    </a>",
"    ]. Interpreting causality is often confounded by the presence of the underlying disease for which the drugs are being used. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/44/6856?source=see_link\">",
"     \"Drug-induced myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/44/6856?source=see_link&amp;anchor=H2#H2\">",
"     \"Drug-induced myopathies\", section on 'Mechanisms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18308534\">",
"     'Immune-mediated necrotizing myopathy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/65?source=see_link&amp;anchor=H14#H14\">",
"     \"Risk factors for and possible causes of systemic sclerosis (scleroderma)\", section on 'L-tryptophan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2535303\">",
"    <span class=\"h1\">",
"     OTHER MYOPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other forms of myositis have been described, some of which exhibit characteristic histologic features. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eosinophilic myositis &mdash; Eosinophilic myositis is sometimes classified as a form of polymyositis. The only distinctive feature is the presence of eosinophils in muscle biopsy sections and, occasionally, blood eosinophilia. Chronic parasitic infection is one known cause of this syndrome. Remarkably, some patients with eosinophilic myositis have mutations in calpain-3 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/107,108\">",
"       107,108",
"      </a>",
"      ]. Mutations in this gene also result in an inherited muscular dystrophy syndrome (limb-girdle muscular dystrophy type 2A). The mechanisms by which calpain-3 mutations lead to recruitment of eosinophils to muscle are unknown.",
"     </li>",
"     <li>",
"      Granulomatous myositis &mdash; Granulomatous myositis is a clinical syndrome of distal asymmetric weakness and the presence of granulomas in muscle biopsy sections (",
"      <a class=\"graphic graphic_picture graphicRef74647 \" href=\"mobipreview.htm?16/36/16967\">",
"       picture 9",
"      </a>",
"      ). It may occur with systemic involvement leading to a diagnosis of sarcoidosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/109\">",
"       109",
"      </a>",
"      ] or graft-versus-host disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/110,111\">",
"       110,111",
"      </a>",
"      ], or it can be idiopathic, without another associated illness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/109,112\">",
"       109,112",
"      </a>",
"      ]. Macrophages, lymphocytes, and plasma cells are present in the affected muscle, but the mechanisms of idiopathic granulomatous myositis are unknown [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Myositis associated with graft-versus-host-disease &mdash; Graft-versus-host-disease may be associated with myositis, characterized pathologically as a number of syndromes including dermatomyositis (",
"      <a class=\"graphic graphic_picture graphicRef73055 \" href=\"mobipreview.htm?27/0/27657\">",
"       picture 10",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/113-116\">",
"       113-116",
"      </a>",
"      ], polymyositis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/117\">",
"       117",
"      </a>",
"      ] and granulomatous myositis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42121/abstract/110,111\">",
"       110,111",
"      </a>",
"      ]. The pathogenesis of these syndromes is poorly understood, but the presence of infarction in some of these clearly indicates vascular injury (see panels C and D in the picture) (",
"      <a class=\"graphic graphic_picture graphicRef73055 \" href=\"mobipreview.htm?27/0/27657\">",
"       picture 10",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14593170\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The inflammatory myopathies, including dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), and related disorders, share the common feature of immune-mediated muscle injury. Clinical and histopathological distinctions between these conditions suggest that different pathogenic processes underlie each of the inflammatory myopathies, but the precise mechanisms leading to tissue injury in the inflammatory myopathies are poorly defined. (See",
"      <a class=\"local\" href=\"#H18308386\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The precise mechanisms responsible for DM are unknown, and several different models have been proposed. One model, which the author favors, focuses on a central role for type 1 interferons. An alternative view centers on the hypothesis that DM myofiber injury results from an antibody and complement-mediated microangiopathy. The pathogenic role of myositis-specific autoantibodies is uncertain. (See",
"      <a class=\"local\" href=\"#H18308393\">",
"       'Dermatomyositis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H206354349\">",
"       'Type 1 interferon'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18308436\">",
"       'Autoantibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanisms of myofiber injury in IBM are poorly understood. Some myofibers appear to be injured by invading cytotoxic T cells, while others have no apparent cause for their morphological abnormalities and have been called degenerative. Several hypotheses have been developed to explain the pathophysiology of IBM, but no single well-supported theory explains all the features of this condition. The evidence for a role in IBM of an adaptive immune response is the strongest of all the inflammatory myopathies, but the targets of this response are largely unknown. (See",
"      <a class=\"local\" href=\"#H28307286\">",
"       'Role of adaptive immune responses'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10454645\">",
"       'Myofiber abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The immune mechanisms involved in PM appear similar to those responsible for IBM, despite the greater clinical similarity of PM to DM. Challenges to understanding the pathogenesis of PM are the very heterogeneous nature of this group of patients and the lack of agreement on diagnostic criteria. However, in PM, unlike IBM, there is evidence of circulating autoantibodies and high expression in blood, but not in muscle, of type 1 interferon-inducible transcripts. In PM, by contrast with DM, the cellular infiltrate is predominantly within the fascicle, muscle fiber injury is diffuse, there are no signs of vasculopathy, and there is increased expression of class I MHC antigens by muscle fibers. Myofiber injury appears to be mediated directly by CD8+ cytotoxic T lymphocytes that surround and invade myofibers. (See",
"      <a class=\"local\" href=\"#H18308520\">",
"       'Polymyositis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immune mediated necrotizing myopathy may occur in several settings, including as a paraneoplastic disorder; in association with the use of certain drugs, including statins; or without apparent cause. Scattered necrotic muscle fibers are present, and the condition is sometimes associated with anti-SRP antibodies. The small amount of immune cells present in muscle is macrophages, which appear to be invading necrotic myofibers. Inflammatory cells are not present in perivascular or endomysial locations, unlike in DM, PM, or IBM, but the condition may respond to immunosuppressive therapies. Unlike those with DM, these patients do not exhibit perifascicular atrophy. One hypothesis is that circulating soluble molecules may injure myofibers, but the mechanisms underlying this condition are unknown. (See",
"      <a class=\"local\" href=\"#H18308534\">",
"       'Immune-mediated necrotizing myopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/1\">",
"      Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/2\">",
"      van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003; 61:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/3\">",
"      Greenberg SA. Type 1 interferons and myositis. Arthritis Res Ther 2010; 12 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/4\">",
"      Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol Rep 2010; 12:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/5\">",
"      Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007; 69:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/6\">",
"      Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/7\">",
"      Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 2004; 17:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/8\">",
"      Salajegheh M, Kong SW, Pinkus JL, et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010; 67:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/9\">",
"      Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/10\">",
"      McDouall RM, Dunn MJ, Dubowitz V. Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J Neurol Sci 1990; 99:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/11\">",
"      Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/12\">",
"      L&oacute;pez de Padilla CM, Vallejo AN, McNallan KT, et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007; 56:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/13\">",
"      Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/14\">",
"      Wenzel J, Schmidt R, Proelss J, et al. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 2006; 31:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/15\">",
"      Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/16\">",
"      Gallardo E, de Andr&eacute;s I, Illa I. Cathepsins are upregulated by IFN-gamma/STAT1 in human muscle culture: a possible active factor in dermatomyositis. J Neuropathol Exp Neurol 2001; 60:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/17\">",
"      Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/18\">",
"      Pedrol E, Grau JM, Casademont J, et al. Idiopathic inflammatory myopathies. Immunohistochemical analysis of the major histocompatibility complex antigen expression, inflammatory infiltrate phenotype and activation cell markers. Clin Neuropathol 1995; 14:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/19\">",
"      Banwell BL, Engel AG. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000; 54:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/20\">",
"      Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/21\">",
"      Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/22\">",
"      Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology 2002; 59:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/23\">",
"      Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 2005; 128:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/24\">",
"      Greenberg SA. A gene expression approach to study perturbed pathways in myositis. Curr Opin Rheumatol 2007; 19:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/25\">",
"      Walsh RJ, Kong SW, Yao Y, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007; 56:3784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/26\">",
"      Grimley PM, Rutherford MN, Kang YH, et al. Formation of tubuloreticular inclusions in human lymphoma cells compared to the induction of 2'-5'-oligoadenylate synthetase by leucocyte interferon in dose-effect and kinetic studies. Cancer Res 1984; 44:3480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/27\">",
"      Feldman D, Goldstein AL, Cox DC, Grimley PM. Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2',5' oligoadenylate synthetase induction. Lab Invest 1988; 58:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/28\">",
"      Kuyama J, Kanayama Y, Mizutani H, et al. Formation of tubuloreticular inclusions in mitogen-stimulated human lymphocyte cultures by endogenous or exogenous alpha-interferon. Ultrastruct Pathol 1986; 10:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/29\">",
"      Rich SA, Owens TR, Bartholomew LE, Gutterman JU. Immune interferon does not stimulate formation of alpha and beta interferon induced human lupus-type inclusions. Lancet 1983; 1:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/30\">",
"      Grimley PM, Davis GL, Kang YH, et al. Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with alpha-interferon. Lab Invest 1985; 52:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/31\">",
"      Norton WL, Velayos E, Robison L. Endothelial inclusions in dermatomyositis. Ann Rheum Dis 1970; 29:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/32\">",
"      De Visser M, Emslie-Smith AM, Engel AG. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J Neurol Sci 1989; 94:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/33\">",
"      Banker BQ. Dermatomyostis of childhood, ultrastructural alteratious of muscle and intramuscular blood vessels. J Neuropathol Exp Neurol 1975; 34:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/34\">",
"      Fuchsberger M, Hochrein H, O'Keeffe M. Activation of plasmacytoid dendritic cells. Immunol Cell Biol 2005; 83:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/35\">",
"      Vallin H, Blomberg S, Alm GV, et al. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999; 115:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/36\">",
"      Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007; 19:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/37\">",
"      Mammen AL. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/38\">",
"      Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009; 48:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/39\">",
"      Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996; 26:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/40\">",
"      Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008; 63:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/41\">",
"      Stone KB, Oddis CV, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007; 56:3125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/42\">",
"      Soejima M, Kang EH, Gu X, et al. Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis. Arthritis Rheum 2011; 63:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/43\">",
"      Karpati G, Carpenter S, Melmed C, Eisen AA. Experimental ischemic myopathy. J Neurol Sci 1974; 23:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/44\">",
"      Hathaway PW, Engel WK, Zellweger H. Experimental myopathy after microarterial embolization; comparison with childhood x-linked pseudohypertrophic muscular dystrophy. Arch Neurol 1970; 22:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/45\">",
"      Greenberg SA, Amato AA. Uncertainties in the pathogenesis of adult dermatomyositis. Curr Opin Neurol 2004; 17:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/46\">",
"      Kissel JT, Halterman RK, Rammohan KW, Mendell JR. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol 1991; 48:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/47\">",
"      Greenberg SA. Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep 2010; 12:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/48\">",
"      Fukuchi K, Pham D, Hart M, et al. Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. Am J Pathol 1998; 153:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/49\">",
"      Jin LW, Hearn MG, Ogburn CE, et al. Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. Am J Pathol 1998; 153:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/50\">",
"      Capsoni S, Ruberti F, Di Daniel E, Cattaneo A. Muscular dystrophy in adult and aged anti-NGF transgenic mice resembles an inclusion body myopathy. J Neurosci Res 2000; 59:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/51\">",
"      Sugarman MC, Yamasaki TR, Oddo S, et al. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A 2002; 99:6334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/52\">",
"      Strazielle C, Dumont M, Fukuchi K, Lalonde R. Transgenic mice expressing the human C99 terminal fragment of betaAPP: effects on cytochrome oxidase activity in skeletal muscle and brain. J Chem Neuroanat 2004; 27:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/53\">",
"      Kitazawa M, Green KN, Caccamo A, LaFerla FM. Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol 2006; 168:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/54\">",
"      Moussa CE, Fu Q, Kumar P, et al. Transgenic expression of beta-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology. FASEB J 2006; 20:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/55\">",
"      Sugarman MC, Kitazawa M, Baker M, et al. Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiol Aging 2006; 27:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/56\">",
"      Chen X, Ghribi O, Geiger JD. Rabbits fed cholesterol-enriched diets exhibit pathological features of inclusion body myositis. Am J Physiol Regul Integr Comp Physiol 2008; 294:R829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/57\">",
"      Delaunay A, Bromberg KD, Hayashi Y, et al. The ER-bound RING finger protein 5 (RNF5/RMA1) causes degenerative myopathy in transgenic mice and is deregulated in inclusion body myositis. PLoS One 2008; 3:e1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/58\">",
"      Kitazawa M, Trinh DN, LaFerla FM. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 2008; 64:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/59\">",
"      Rebolledo DL, Minniti AN, Grez PM, et al. Inclusion body myositis: a view from the Caenorhabditis elegans muscle. Mol Neurobiol 2008; 38:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/60\">",
"      Kitazawa M, Vasilevko V, Cribbs DH, LaFerla FM. Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model. J Neurosci 2009; 29:6132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/61\">",
"      Greenberg SA, Bradshaw EM, Pinkus JL, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005; 65:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/62\">",
"      Bradshaw EM, Orihuela A, McArdel SL, et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007; 178:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/63\">",
"      Needham M, Mastaglia FL, Garlepp MJ. Genetics of inclusion-body myositis. Muscle Nerve 2007; 35:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/64\">",
"      Tian L, Greenberg SA, Kong SW, et al. Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci U S A 2005; 102:13544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/65\">",
"      Greenberg SA, Pinkus GS, Amato AA, Pinkus JL. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007; 35:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/66\">",
"      Salajegheh M, Lin YY, Parker KC, et al. Using humoral immunity for the identification of candidate antigens in inclusion body myositis. Neurology 2007; 68(Suppl 1):A361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/67\">",
"      Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol 1988; 23:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/68\">",
"      Greenberg SA, Pinkus JL, Amato AA. Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 2006; 34:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/69\">",
"      Chou SM. Myxovirus-like structures and accompanying nuclear changes in chronic polymyositis. Arch Pathol 1968; 86:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/70\">",
"      Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 1978; 28:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/71\">",
"      Nalbantoglu J, Karpati G, Carpenter S. Conspicuous accumulation of a single-stranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. Am J Pathol 1994; 144:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/72\">",
"      Carpenter S. Inclusion body myositis, a review. J Neuropathol Exp Neurol 1996; 55:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/73\">",
"      Karpati G, Carpenter S. Pathology of the inflammatory myopathies. Baillieres Clin Neurol 1993; 2:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/74\">",
"      Nakano S, Shinde A, Fujita K, et al. Histone H1 is released from myonuclei and present in rimmed vacuoles with DNA in inclusion body myositis. Neuromuscul Disord 2008; 18:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/75\">",
"      Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009; 40:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/76\">",
"      K&uuml;sters B, van Hoeve BJ, Schelhaas HJ, et al. TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathol 2009; 117:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/77\">",
"      Oliv&eacute; M, Janu&eacute; A, Moreno D, et al. TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 2009; 68:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/78\">",
"      Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008; 79:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/79\">",
"      Greenberg SA. How citation distortions create unfounded authority: analysis of a citation network. BMJ 2009; 339:b2680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/80\">",
"      Askanas V, Engel WK. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006; 66:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/81\">",
"      Greenberg SA. Inclusion body myositis: review of recent literature. Curr Neurol Neurosci Rep 2009; 9:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/82\">",
"      Sarkozi E, Askanas V, Johnson SA, et al. Expression of beta-amyloid precursor protein gene is developmentally regulated in human muscle fibers in vivo and in vitro. Exp Neurol 1994; 128:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/83\">",
"      Schmidt J, Barthel K, Wrede A, et al. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008; 131:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/84\">",
"      Sarkozi E, Askanas V, Johnson SA, et al. beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport 1993; 4:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/85\">",
"      Salajegheh M, Pinkus JL, Nazareno R, et al. Nature of \"Tau\" immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve 2009; 40:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/86\">",
"      Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/87\">",
"      Hohlfeld R, Engel AG. The immunobiology of muscle. Immunol Today 1994; 15:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/88\">",
"      Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989; 20:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/89\">",
"      Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 2009; 80:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/90\">",
"      Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/91\">",
"      Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010; 62:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/92\">",
"      Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/93\">",
"      Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/94\">",
"      Cirigliano G, Della Rossa A, Tavoni A, et al. Polymyositis occurring during alpha-interferon treatment for malignant melanoma: a case report and review of the literature. Rheumatol Int 1999; 19:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/95\">",
"      Dietrich LL, Bridges AJ, Albertini MR. Dermatomyositis after interferon alpha treatment. Med Oncol 2000; 17:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/96\">",
"      John A, El Emadi S, Al Kaabi S, et al. Polymyositis during pegylated alpha-interferon ribavirin therapy for chronic hepatitis. Indian J Gastroenterol 2007; 26:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/97\">",
"      K&auml;lkner KM, R&ouml;nnblom L, Karlsson Parra AK, et al. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998; 91:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/98\">",
"      Lee SW, Kim KC, Oh DH, et al. A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B. J Korean Med Sci 2002; 17:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/99\">",
"      Matsuya M, Abe T, Tosaka M, et al. The first case of polymyositis associated with interferon therapy. Intern Med 1994; 33:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/100\">",
"      Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/101\">",
"      Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2006; 55:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/102\">",
"      Hengstman GJ, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008; 59:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/103\">",
"      Ramos-Casals M, Brito-Zer&oacute;n P, Mu&ntilde;oz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/104\">",
"      Jego G, Pascual V, Palucka AK, Banchereau J. Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun 2005; 8:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/105\">",
"      Hollander D, Adelman LS. Eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan: muscle biopsy findings in 4 patients. Neurology 1991; 41:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/106\">",
"      Somani AK, Swick AR, Cooper KD, McCormick TS. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 2008; 144:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/107\">",
"      Amato AA. Adults with eosinophilic myositis and calpain-3 mutations. Neurology 2008; 70:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/108\">",
"      Krahn M, Lopez de Munain A, Streichenberger N, et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol 2006; 59:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/109\">",
"      Le Roux K, Streichenberger N, Vial C, et al. Granulomatous myositis: a clinical study of thirteen cases. Muscle Nerve 2007; 35:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/110\">",
"      Bagdasaryan R, Donahue JE. Granulomatous myositis in association with chronic graft vs. host disease. Med Health R I 2007; 90:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/111\">",
"      Kaushik S, Flagg E, Wise CM, et al. Granulomatous myositis: a manifestation of chronic graft-versus-host disease. Skeletal Radiol 2002; 31:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/112\">",
"      Prayson RA. Granulomatous myositis. Clinicopathologic study of 12 cases. Am J Clin Pathol 1999; 112:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/113\">",
"      Arin MJ, Scheid C, H&uuml;bel K, et al. Chronic graft-versus-host disease with skin signs suggestive of dermatomyositis. Clin Exp Dermatol 2006; 31:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/114\">",
"      Ollivier I, Wolkenstein P, Gherardi R, et al. Dermatomyositis-like graft-versus-host disease. Br J Dermatol 1998; 138:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/115\">",
"      Allen JA, Greenberg SA, Amato AA. Dermatomyositis-like muscle pathology in patients with chronic graft-versus-host disease. Muscle Nerve 2009; 40:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/116\">",
"      Nozaki K, Pestronk A. High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology. J Neurol Neurosurg Psychiatry 2009; 80:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42121/abstract/117\">",
"      Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford) 2003; 42:34.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14918 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-877DD6BC00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42121=[""].join("\n");
var outline_f41_8_42121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14593170\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18308386\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18308393\">",
"      DERMATOMYOSITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H206354349\">",
"      Type 1 interferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18308436\">",
"      Autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18308464\">",
"      INCLUSION BODY MYOSITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28307279\">",
"      IBM disease mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28307286\">",
"      - Role of adaptive immune responses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10454645\">",
"      - Myofiber abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18308492\">",
"      - Nuclear degeneration and TDP-43 sarcoplasmic redistribution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18308499\">",
"      - Beta-amyloid (A-beta) mediated myofiber injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18308506\">",
"      - Tau protein and other molecules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18308520\">",
"      POLYMYOSITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18308534\">",
"      IMMUNE-MEDIATED NECROTIZING MYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18308562\">",
"      DRUG ASSOCIATED MYOSITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2535303\">",
"      OTHER MYOPATHIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14593170\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/14918\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/14918|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?40/10/41120\" title=\"algorithm 1\">",
"      Proposed DM model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/14918|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/50/10023\" title=\"picture 1\">",
"      Plasmacytoid dendritic cells anti-BDCA-2 in DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/40/34437\" title=\"picture 2\">",
"      Inflammatory cells surrounding non-necrotic myofiber in IBM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/9/18581\" title=\"picture 3\">",
"      Inflammatory cells displacing myofibers in IBM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/7/29812\" title=\"picture 4\">",
"      Invasion of inflammatory cells into center of myofiber in IBM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/54/26470\" title=\"picture 5\">",
"      BDCA1 immunoreactive mixed with other inflammatory cells in IBM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/28/1481\" title=\"picture 6\">",
"      TDP43 in IBM myofibers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/54/2918\" title=\"picture 7\">",
"      TDP43 redistribution myonuclei",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/43/696\" title=\"picture 8\">",
"      Muscle biopsy polymyositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/36/16967\" title=\"picture 9\">",
"      CD68 cells in muscle granuloma in sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/0/27657\" title=\"picture 10\">",
"      DM in graft-versus-host",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15735?source=related_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38566?source=related_link\">",
"      Malignancy in dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=related_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/65?source=related_link\">",
"      Risk factors for and possible causes of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/30/28133?source=related_link\">",
"      Treatment and prognosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13065?source=related_link\">",
"      Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42968?source=related_link\">",
"      Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_8_42122="Screening for prostate cancer";
var content_f41_8_42122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/8/42122/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/8/42122/contributors\">",
"     Richard M Hoffman, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/8/42122/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/8/42122/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/8/42122/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/8/42122/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/8/42122/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/8/42122/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer is common and a frequent cause of cancer death. In the United States, prostate cancer is the most commonly diagnosed visceral cancer; in 2012, there were expected to be about 239,000 new prostate cancer diagnoses and about 30,000 prostate cancer deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/1\">",
"     1",
"    </a>",
"    ]. Prostate cancer is second only to nonmelanoma skin cancer and lung cancer as the leading cause of cancer and cancer death, respectively, in US men. Worldwide, in 2008 there were estimated to be 903,000 new cases of prostate cancer and 258,000 prostate cancer deaths making it the second most commonly diagnosed cancer in men and the sixth leading cause of male cancer death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For an American male, the lifetime risk of developing prostate cancer is 16 percent, but the risk of dying of prostate cancer is only 2.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/3\">",
"     3",
"    </a>",
"    ]. Many more cases of prostate cancer do not become clinically evident, as indicated in autopsy series, where prostate cancer is detected in one-third of men under the age of 80 and in two-thirds of older men (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link&amp;anchor=H2#H2\">",
"     \"Risk factors for prostate cancer\", section on 'Age'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/4\">",
"     4",
"    </a>",
"    ]. These data suggest that prostate cancer often grows so slowly that most men die of other causes before the disease becomes clinically advanced.",
"   </p>",
"   <p>",
"    Prostate cancer survival is related to many factors, especially the extent of tumor at the time of diagnosis. The five-year relative survival among men with cancer confined to the prostate (localized) or with just regional spread is 100 percent compared with 31.9 percent among those diagnosed with distant metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/3\">",
"     3",
"    </a>",
"    ]. While men with advanced stage disease may benefit from palliative treatment, their tumors are generally not curable.",
"   </p>",
"   <p>",
"    Thus, a screening program that could identify asymptomatic men with aggressive localized tumors might be expected to substantially reduce prostate cancer morbidity, including urinary obstruction and painful metastases, and mortality.",
"   </p>",
"   <p>",
"    Prostate-specific antigen (PSA) testing revolutionized prostate cancer screening. Although PSA was originally introduced as a tumor marker to detect cancer recurrence or disease progression following treatment, it became widely adopted for cancer screening by the early 1990s. Subsequently, professional societies issued guidelines supporting prostate cancer screening with PSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. PSA testing led to a dramatic increase in the incidence of prostate cancer, peaking in 1992 (",
"    <a class=\"graphic graphic_figure graphicRef75684 \" href=\"mobipreview.htm?6/2/6190\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/7\">",
"     7",
"    </a>",
"    ]. The majority of these newly-diagnosed cancers were clinically localized (",
"    <a class=\"graphic graphic_figure graphicRef74832 \" href=\"mobipreview.htm?14/14/14574\">",
"     figure 2",
"    </a>",
"    ), which led to an increase in radical prostatectomy and radiation therapy, aggressive treatments intended to cure these early-stage cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, prostate cancer screening has been a controversial issue because decisions were made about adopting PSA testing in the absence of efficacy data from randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/12\">",
"     12",
"    </a>",
"    ]. Subsequently, the European Randomized Study of Screening for Prostate Cancer (ERSPC) reported a small absolute survival benefit with PSA screening after nine years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/13\">",
"     13",
"    </a>",
"    ]; however, 48 additional patients would need to be diagnosed with prostate cancer to prevent one prostate cancer death. Although the report did not address quality of life outcomes, considerable data show the potential harms from aggressive treatments, including erectile dysfunction, urinary incontinence, and bowel problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/14\">",
"     14",
"    </a>",
"    ]. Further sustaining the uncertainty surrounding screening, a report from the large United States trial, the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, published concurrently with the European trial, found no benefit for annual PSA and digital rectal examination (DRE) screening after 7 to 10 years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the screening tests that are available for prostate cancer, the efficacy of screening, and the recommendations of major medical associations and societies regarding screening for prostate cancer. Risk factors and the clinical manifestations and diagnosis of prostate cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link\">",
"     \"Risk factors for prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROSTATE SPECIFIC ANTIGEN (PSA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSA is a glycoprotein produced by prostate epithelial cells. PSA levels may be elevated in men with prostate cancer because PSA production is increased and because tissue barriers between the prostate gland lumen and the capillary are disrupted, releasing more PSA into the serum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=see_link\">",
"     \"Measurement of prostate specific antigen\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies have estimated that PSA elevations can precede clinical disease by 5 to 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] or even longer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/18\">",
"     18",
"    </a>",
"    ]. However, PSA is also elevated in a number of benign conditions (",
"    <a class=\"graphic graphic_table graphicRef79754 \" href=\"mobipreview.htm?4/61/5083\">",
"     table 1",
"    </a>",
"    ), particularly benign prostatic hyperplasia (BPH) and prostatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4776?source=see_link\">",
"     \"Acute bacterial prostatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Measuring PSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the PSA elevations seen with BPH, there are transient causes of PSA elevation (",
"    <a class=\"graphic graphic_table graphicRef79754 \" href=\"mobipreview.htm?4/61/5083\">",
"     table 1",
"    </a>",
"    ), some of which are significant enough to affect the performance of PSA measurement as a screening test. We describe PSA values in",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    throughout this topic, but this is equivalent to the SI units of",
"    <span class=\"nowrap\">",
"     mcg/L;",
"    </span>",
"    that is, 4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    = 4",
"    <span class=\"nowrap\">",
"     mcg/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=see_link&amp;anchor=H9#H9\">",
"     \"Measurement of prostate specific antigen\", section on 'Causes of an elevated serum PSA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PSA has a half-life of 2.2 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/19\">",
"     19",
"    </a>",
"    ], and levels elevated by different benign conditions will have variable recovery times [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. PSA testing should be deferred accordingly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Digital rectal examination (DRE) has minimal effect on PSA levels, leading to transient elevations of only 0.26 to 0.4",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      and PSA can be measured immediately after DRE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ejaculation can increase PSA levels by up to 0.8",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      though levels return to normal within 48 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. We do not usually ask men to abstain from sexual activity prior to PSA measurement. However, if an initial measurement is high enough to potentially prompt an intervention (ie, biopsy), but close to a borderline value, it is appropriate to repeat the PSA measurement after having the man abstain from ejaculation for at least 48 hours.",
"     </li>",
"     <li>",
"      Bacterial prostatitis may elevate PSA levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/27\">",
"       27",
"      </a>",
"      ], but they generally return to baseline six to eight weeks after symptoms resolve. Asymptomatic prostatic inflammation can also elevate PSA levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/28\">",
"       28",
"      </a>",
"      ], but this diagnosis is made on biopsy and so cannot generally be used to defer screening tests [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prostate biopsy may elevate PSA levels by a median of 7.9",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      within 4 to 24 hours following the procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/20\">",
"       20",
"      </a>",
"      ]. Levels will remain elevated for two to four weeks. Similarly, a transurethral resection of the prostate (TURP) can elevate PSA levels by a median of 5.9",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/20\">",
"       20",
"      </a>",
"      ]. Levels will remain elevated for a median time of approximately three weeks. A screening PSA test should not be performed for at least six weeks following either of these procedures.",
"     </li>",
"     <li>",
"      Acute urinary retention may elevate PSA levels, but the levels can be expected to decrease by 50 percent within one to two days following resolution. A screening PSA test should not be performed for at least two weeks following an episode of acute urinary retention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The five-alpha reductase inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    lower PSA levels. Finasteride lowers PSA by a median 50 percent within six months of use, though the effects can vary widely, ranging from &ndash;81 percent to +20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/29\">",
"     29",
"    </a>",
"    ]; dutasteride has been reported to reduce PSA 48 to 57 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/30\">",
"     30",
"    </a>",
"    ]. Some experts recommend doubling the measured PSA value before interpreting the result for patients on finasteride [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/31\">",
"     31",
"    </a>",
"    ]. Longitudinal results from the Prostate Cancer Prevention Trial suggest that PSA values be corrected by a factor of 2 for the first two years of finasteride therapy, and by 2.5 for longer-term use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Test performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the accuracy of PSA testing has been difficult because most men with normal PSA values will not undergo biopsy unless their digital examination is abnormal. This work-up bias tends to overestimate sensitivity and underestimate specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/33\">",
"     33",
"    </a>",
"    ]. Performance can also be overestimated because PSA often detects clinically-unimportant cancers. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Overdiagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another problem in assessing the accuracy of PSA is that the transrectal needle biopsy is not a perfect gold standard. Investigators have suggested that the false-negative rate can range from 10 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], though the recent trend towards obtaining 12 samples has increased the detection rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, protocols that use large numbers of biopsies to evaluate patients with an elevated PSA may be detecting incidental cancers that were not the etiology of the PSA elevation. One review that assumed that nonpalpable cancers smaller than 1.0 cm",
"    <sup>",
"     3",
"    </sup>",
"    would not cause elevated PSA levels estimated that approximately 25 percent of cancers detected by PSA screening were too small to have accounted for the PSA rise that prompted a biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic performance of PSA ideally needs to be calibrated against clinically-important cancers. However, there is no consensus on defining such cancers. Although many experts consider tumors with Gleason scores &ge;7 and volumes &gt;0.5 cm",
"    <sup>",
"     3",
"    </sup>",
"    to have a greater risk for progression, there is no certainty that these cancers will lead to early death or reduce quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Sensitivity and specificity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional cutoff for an abnormal PSA level in the major screening studies has been 4.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. The American Cancer Society systematically reviewed the literature assessing PSA performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/44\">",
"     44",
"    </a>",
"    ]. In a pooled analysis, the estimated sensitivity of a PSA cutoff of 4.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    was 21 percent for detecting any prostate cancer and 51 percent for detecting high-grade cancers (Gleason &ge;8). Using a cutoff of 3.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    increased these sensitivities to 32 and 68 percent, respectively. The estimated specificity was 91 percent for a PSA cutoff of 4.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and 85 percent for a 3.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    cutoff. &nbsp;PSA has poorer discriminating ability in men with symptomatic benign prostatic hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Positive predictive value",
"    </span>",
"    &nbsp;&mdash;&nbsp;The test performance statistic that has been best characterized by screening studies is the positive predictive value: the proportion of men with an elevated PSA who have prostate cancer.",
"   </p>",
"   <p>",
"    Overall, the positive predictive value for a PSA level &gt;4.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    is approximately 30 percent, meaning that slightly less than one in three men with an elevated PSA will have prostate cancer detected on biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/40,46,47\">",
"     40,46,47",
"    </a>",
"    ]. For PSA levels between 4.0 to 10.0",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    the positive predictive value is about 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/46\">",
"     46",
"    </a>",
"    ]; this increases to 42 to 64 percent for PSA levels &gt;10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/46,48\">",
"     46,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, nearly 75 percent of cancers detected within the \"gray zone\" of PSA values between 4.0 to 10.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    are organ confined and potentially curable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/46\">",
"     46",
"    </a>",
"    ]. The proportion of organ-confined cancers drops to less than 50 percent for PSA values above 10.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, detecting the curable cancers in men with PSA levels less than 10.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    presents a diagnostic challenge because the high false-positive rate leads to many unnecessary biopsies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7597682\">",
"    <span class=\"h3\">",
"     Negative predictive value",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Prostate Cancer Prevention Trial, which biopsied men with normal PSA levels, estimated a negative predictive value of 85 percent for a PSA value &le;4.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Effect of lowering PSA cutoffs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some investigators have suggested using a lower PSA cutoff because some men with PSA levels below 4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and normal digital rectal examinations are found to have prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/50-53\">",
"     50-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subset analysis from the placebo arm of the Prostate Cancer Prevention Trial, 449 of 2950 men (15.2 percent) ages 62 to 91 years who had consistently normal PSA levels and digital rectal examinations during the seven years of annual screening had prostate cancer on an end-of-study biopsy; 67 (2.3 percent) had high-grade prostate cancer with a Gleason score of 7 or higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/49\">",
"     49",
"    </a>",
"    ]. Among men with a PSA concentration between 2.1 and 4.0",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    24.7 percent had prostate cancer, and 5.2 percent had prostate cancer with a Gleason score of 7 or higher.",
"   </p>",
"   <p>",
"    These observations indicate that there is not a clear cutpoint between \"normal\" and \"abnormal\" PSA levels. The Prostate Cancer Prevention Trial found that for biopsies performed during follow-up in the control group even a PSA cutoff of 1.1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    would miss 17 percent of cancers, including 5 percent of poorly differentiated cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/54\">",
"     54",
"    </a>",
"    ]. Thus, any choice of PSA cutoff involves a tradeoff between sensitivity and specificity. While lowering the PSA cutoff would improve test sensitivity, a lower PSA cutoff would also reduce specificity, leading to far more false-positive tests and unnecessary biopsies. It has been projected that if the PSA threshold were to be lowered to 2.5",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    the number of men defined as abnormal would double, to up to six million in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/55\">",
"     55",
"    </a>",
"    ]. Additionally, many of the cancers detected at these lower levels may never have become clinically evident, thereby leading to overdiagnosis and overtreatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also evidence that diagnosing prostate cancer at low PSA levels does not affect outcome. A study of 875 men undergoing radical prostatectomy found only a limited association between preoperative PSA levels of 2 to 9",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and cure rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/57\">",
"     57",
"    </a>",
"    ]. The disease-free survival curves did not significantly diverge until the preoperative PSA levels reached 7",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    suggesting that diagnosing cancers at a lower PSA level may be unnecessary. Most of the PSA elevation below 7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    was attributed to benign hyperplastic tissue. The investigators emphasized the need for a better serum marker to identify early-stage aggressive cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Serial PSA measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both detection rates and positive predictive values decline substantially with serial testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During four rounds of annual PSA screening in the PLCO trial, the number of cancers detected per 1000 men decreased from 14.2 to 9.3 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/60\">",
"       60",
"      </a>",
"      ]. Similarly, the positive predictive value of a PSA level &gt;4.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      decreased from 44.5 to 34.9 percent.",
"     </li>",
"     <li>",
"      The cancer detection rate for PSA in the ERSPC, which used a 4-year screening interval, decreased from 5.1 percent in the first round of screening to 4.4 percent in the second round [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/61\">",
"       61",
"      </a>",
"      ]. The positive predictive value for a PSA level of 3.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or greater decreased from 29.2 to 19.9 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies also found that repeated testing increases the likelihood that detected tumors will be clinically organ-confined and be moderately or well differentiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/41,60-62\">",
"     41,60-62",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H36\">",
"     'Frequency and method of screening'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the PLCO, the proportion of screening-detected cancers diagnosed at clinical stage I or II increased from 94.2 percent in round one to 98.5 percent in round 2, while the proportion with Gleason scores &ge;7 decreased from 10.0 to 6.8 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the ERSPC, the proportion of clinical stage I and II cancers increased from 81.5 to 96.3 percent, while the proportion of poorly-differentiated cancers decreased from 8.1 to 3.3 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Secular trends in the utility of PSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A United States study that looked at the correlation between PSA level and prostate cancer during five-year intervals at a university hospital found that while serum PSA was correlated with prostate cancer stage, grade, and size in the interval from 1983 to 1988, in the interval from 1998 to 2003 it was correlated only with prostate weight (related to benign prostatic hypertrophy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors concluded that in this era of intense screening for prostate cancer, PSA has ceased to be a useful marker, and biopsies in men with an elevated PSA level are only picking up the background prevalence of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. That is, the same rates of prostate cancer could be found in men of the same age without regard to PSA level, and in many cases the detected tumors would never become clinically significant. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Overdiagnosis'",
"    </a>",
"    below.) The authors point out that a study that performed saturation prostate biopsies in men with negative sextant biopsies also found no significant association between PSA level and prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of these studies raise further concerns about the utility of PSA as a marker for clinically significant prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Improving the accuracy of PSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous strategies have been proposed to improve the diagnostic performance of PSA when levels are less than 10.0",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    These strategies include measuring PSA velocity (change in PSA over time), PSA density (PSA per unit volume of prostate), free PSA, complexed PSA, and using age- and race-specific reference ranges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/66\">",
"     66",
"    </a>",
"    ]. We suggest not routinely using any of these strategies in deciding which men to refer for biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=see_link\">",
"     \"Measurement of prostate specific antigen\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     PSA velocity",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSA increases more rapidly in men with prostate cancer than in healthy men. The Baltimore Longitudinal Study of Aging (BLSA) found that men with a PSA rate of change (PSA velocity) greater than 0.75",
"    <span class=\"nowrap\">",
"     ng/mL/year",
"    </span>",
"    were at increased risk of being diagnosed with prostate cancer and that PSA velocity was more specific than a 4.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    PSA cutoff (90 versus 60 percent specificity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/67\">",
"     67",
"    </a>",
"    ]. The study results, though, were based on analyzing the banked serum of only 18 cancer cases. Furthermore, there are significant short-term physiologic variations in the PSA level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/68\">",
"     68",
"    </a>",
"    ]. Accurately measuring PSA velocity requires three serial readings, ideally with the same assay, obtained over at least a 12- to 24-month period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/66,69,70\">",
"     66,69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, analyses of more recent clinical data from randomized trials suggest that PSA velocity adds little predictive information to the total PSA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The European Randomized Study of Screening for Prostate Cancer (ERSPC) data from Rotterdam found that PSA velocity was significantly higher in men with prostate cancer than in men with a negative biopsy (0.62 versus 0.46",
"      <span class=\"nowrap\">",
"       ng/mL/year)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/71\">",
"       71",
"      </a>",
"      ]. However, PSA velocity did not independently predict cancer after adjusting for PSA level.",
"      <br/>",
"      <br/>",
"      Another analysis of pooled ERSPC data from the Netherlands and Sweden similarly found that PSA velocity only slightly improved the predictive accuracy of total PSA (area under the ROC curve 0.57 versus 0.53), but not for detecting high-grade disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/72\">",
"       72",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Among the 774 Rotterdam men with a PSA level below 4.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      who underwent their first biopsies in the second round of ERSPC, 149 were found to have cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/73\">",
"       73",
"      </a>",
"      ]. PSA velocity did not discriminate between men with cancer and those with negative biopsies. The sensitivity of a PSA velocity cutoff of 0.3",
"      <span class=\"nowrap\">",
"       ng/mL/year",
"      </span>",
"      was only 39 percent, with a false positive rate of 33 percent.",
"     </li>",
"     <li>",
"      In two separate analyses, the Prostate Cancer Prevention Trial reported on the 5519 men from the placebo group who underwent prostate biopsy following at least two PSA measurements in the preceding two or three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/74,75\">",
"       74,75",
"      </a>",
"      ]. While PSA level was a significant predictor of prostate cancer diagnosis on multivariate modeling, incorporating PSA velocity did not add clinically important predictive information to PSA level alone, particularly for PSA values &ge;4.0",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      When total PSA was less than 4.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      and the DRE was normal, a PSA velocity above 0.35",
"      <span class=\"nowrap\">",
"       ng/mL/year",
"      </span>",
"      predicted cancer. However, using velocity would substantially increase the number of unnecessary biopsies while missing more high-grade cancers than would be identified by just lowering the PSA cutoff.",
"     </li>",
"     <li>",
"      A systematic review of PSA velocity, including 12 comparisons with total PSA for predicting prostate cancer diagnosis, found numerous methodological limitations and essentially no evidence supporting the use of PSA velocity for clinical decision-making [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some investigators have argued that PSA doubling time or percent change is a more appropriate measure of PSA kinetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/77\">",
"     77",
"    </a>",
"    ]. PSA velocity is correlated with the total PSA level, which increases exponentially before clinical diagnosis.",
"   </p>",
"   <p>",
"    Even though PSA velocity may be independently correlated with cancer diagnosis, it adds little to the diagnostic accuracy of PSA alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     PSA density",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PSA density measurement is based upon the observation that prostate cancers can produce approximately 10 times more PSA per volume of prostate tissue than benign conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/19,79\">",
"     19,79",
"    </a>",
"    ]. PSA density measurements, which adjust PSA values for prostate volume, have been reported to better discriminate between cancer and noncancer groups than PSA levels alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, PSA density measurements require transrectal ultrasound or magnetic resonance imaging to assess prostate volume, which limits applicability in primary care settings. Additionally, precisely estimating prostate volume is difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from a large multicenter screening trial suggested that using a cutoff PSA density of 0.15",
"    <span class=\"nowrap\">",
"     ng/mL/cm3",
"    </span>",
"    (a commonly-recommended cutoff value) would miss nearly 50 percent of cancers detected in men with a normal digital rectal examination and PSA levels between 4.0 to 10.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/81\">",
"     81",
"    </a>",
"    ]. Adjusting the PSA density cutoff value for total PSA level might improve the test sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measuring the PSA density of the prostatic transition zone has also been proposed to improve the specificity of PSA since the hyperplastic tissue that can elevate PSA is almost completely localized to this area of the prostate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/66\">",
"     66",
"    </a>",
"    ]. Using a PSA transition zone density greater than 0.22",
"    <span class=\"nowrap\">",
"     ng/mL/cm3",
"    </span>",
"    as a biopsy criterion was estimated to reduce the number of negative biopsies by 24.4 percent based upon data from an Austrian screening study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/83\">",
"     83",
"    </a>",
"    ]. However, given the logistic difficulties of performing density measurements as well as their lack of reproducibility, the transition zone density is not currently accepted for routine clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Free PSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that PSA exists in a free form as well as bound to macromolecules has been used to develop additional assays to improve test specificity. The ratio of free-to-total PSA is reduced in men with prostate cancer. Investigators have proposed that biopsies be performed only in men with lower ratios. A large multicenter, prospective trial evaluated men 50 to 75 years with PSA levels between 4.0 and 10.0",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    including 379 with prostate cancer and 394 with benign prostate disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/84\">",
"     84",
"    </a>",
"    ]. The cancer detection rate for this PSA range in screening populations is about 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/46\">",
"     46",
"    </a>",
"    ]. However, the detection rate increased to 56 percent for men with a free-to-total PSA ratio less than 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/84\">",
"     84",
"    </a>",
"    ]. The investigators selected an optimal cutoff of 25 percent as a criterion for biopsy, which would have reduced the number of unnecessary biopsies by 20 percent in their study cohort. However, men with a normal free-to-total PSA ratio still had an 8 percent probability of having cancer, which may not be low enough to convince patients and clinicians to forego biopsy. A meta-analysis came to similar conclusions that free-to-total PSA ratio is generally only clinically helpful at extreme values of the ratio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate meta-analysis of free PSA noted considerable variability in free PSA assays, specimen handling, cutoffs, and patient populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/86\">",
"     86",
"    </a>",
"    ]. The authors concluded that more research was necessary to determine the optimal cutoff and to accurately assess the diagnostic performance and utility of the test in screening populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Complexed PSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another strategy to improve PSA specificity has been to measure complexed PSA (cPSA). Most circulating PSA is bound to alpha-1-antichymotripsin. A study using archival serum found that, at 95 percent sensitivity, cPSA had a specificity of 26.7 percent compared with 15.6 percent for the free-to-total PSA ratio and 21.8 percent for total PSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective study in 831 men undergoing prostate biopsy found that cPSA was more specific than total PSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/88\">",
"     88",
"    </a>",
"    ]. For men with a total PSA concentration between 4 to 10",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    when a cPSA cutpoint was chosen to achieve a sensitivity of 90 percent, cPSA had a higher specificity than total PSA (13.3 versus 8.6 percent), but it was less specific than percent free PSA and percent complexed PSA (21.5 and 21.9 percent, respectively). For men with a total PSA concentration between 2 to 6",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    cPSA was more specific than other methods.",
"   </p>",
"   <p>",
"    The marginal benefit of measuring complexed PSA over total PSA remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2782134\">",
"    <span class=\"h3\">",
"     [-2]ProPSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;[-2]ProPSA (also known as p2PSA) is a specific isoform of the PSA proenzyme proPSA. It has been used to increase the detection of prostate cancer for men with PSA values between 2.0 to 10.0",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    One prospective observational study estimated that using the p2PSA assay (which is not available in the United States) could reduce the number of unnecessary biopsies by 7.6 percent while maintaining a sensitivity of 95 percent for detecting prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/89\">",
"     89",
"    </a>",
"    ]. The cohort included 892 men with normal digital rectal examinations, some of whom previously had negative prostate biopsies. Another prospective study of 268 subjects, using the ratio of p2PSA over free PSA, estimated about a 35 percent reduction in the number of unnecessary biopsies while maintaining 95 percent sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/90\">",
"     90",
"    </a>",
"    ]. Neither study presented data on the performance of p2PSA for detecting high-risk cancers. The clinical utility of this biomarker is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Age-specific reference ranges",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSA levels increase with age, largely due to a higher prevalence of benign prostatic hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/92\">",
"     92",
"    </a>",
"    ]. Although we do not recommend their use, age-specific reference ranges have been developed from normal populations to improve the discriminating power of PSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/93\">",
"     93",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      40 to 49 years &mdash; 0 to 2.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"     <li>",
"      50 to 59 years &mdash; 0 to 3.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"     <li>",
"      60 to 69 years &mdash; 0 to 4.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"     <li>",
"      70 to 79 years &mdash; 0 to 6.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Raising the PSA biopsy threshold in older men improves specificity, reducing the number of unnecessary biopsies. Conversely, lowering the threshold in younger men improves sensitivity and increases detection of early-stage tumors.",
"   </p>",
"   <p>",
"    A retrospective analysis of a large screening cohort reported that applying age-specific reference standards would miss 47 percent of clinically localized cancers in men 70 and older and lead to a 45 percent increase in unnecessary biopsies for men in their 50s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical utility of age-specific reference ranges remains uncertain, and they are not recommended by the US Food and Drug Administration (FDA) or PSA assay manufacturers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Race-specific reference ranges",
"    </span>",
"    &nbsp;&mdash;&nbsp;Black men in the United States have the world's highest incidence of prostate cancer and are the most likely to present with advanced stage disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/11\">",
"     11",
"    </a>",
"    ]. PSA levels in blacks are higher compared with whites even after adjusting for age, clinical stage, and histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/95\">",
"     95",
"    </a>",
"    ]. This difference has been attributed to blacks having larger tumor volumes across all clinical stages.",
"   </p>",
"   <p>",
"    Although we do not recommend their use, race-specific PSA reference ranges have been established in the hope of achieving earlier diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/96\">",
"     96",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      40 to 49 years &mdash; 0 to 2.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (whites); 0 to 2.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (blacks)",
"     </li>",
"     <li>",
"      50 to 59 years &mdash; 0 to 3.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (whites); 0 to 4.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (blacks)",
"     </li>",
"     <li>",
"      60 to 69 years &mdash; 0 to 3.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (whites); 0 to 4.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (blacks)",
"     </li>",
"     <li>",
"      70 to 79 years &mdash; 0 to 3.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (whites); 0 to 5.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (blacks)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a study of 651 men undergoing radical prostatectomy found that the race-specific reference ranges, which raise the cutoff for blacks 50 years and older compared with whites, would be associated with similar or worse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/97\">",
"     97",
"    </a>",
"    ]. The clinical utility of the race-specific reference ranges, which have also been developed for Asians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/98\">",
"     98",
"    </a>",
"    ], remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on using any of the PSA modifications, and none of them has been shown to reduce the number of unnecessary biopsies or improve clinical outcomes. The total PSA cutoff of 4.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    has been the most accepted standard because it balances the tradeoff between missing important cancers at a curable stage and avoiding both detection of clinically insignificant disease and subjecting men to unnecessary prostate biopsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/39,56,66\">",
"     39,56,66",
"    </a>",
"    ]. Ongoing efforts are targeted at identifying new serum markers that will have greater diagnostic accuracy for prostate cancer, particularly for aggressive tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/66,99\">",
"     66,99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=see_link\">",
"     \"Measurement of prostate specific antigen\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIGITAL RECTAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digital rectal examination (DRE) has long been used to diagnose prostate cancer. Abnormal prostate findings include nodules, asymmetry, or induration. DRE can detect tumors in the posterior and lateral aspects of the prostate gland; an inherent limitation to the digital examination is that only 85 percent of cancers arise peripherally where they can be detected with a finger examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/100\">",
"     100",
"    </a>",
"    ]. Stage T1 cancers are nonpalpable by definition.",
"   </p>",
"   <p>",
"    No controlled studies have shown a reduction in the morbidity or mortality of prostate cancer when detected by DRE at any age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/101\">",
"     101",
"    </a>",
"    ]. The majority of cancers detected by digital examination alone are clinically or pathologically advanced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/102\">",
"     102",
"    </a>",
"    ]. Thus, the greatest value of DRE may be its use in combination with PSA testing. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Combining PSA and DRE'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Test performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urologists have been found to have relatively low interrater agreement for detecting prostate abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/103\">",
"     103",
"    </a>",
"    ]. No data are available for the test performance characteristics of DRE in primary care.",
"   </p>",
"   <p>",
"    Approximately 2 to 3 percent of men 50 or more years old who undergo a single DRE have induration, marked asymmetry, or nodularity of the prostate. In one analysis, an abnormal screening DRE doubled the odds of detecting a clinically important cancer (defined as a having a tumor volume greater than 0.5 mL) that was confined to the prostate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/48\">",
"     48",
"    </a>",
"    ]. Although screening DRE increased the likelihood of finding early disease, it also increased the odds three- to ninefold of finding extraprostatic extension of tumor (presumably not amenable to curative therapy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Sensitivity and specificity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of DRE estimated a sensitivity for detecting prostate cancer of 59 percent and a specificity of 94 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Positive predictive value",
"    </span>",
"    &nbsp;&mdash;&nbsp;The positive predictive value of an abnormal DRE for prostate cancer varies from 5 to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/46,102,105-108\">",
"     46,102,105-108",
"    </a>",
"    ]. A meta-analysis calculated an overall positive predictive value of 28 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COMBINING PSA AND DRE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate specific antigen (PSA) and digital rectal examination (DRE) are somewhat complementary, and their combined use can increase the overall rate of cancer detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/39,46,109-111\">",
"     39,46,109-111",
"    </a>",
"    ]. As an example, a multicenter screening study of 6630 men reported a detection rate of 3.2 percent for DRE, 4.6 percent for PSA, and 5.8 percent for the two methods combined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/46,106\">",
"     46,106",
"    </a>",
"    ]. PSA detected significantly more of the cancers than digital examination (82 versus 55 percent). Overall, 45 percent of the cancers were detected only by PSA, while just 18 percent were detected solely by digital examination.",
"   </p>",
"   <p>",
"    Investigators reported a positive predictive value of 10 percent for a suspicious digital examination when the PSA level was normal. However, the positive predictive value was 24 percent for an elevated PSA level with a normal digital examination. Among men with a normal PSA level, abnormalities on DRE appear less likely to be from a cancer if the PSA concentration is below 1.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    than if the PSA concentration is between 3.0 to 4.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these data suggest a potential benefit for combining PSA and DRE in detecting prostate cancer, randomized trials have not confirmed a benefit on prostate cancer outcomes. The ERSPC, which found a small survival benefit with PSA screening, did not consistently require DRE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/13\">",
"     13",
"    </a>",
"    ]. The PLCO found no survival benefit with combined PSA and DRE screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OTHER TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H988952102\">",
"    <span class=\"h2\">",
"     PCA3",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prostate cancer antigen 3 gene (PCA3), which was identified in 1999, is highly overexpressed in almost all prostate cancer tissue specimens, but not in normal or hypertrophied tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/112\">",
"     112",
"    </a>",
"    ]. A PCA3 score, based on the ratio of PCA3 mRNA over PSA mRNA (which is not related to serum PSA levels or cancer), can be determined from a urine specimen collected after a vigorous digital rectal examination. PCA3 has been evaluated for guiding biopsy decisions when PSA levels are in an indeterminate range (2.5 to 10.0",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    and for men with previously negative biopsies but persistently elevated PSA levels.",
"   </p>",
"   <p>",
"    A 2010 review identified 11 clinical trials, representing 2737 subjects, evaluating the diagnostic performance of PCA3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/113\">",
"     113",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In four studies evaluating patients with indeterminate PSA, sensitivity ranged from 53 to 84 percent and specificity ranged from 71 to 80 percent.",
"     </li>",
"     <li>",
"      In three studies with at least 200 patients that provided data on PCA3 performance following a previous negative biopsy, sensitivity ranged from 47 to 58 percent, and specificity ranged from 71 to 72 percent. PCA3 outperformed PSA and percent free PSA in independently predicting a positive biopsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, determining the clinical utility of PCA3 from these studies is difficult. Aside from the relatively small sample sizes, studies differed in their criteria for biopsy referral (PSA levels 2.5 to 3.0",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    digital rectal examination findings, or risk factors), the generation of the PCA3 test used, and the cutpoint for defining an abnormal test. Additionally, none of the studies used PCA3 scores as an indication for biopsy.",
"   </p>",
"   <p>",
"    The Rotterdam site of the ERSPC subsequently reported the results of using PCA3 as an initial screening test, with sextant biopsy performed if either the PSA level was &ge;3 or the PCA3 score was &ge;10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/114\">",
"     114",
"    </a>",
"    ]. Based on receiver operating characteristic (ROC) curve analysis of 721 subjects undergoing biopsy, PCA3 performed only marginally better than total PSA (area under the curve 0.64 versus 0.58, p = 0.14); PCA3 also missed the majority of cancers with Gleason &gt;6 or stage &ge;T2a, though only 19 men met these criteria. However, the generalizability of these results is uncertain because all subjects had already undergone three rounds of screening, and 29 percent had previous negative biopsies. &nbsp;",
"   </p>",
"   <p>",
"    While PCA3 may eventually have a role in reducing unnecessary biopsies, there are insufficient data on clinical outcomes to currently support routine use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Transrectal ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transrectal ultrasonography (TRUS) is an outpatient procedure that requires no sedation or analgesia and is relatively well tolerated by most men.",
"   </p>",
"   <p>",
"    TRUS is not recommended as a primary screening test for prostate cancer because of its low sensitivity and positive predictive value. As an example, in one study almost 40 percent of cancers would have been missed if prostate biopsies had been performed only in men with suspicious findings on TRUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/46\">",
"     46",
"    </a>",
"    ]. Furthermore, TRUS is not a feasible screening test in primary care clinics. TRUS is typically used to guide prostate biopsy rather than as a screening test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS OF PROSTATE CANCER SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apart from issues of cost and acceptability, in order for prostate cancer screening to be valuable, it must reduce disease-specific morbidity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Evidence from randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two well-designed large randomized trials have evaluated the effectiveness of screening for prostate cancer and found somewhat differing results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the European Randomized Study of Screening for Prostate Cancer (ERSPC), 182,160 men between the ages of 50 and 74 were randomly assigned to PSA screening (an average of once every four years) or a control group that was not offered screening [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/13\">",
"       13",
"      </a>",
"      ]. This study used different recruiting and randomization procedures across seven centers in Europe. The study used PSA cutoffs between 2.5 and 4.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (most centers used a cutoff of 3.0",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      as indications for referral for biopsy, variably supplemented with DRE, transrectal ultrasonography,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      measurements of free PSA levels. The overall rate of prostate cancer screening in the control group was not reported, though 31 percent of cancers were categorized as stage T1c (diagnosed based on elevated PSA level). Investigators subsequently reported PSA testing among 24 percent of the Rotterdam site controls and estimated that 50 percent of the tests were for screening [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/115\">",
"       115",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      After a median follow-up of 11 years, for the 162,243 men between the ages of 55 and 69 the primary outcome of prostate cancer mortality was 21 percent lower in the group offered screening (rate ratio 0.79, 95% CI 0.68-0.91) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/116\">",
"       116",
"      </a>",
"      ]. The absolute rates of prostate cancer mortality were 0.39 versus 0.50 per 1000 person-years (absolute reduction of 0.10 deaths per 1000 person-years; 1055 men needed to be invited for screening to prevent one prostate cancer death over 11 years). Prostate cancer was diagnosed more frequently in the screening group (9.7 versus 6.0 cases per 1000 person-years), such that 37 additional cases of prostate cancer would need to be detected by screening to prevent one death from prostate cancer over 11 years. All-cause mortality was not reduced with screening (18.2 versus 18.5 deaths per 1000 person-years; rate ratio 0.99, CI 0.97-1.01). Prostate cancer mortality was also reduced in the entire cohort of men ages 50 to 74 (rate ratio 0.83, CI 0.73-0.95). Several centers collected quality-of-life data; however, these results have not yet been published.",
"      <br/>",
"      <br/>",
"      Although the absolute mortality benefit for screening was low, several factors could have biased the results toward no effect. About 24 percent of subjects invited for screening did not undergo PSA testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/13\">",
"       13",
"      </a>",
"      ]. While not definitively characterized, a substantial proportion of the control group likely received PSA testing (31 percent of cancers were screening-detected). A subsequent analysis of the Rotterdam site data used patient surveys and linkages with a central national laboratory to estimate contamination. Adjusting for contamination and non-adherence with screening, investigators estimated that prostate cancer screening could reduce prostate cancer mortality by as much as 31 percent (95% CI 8-49 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/117\">",
"       117",
"      </a>",
"      ]. Additionally, at least 25 percent of cancers detected in the screening group did not receive curative treatment with either surgery or radiation. Finally, given the indolent course of prostate cancer and the five to ten year lead time associated with PSA testing, follow-up duration may have been insufficient to accurately estimate the survival benefit. A modeling study using data from all ERSPC sites concluded that the screening benefit could increase over time, with numbers needed to screen of 837 at year 10 and 503 at year 12 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/118\">",
"       118",
"      </a>",
"      ]. However, any survival benefit from screening would not be realized for many years, while the burdens of screening and treatment, including harms from overdiagnosis and overtreatment, would occur immediately and potentially have lifelong consequences.",
"      <br/>",
"      <br/>",
"      Several biases could also have favored the screening group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/119\">",
"       119",
"      </a>",
"      ]. A higher proportion of cancers diagnosed in the screening group were aggressively treated (surgery or radiation) compared to the control group, so some of the outcome differences could be related more to improved treatment than screening. Additionally, the committee adjudicating cause of death was aware of cancer treatments. Previous studies have suggested that cause of death is less likely to be attributed to prostate cancer for patients who received aggressive treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/120\">",
"       120",
"      </a>",
"      ]. The ERSPC investigators did not report the association of cancer death and receipt of treatment.",
"      <br/>",
"      <br/>",
"      The ERSPC site from G&ouml;teborg, Sweden subsequently reported a cumulative mortality reduction of 44 percent for the PSA screening group after a median 14 years of follow up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/121\">",
"       121",
"      </a>",
"      ]. The G&ouml;teborg site, which used population registries to randomly allocate men to either the screening or control groups, could plausibly be more likely to demonstrate benefit than the other ERSCP sites because it offered screening every two years (versus every four years) and the median follow up was 5 years longer than for the initial report. Additionally, the G&ouml;teborg results were based on a cohort of men ages 50 to 64, compared to ages 55 to 69 in the combined ERSPC report. This suggests that screening may be less beneficial for men 65 and older, consistent with the finding that radical prostatectomy did not confer a survival benefit compared to watchful waiting for men in this age range [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/122\">",
"       122",
"      </a>",
"      ]. Nevertheless, the 95 percent confidence interval for mortality reduction ranged from 18 to 61 percent, which overlaps the overall 20 percent risk reduction previously reported by ERSPC, and the absolute cumulative risk reduction was only 0.40 percent (95% CI 0.17-0.64%). Screening also increased the risk for prostate cancer diagnosis by 55 percent. Finally, men in the screening group were more likely to receive attempted curative therapy than those in the control group, particularly radical prostatectomy.",
"     </li>",
"     <li>",
"      In the United States Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial, 76,693 men between the ages of 55 and 74 were randomly assigned to annual screening with PSA and DRE or to usual care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/15\">",
"       15",
"      </a>",
"      ]. A PSA level above 4.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or an abnormal DRE were indications for biopsy. A high proportion of men in the control group underwent PSA testing (52 percent in the sixth year of the study) and over 40 percent of study subjects had undergone PSA testing within three years before enrolling in the trial.",
"      <br/>",
"      <br/>",
"      In contrast to the ERSPC, after seven years of follow-up there was no reduction in the primary outcome of prostate cancer mortality (50 versus 44 deaths in the screening and control groups, respectively; rate ratio 1.13, 95% CI 0.75-1.70). Cancer detection in the screening group was significantly higher than in the control group (2820 versus 2322, rate ratio 1.22, CI 1.16-1.29). A subsequent publication looking at longer-term follow-up within the PLCO (92 percent follow-up through 10 years; 57 percent through 13 years) found similar prostate cancer mortality results (RR 1.12, CI 1.07-1.17) with no suggestion of reduced mortality in the patients followed for 13 years (RR 1.09, CI 0.87-1.36) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/123\">",
"       123",
"      </a>",
"      ]. This suggests that the differences in results between the ERSPC and the PLCO were not related to the duration of follow-up. Additionally, the investigators found no evidence that screening could be beneficial in any subgroups defined by comorbidity, age, or pretrial PSA testing.",
"      <br/>",
"      <br/>",
"      The negative results could be attributable to the high rate of PSA testing in the control arm, the high proportion of subjects with recent PSA testing at baseline (because serial testing is associated with finding fewer and less aggressive cancers), the higher PSA cutoff for biopsy compared with that used in the ERSPC, or the small number of prostate cancer deaths. An earlier PLCO publication also indicated that substantial proportions of men with abnormal PSA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      DRE results had not undergone biopsy within three years following the positive screen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/60\">",
"       60",
"      </a>",
"      ]. All of these factors could bias the PLCO trial toward a null result, and also suggest that further follow-up is not likely to yield positive results.",
"      <br/>",
"      <br/>",
"      One earlier randomized trial of screening for prostate cancer reported positive findings, but the data analysis was flawed. In this population-based study in Quebec, 46,193 men aged 45 to 80 years identified from electoral records were randomly assigned to screening with prostate specific antigen (PSA) and digital rectal examination (DRE) versus no screening [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/58\">",
"       58",
"      </a>",
"      ]. In an analysis that excluded the 77 percent of men in the screening arm who declined screening and excluded the 6.5 percent of men in the control group who were screened, the prostate cancer mortality rate in men undergoing screening was reported to be 67.1 percent lower than in the control group. When the data were evaluated by a more appropriate intention-to-screen analysis, there were no mortality differences between the two groups (4.6 versus 4.8 deaths per 1000 persons, respectively). Additionally, the results suggesting benefit seemed biologically implausible, since the survival benefit became apparent within only three years, a very short time for a screening program to be effective given the long lead time for prostate cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2010 meta-analysis summarized results from six randomized trials (including unique data from two ERSPC sites), with a total of 387,286 participants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/124\">",
"     124",
"    </a>",
"    ]. Screening with PSA with or without DRE compared to no screening did not reduce death from prostate cancer (relative risk [RR] 0.88, 95% CI 0.71-1.09). However, screening significantly increased the probability of cancer diagnosis (RR 1.46, CI 1.21-1.77). In a 2011 Cochrane meta-analysis that had similar findings, the estimated prostate cancer-specific mortality difference was not statistically significant (RR 0.95, 95% CI 0.85-1.07), but cancer was diagnosed significantly more often in men randomized to screening (RR 1.35, 95% CI 1.06-1.72) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concerns that ERSPC mortality findings favoring screening could have been due to differential treatment between the screening and control arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/119,126\">",
"     119,126",
"    </a>",
"    ] have been partially addressed by results from the Prostate Cancer Intervention versus Observation Trial (PIVOT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/127\">",
"     127",
"    </a>",
"    ]. PIVOT randomly assigned men with localized prostate cancer, the majority of whom had been detected by PSA screening, to either radical prostatectomy or watchful waiting. After a median follow-up of 10 years, men who were assigned to radical prostatectomy had a reduction in prostate cancer mortality that was not statistically significant (5.8 versus 8.4 percent; HR 0.63, 95% CI 0.36-1.09). Subgroup analyses suggested a potentially greater survival benefit for radical prostatectomy among men with PSA values above 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or high-risk tumor characteristics (based on tumor stage, Gleason, PSA) compared with the group as a whole. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24313?source=see_link&amp;anchor=H167060109#H167060109\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Survival impact of radical prostatectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Evidence from observational studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before publication of the randomized trials, other data had been cited to support the effectiveness of screening. Given the conflicting results discussed above, observational studies provide information that can fill in some gaps in evidence from the trials.",
"   </p>",
"   <p>",
"    Over the past decade, Surveillance Epidemiology and End Results (SEER) tumor registry data have shown a significant decline in the incidence of advanced stage disease, potentially consistent with effective screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/128\">",
"     128",
"    </a>",
"    ]. Prostate cancer mortality rates, which initially increased following the advent of PSA testing, have now declined to slightly below pre-PSA levels (",
"    <a class=\"graphic graphic_figure graphicRef75684 \" href=\"mobipreview.htm?6/2/6190\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These mortality trends, however, are difficult to interpret. Some ecologic data suggest an association between PSA testing and declining mortality rates:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Austria, the state of Tyrol introduced mass screening in 1993. Within five years, investigators observed a more than threefold adjusted decrease in prostate cancer mortality rates in Tyrol compared with the rest of the country where screening was less common [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/129\">",
"       129",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from Olmsted County in Minnesota demonstrated that age-adjusted 1993 to 1997 prostate cancer mortality rates declined 22 percent (95% CI &ndash;49 to 17) compared with rates measured in years before PSA testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/130\">",
"       130",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study found that age-adjusted prostate cancer mortality peaked in the early 1990s in both the United States and the United Kingdom, but then declined much faster in the US, where PSA screening became common, than in the UK, where PSA screening was less common (yearly decline -4.2 versus -1.1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/131\">",
"       131",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, other ecologic studies have shown declining mortality rates even in the absence of intensive screening:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trends in prostate cancer mortality rates in Wales and England from 1991 to 1997 were comparable to trends in the United States. Mortality rates declined by 1.7 percent in the United Kingdom, even though PSA screening was not routinely performed and even discouraged [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/132\">",
"       132",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regional practice variation has allowed investigators to evaluate the effect of screening and treatment on prostate cancer mortality within the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medicare beneficiaries in Seattle received more intensive PSA screening and aggressive cancer treatment from 1987 to 1990 than beneficiaries in Connecticut. However, there were no differences in prostate cancer-specific mortality over 11 years of follow-up; the adjusted mortality rate ratio was 1.03 (95% CI 0.95-1.11) in Seattle compared with Connecticut [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/133\">",
"       133",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternative explanations have been proposed for declining mortality rates. Better primary treatments could reduce mortality rates among men diagnosed with localized cancer. Additionally, the use of androgen deprivation therapy and other chemotherapies for men with advanced-stage cancer could allow men to survive long enough to die from a comorbid condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21930?source=see_link\">",
"     \"Initial management of regionally localized intermediate and high risk prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10442?source=see_link\">",
"     \"Overview of the treatment of disseminated prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Evidence from modeling studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simulation models using data from Surveillance Epidemiology and End Results (SEER) registries suggest that PSA screening could account for 45 to 70 percent of the observed decline in prostate cancer mortality rates, mainly by decreasing the incidence of distant stage disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/134\">",
"     134",
"    </a>",
"    ]. However, treatment advancements may have also contributed to the declining mortality rates.",
"   </p>",
"   <p>",
"    The European Randomized Study of Screening for Prostate Cancer (ERSPC) investigators used simulation models based on their data and observational studies reporting quality of life outcomes to project lifetime numbers of cancer diagnoses, treatments, deaths, and quality-adjusted life years gained after PSA screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/135\">",
"     135",
"    </a>",
"    ]. Overall, annual screening between ages 55 to 69 would result in nine fewer prostate cancer deaths per 1000 men followed for an entire lifetime, with a total of 73 life-years gained. Investigators projected that 98 men would need to be screened and five cancers detected to prevent one prostate cancer death. However, after adjusting for the adverse effects of screening, PSA screening resulted in an estimated loss of 16.7 quality-adjusted life-years, ranging from 24.4 life-years gained to 93.8 life-years lost. An editorialist noted that these results demonstrate that screening decisions are very sensitive to patient preferences for potential future health states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study used microsimulation modeling of observational and clinical trial data to try to determine the comparative effectiveness of alternative PSA screening strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/137\">",
"     137",
"    </a>",
"    ]. Outcome measures included the lifetime number of PSA tests, false-positive results, cancer detection, overdiagnosis, prostate cancer deaths, and lives saved. Compared to a reference strategy of annual PSA testing between ages 50 to 74 with a PSA threshold of 4.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for biopsy referral, strategies that stopped screening at an earlier age, widened testing intervals,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    used age-adjusted PSA biopsy criteria appeared to reduce the number of tests and the risks for false-positive results and overdiagnosis, while increasing the absolute risk of prostate cancer death by only a fraction of one percentage point. Conversely, screening strategies that lowered the starting age",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PSA threshold for biopsy referral appeared to markedly increase the number of tests and the risks for false-positive results and overdiagnosis, while only marginally decreasing the risk of prostate cancer death. However, concerns were raised about the analyses, including the failure to model risk factors, the use of simplified measures for stage and grade, and not considering patient preferences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     HARM FROM SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Risks of biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although early reports indicated that prostate biopsies very rarely (&lt;1 percent) caused complications (eg, bleeding, infection) serious enough to require hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/139\">",
"     139",
"    </a>",
"    ], more recent studies suggest both higher rates of infectious complications and that the rate of infectious complications may be increasing over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/140-142\">",
"     140-142",
"    </a>",
"    ]. Hospitalization rates for infectious complications in these studies have ranged from 0.6 to 4.1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infectious complications can lead to sepsis, which can very rarely lead to death. A modeling study, assuming a biopsy mortality rate of 0.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/143\">",
"     143",
"    </a>",
"    ], concluded that prostate cancer screening could be associated with a net increased overall mortality, particularly under the conditions that biopsy rates are high and screening is relatively ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/144\">",
"     144",
"    </a>",
"    ]. However, other studies have suggested much lower mortality rates following biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/142\">",
"     142",
"    </a>",
"    ]. Population-based studies include an analysis of US Medicare data that found a mortality rate of 0.3 percent in the 30 days following biopsy; this was actually 70 percent lower than the 30-day mortality in a comparison population not undergoing biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/140\">",
"     140",
"    </a>",
"    ]. An analysis of registry data from Canada found a 30-day mortality rate of 0.09 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/141\">",
"     141",
"    </a>",
"    ]. Randomized trials with follow-up on 1147 biopsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/145\">",
"     145",
"    </a>",
"    ], and 10,474 biopsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/146\">",
"     146",
"    </a>",
"    ], reported no biopsy-related deaths.",
"   </p>",
"   <p>",
"    Prostate biopsy can also lead to anxiety and physical discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/147\">",
"     147",
"    </a>",
"    ]. Among 116 men undergoing biopsy in the Rotterdam screening study, 55 percent reported discomfort with the procedure, including 2 percent who had pain persisting longer than one week.",
"   </p>",
"   <p>",
"    Being diagnosed with prostate cancer is psychologically distressing, but even patients with a negative biopsy result may be distressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/148,149\">",
"     148,149",
"    </a>",
"    ]. Chronic anxiety can follow a negative prostate biopsy because this apparently favorable result cannot completely rule out prostate cancer given the relatively high false-negative biopsy rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Overdiagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overdiagnosis refers to the detection by screening of conditions that would not have become clinically significant. When screening finds cancer that would never have become clinically significant, patients are subject to the risks of screening, confirmatory diagnosis, and treatment, as well as suffering potential psychosocial harm from anxiety and labeling. Overdiagnosis is of particular concern because most men with screening-detected prostate cancers have early-stage disease and will be offered aggressive treatment.",
"   </p>",
"   <p>",
"    A number of reports have raised concerns about the risk of overdiagnosis with screening:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While the lifetime risk of being diagnosed with prostate cancer has increased from 1 in 11 to 1 in 6, the lifetime risk of dying from prostate cancer has remained around 1 in 34 following the advent of PSA testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although about 80 percent of detected cancers are considered clinically important based on tumor size and grade [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/151\">",
"       151",
"      </a>",
"      ], these are relatively crude prognostic markers. Autopsy series in men who died from other causes have shown a 30 to 45 percent prevalence of prostate cancer in men in their fifties and an 80 percent prevalence in men in their seventies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/152-154\">",
"       152-154",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study that applied computer-simulation models of PSA testing to SEER cancer incidence data estimated that 29 percent of cancers detected in whites and 44 percent of cancers detected in blacks were overdiagnosed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/155\">",
"       155",
"      </a>",
"      ]. An updated analysis, that also used ERSPC Rotterdam clinical data, estimated an overdiagnosis fraction ranging from 23 to 42 percent among cancers diagnosed by PSA screening [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/156\">",
"       156",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, a study that applied simulation models to the results of the ERSPC estimated a 50 percent overdetection rate with annual screening for men ages 55 to 67 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/17\">",
"       17",
"      </a>",
"      ]. Given that the screening group in the ERSPC had a 71 percent higher cumulative incidence of prostate cancer than the control group (8.2 versus 4.8 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/13\">",
"       13",
"      </a>",
"      ], the potential absolute risk for overdiagnosis is substantial.",
"     </li>",
"     <li>",
"      A study examined the number of men diagnosed and treated for prostate cancer in the United States (US) each year after 1986, the year before PSA screening was introduced, until 2005 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/157\">",
"       157",
"      </a>",
"      ]. The study estimated that approximately 1.3 million additional men were diagnosed with prostate cancer as a result of screening, of whom approximately 1 million were treated. Assuming that the entire decline in prostate cancer mortality in the US from 1986 through 2005 was due to screening, an extremely optimistic assumption for PSA screening, approximately 23 men had to be diagnosed and 18 men treated for prostate cancer to prevent one death. The authors concluded that most of the additional cases of prostate cancer found since 1986 represent overdiagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of overdiagnosis of prostate cancer appears to increase with increasing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Risks of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even in the absence of treatment, many men found to have prostate cancer as a result of screening will have a lengthy period of time without clinical problems. However, undergoing radical prostatectomy and radiation therapies can lead to immediate complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The operative mortality rate is about 0.5 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/159\">",
"       159",
"      </a>",
"      ], though the rate approaches 1 percent in men over 75 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/160\">",
"       160",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Less serious, but more common complications include urinary incontinence, sexual dysfunction, and bowel problems. Radical prostatectomy can substantially decrease sexual function in 20 to 70 percent of men and lead to urinary problems in 15 to 50 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/14,161,162\">",
"       14,161,162",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    External beam radiation therapy has been reported to cause erectile dysfunction in 20 to 45 percent of men with previously normal erectile function, urinary incontinence in 2 to 16 percent of previously continent men, and bowel dysfunction in 6 to 25 percent of men with previously normal bowel function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/14,161,163\">",
"     14,161,163",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the ERSPC study estimate that 48 men need to be diagnosed with prostate cancer (of whom at least 60 percent received surgery or radiation) to prevent one prostate cancer death during nine years of follow-up, the quality of life issues related to treatment selection are very important decision-making factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     APPROACH TO SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although screening for prostate cancer with PSA can reduce mortality from prostate cancer, the absolute risk reduction is very small. Given limitations in the design and reporting of the randomized trials, there remain important concerns about whether the benefits of screening outweigh the potential harms to quality of life, including the substantial risks for overdiagnosis and treatment complications. Men who are willing to accept a substantial risk of morbidity associated with treatment in return for a small reduction in mortality might reasonably choose to be screened. Men who are at increased risk of prostate cancer because of race or family history may be more likely to benefit from screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Informed decision making",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the important tradeoffs between potential benefits and harms involved with either screening or not screening for prostate cancer, and the lack of definitive data on screening outcomes, it is particularly important that patients make informed decisions about undergoing testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/126,164-166\">",
"     126,164-166",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States Preventive Services Task Force Guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/167\">",
"     167",
"    </a>",
"    ], American College of Physicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/168\">",
"     168",
"    </a>",
"    ], American Urologic Association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/169\">",
"     169",
"    </a>",
"    ], American Cancer Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/44\">",
"     44",
"    </a>",
"    ], and the Canadian Task Force on the Periodic Health Examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/170\">",
"     170",
"    </a>",
"    ] all stress the importance of informed decision making.",
"   </p>",
"   <p>",
"    The American College of Physicians and the American Cancer Society have provided useful summaries of discussion points to consider when counseling patients about prostate cancer screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/44,168\">",
"     44,168",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prostate cancer is an important health problem; it is one of the most frequently diagnosed cancers in the United States and a leading cause of cancer death in men.",
"     </li>",
"     <li>",
"      Men should be involved in making the decision whether or not to be screened.",
"     </li>",
"     <li>",
"      Prostate cancer screening may reduce the chance of dying from prostate cancer. However, the evidence is mixed and the absolute benefit is small.",
"     </li>",
"     <li>",
"      Prostate cancer screening is associated with a substantial risk of being diagnosed with prostate cancer. Many cancers detected by screening are considered \"overdiagnosed\", meaning that they never would have caused problems during a man's lifetime.",
"     </li>",
"     <li>",
"      In order to determine whether a cancer is causing an abnormal test, men need to undergo a prostate biopsy. However, the PSA test and digital rectal exam (DRE) can both have false positive and false negative results and prostate biopsies may also miss finding cancers.",
"     </li>",
"     <li>",
"      The PSA blood test with or without the DRE can detect cancer at an earlier stage than when cancers are found because they are causing problems.",
"     </li>",
"     <li>",
"      Aggressive therapy is necessary to realize any benefit from finding an early-stage prostate cancer.",
"     </li>",
"     <li>",
"      Surgery and radiation therapies are the treatments most commonly offered in an attempt to cure prostate cancer; however, they can lead to problems with urinary, bowel, and sexual function.",
"     </li>",
"     <li>",
"      No current tests can accurately determine which men with a cancer found by screening are most likely to benefit from aggressive treatment (ie, those whose cancers are destined to cause health problems). Most men with prostate cancer will die from other causes, many will never experience health problems from their cancer.",
"     </li>",
"     <li>",
"      A strategy of active surveillance may be appropriate for men who are at low risk for complications from prostate cancer. This means not immediately treating a cancer but following PSA tests, DRE, and repeating biopsies to determine whether aggressive treatment is indicated because the cancer is progressing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians find it challenging to provide comprehensive, consistent, and balanced information about prostate cancer screening decisions during clinic visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/12,171\">",
"     12,171",
"    </a>",
"    ]. Consequently, efforts have focused on using decision aids to help patients understand screening issues and make informed decisions for screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/172,173\">",
"     172,173",
"    </a>",
"    ]. The American Cancer Society provided a list of Decision Aids for Prostate Cancer Screening (",
"    <a class=\"graphic graphic_table graphicRef75850 \" href=\"mobipreview.htm?39/21/40283\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigators have evaluated a number of interventions to facilitate such informed prostate cancer screening decisions including videotapes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/174-176\">",
"     174-176",
"    </a>",
"    ], patient group discussions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/174\">",
"     174",
"    </a>",
"    ], brief scripts read to patients during clinic visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/177\">",
"     177",
"    </a>",
"    ], verbal and written material provided before a periodic health examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/178\">",
"     178",
"    </a>",
"    ], and informational pamphlets distributed at study visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/179\">",
"     179",
"    </a>",
"    ] or through the mail [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/180\">",
"     180",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The various strategies of providing information were shown to be consistently effective in increasing patient knowledge about prostate cancer and screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/174-176,179,180\">",
"     174-176,179,180",
"    </a>",
"    ]. One study also found that providing men with screening information increased their involvement in making screening decisions and lowered their levels of decisional conflict [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/178\">",
"     178",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies have also demonstrated that men receiving screening information report less interest in undergoing PSA testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/174-176,180\">",
"     174-176,180",
"    </a>",
"    ] or receiving aggressive prostate cancer treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/174,175,177,180\">",
"     174,175,177,180",
"    </a>",
"    ]. As an example, one study randomly assigned 176 men to usual care, a face-to-face discussion of PSA testing, a videotape developed by The Foundation for Informed Medical Decision Making [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/175\">",
"     175",
"    </a>",
"    ], or a combination of videotape and discussion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/174\">",
"     174",
"    </a>",
"    ]. Among men assigned to usual care, 98 percent selected PSA testing, compared with 82 percent with the discussion, 60 percent with the videotape, and 50 percent with the combined intervention.",
"   </p>",
"   <p>",
"    Another study showed that an educational pamphlet was comparable to the above videotape in enhancing patient knowledge about prostate cancer, increasing participation in decision making for screening, and altering screening preferences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/181\">",
"     181",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The content of a screening discussion or the provision of a decision aid should be documented in the medical record, particularly when the patient decides against screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Age to begin screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening should be discussed with men beginning at age 50, though not with men who have a comorbidity that limits their life expectancy to less than 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/39,44\">",
"     39,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that black men, men with a family history of prostate cancer, particularly in relatives younger than age 65, and men who are known or likely to have the BRCA1 or BRCA2 mutations should first discuss screening at age 40 to 45 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/44,182,183\">",
"     44,182,183",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link&amp;anchor=H4#H4\">",
"     \"Risk factors for prostate cancer\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Others, including other authors for UpToDate, suggest not initiating screening discussions earlier in higher risk men, given that age is a primary determinant of risk and earlier discussions may increase the risk of harms related to screening. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of preventive medicine in adults\", section on 'Prostate cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Frequency and method of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a decision is made to screen for prostate cancer, the recommended strategy has been to perform a digital examination and measure a PSA level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/39,44\">",
"     39,44",
"    </a>",
"    ]. However, the randomized ERSPC found that PSA screening alone, measured at an average interval of four years (range two to four years), resulted in a significant, though small, reduction in prostate cancer mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/13\">",
"     13",
"    </a>",
"    ]. The PLCO study, which screened with annual PSA and DRE, found no reduction in mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/15\">",
"     15",
"    </a>",
"    ]. The optimal interval and combination of tests remains uncertain, however based on current data we suggest screening every two to four years with PSA alone.",
"   </p>",
"   <p>",
"    An analysis from the ERSPC compared outcomes from two centers with different screening intervals, Gothenburg (2 years; n = 4202) and Rotterdam (4 years; n = 13,301) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/184\">",
"     184",
"    </a>",
"    ]. The 10-year incidence of prostate cancer was significantly higher in the center with the shorter screening interval (13.1 versus 8.4 percent). Aggressive interval cancers were uncommon, and cumulative rates of such cancers were similar in the two centers (0.11 versus 0.12 percent, respectively). Follow-up was not long enough to compare mortality rates. There were potentially important differences between the patients and screening methods at these two centers that limit the strength of this nonrandomized comparison of screening intervals.",
"   </p>",
"   <p>",
"    One study that applied modeling to identify an optimal PSA testing strategy concluded that the most efficient strategy would be to screen men at age 40 and 45 years and then biannually from ages 50 to 75, while still using the 4.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    cutoff as a criterion for biopsy referral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/185\">",
"     185",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have also raised the possibility of less frequent retesting in men with lower initial PSA levels (eg, &le;1.0, 1.5. or 2.0",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    while still testing annually in those with higher PSA levels (but still below a cutoff for biopsy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/186-188\">",
"     186-188",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial found that only 1.5 percent (95% CI 1.2-1.7) of men with an initial PSA less than 1",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      converted to a PSA greater than 4.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      after five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/186\">",
"       186",
"      </a>",
"      ]. The report estimated that only 0.12 percent of men with an initial PSA less than 1",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      would be diagnosed with prostate cancer during a five-year interval. The initial PSA level was not correlated with conversion to an abnormal digital rectal examination (DRE); conversion within three years of baseline screening was nearly 10 percent, even for men with an initial PSA level below 1",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"     </li>",
"     <li>",
"      Similar findings for PSA screening were noted in the European Randomized Study of Screening for Prostate Cancer (ERSPC) in which the proportion of men with a baseline PSA below 1.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      who converted to a level above 3.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      was 0.9 percent after four years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/187\">",
"       187",
"      </a>",
"      ]. The estimated cancer detection rate was 0.15 percent during a four-year interval.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the PLCO trial, a four-year screening interval in men with a PSA below 1.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    was estimated to result in a delay in cancer diagnosis of 15.6 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/186\">",
"     186",
"    </a>",
"    ]. A separate report came to a similar estimate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/189\">",
"     189",
"    </a>",
"    ]. The clinical consequences of delayed diagnosis on prostate cancer mortality and morbidity are unknown, although the majority of cancers detected after a four-year screening interval in the ERSPC were early-stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/187\">",
"     187",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Referrals for biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If digital rectal exam is performed, either for screening or for symptoms, men with abnormal prostate exams (nodules, induration, or asymmetry) should be referred to a urologist for a transrectal ultrasound-guided prostate biopsy.",
"   </p>",
"   <p>",
"    Men with abnormal PSA values can also be referred for biopsy, though some experts recommend first repeating the PSA several weeks later, particularly for borderline elevations below 7.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/57,69\">",
"     57,69",
"    </a>",
"    ]. PSA measurements have considerable short-term variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/68,190\">",
"     68,190",
"    </a>",
"    ]. A retrospective analysis of stored serum from 972 men found substantial year-to-year fluctuations with 44 percent of men with a PSA above 4.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    having normal PSA findings at subsequent annual visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/191\">",
"     191",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to biological variability, PSA may be transiently elevated due to ejaculation, perineal trauma, or prostatitis. Before repeating a borderline elevated PSA test, patients should be asked to refrain from sexual activity and bike riding for at least 48 hours and, if there is evidence of prostatitis, complete a course of antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4776?source=see_link\">",
"     \"Acute bacterial prostatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While a PSA level of 4.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    had been considered abnormal, the ERSPC used lower PSA ranges (2.5 to 3.0",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    in conjunction with ancillary tests (DRE, transrectal ultrasonography) to guide biopsy referrals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/13\">",
"     13",
"    </a>",
"    ]. The PLCO, which used a PSA level of 4.0",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    found no survival benefit for screening, which lead investigators to question whether a lower PSA threshold should be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/15\">",
"     15",
"    </a>",
"    ]. We suggest that a PSA level of 3.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    be considered abnormal in determining who should be referred for biopsy.",
"   </p>",
"   <p>",
"    Biopsy referrals may also be based upon PSA velocity, PSA density, measurements of free or complexed PSA, and age- and race-specific PSA levels, although the clinical utility of these modifications is uncertain. However, retrospective analyses of data from the ERSPC suggest that the predictive value of PSA for detecting cancer is not improved by incorporating PSA velocity data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attempts have been made to create risk models for prostate cancer based on multiple variables (eg, PSA, family history, DRE result, PSA velocity, etc.) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/74\">",
"     74",
"    </a>",
"    ]. Until such models have undergone additional study, we do not recommend using them to decide who should undergo biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Repeat biopsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a biopsy is positive, the cancer will be staged, and the patient will be presented with treatment options. AUA guidelines recommend that patients should resume routine screening if the biopsy is negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/39\">",
"     39",
"    </a>",
"    ]. However, given the potential for false-negative results, some investigators have recommended repeating the biopsies.",
"   </p>",
"   <p>",
"    A study that repeated 100 negative sextant biopsies found cancer in 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/35\">",
"     35",
"    </a>",
"    ]. Among five men with high-grade PIN at initial biopsy, all had carcinoma detected on repeat biopsy, as did 5 of 17 (29.4 percent) of men with atypia; only 10 of 69 (14.5 percent) men without PIN or atypia had cancer detected. PSA levels above 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    also predict positive repeat prostate biopsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/192\">",
"     192",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of serial biopsies in 1051 Austrian and Belgian participants in the European Prostate Cancer Detection study with PSA levels between 4.0 to 10.0",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    cancer was detected in 83 of 820 (10 percent) men with BPH who underwent repeat biopsy six weeks after a negative biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/193\">",
"     193",
"    </a>",
"    ]. A percent free PSA less than 30 percent and a PSA density greater than 0.26",
"    <span class=\"nowrap\">",
"     ng/mL/cc",
"    </span>",
"    were the most accurate predictors of cancer detection with areas under the ROC curves of 74.5 and 61.8 percent, respectively. Cancer was detected in 5 percent of men undergoing a third biopsy and 4 percent of men undergoing a fourth biopsy. However, tumors detected with these biopsies were significantly smaller and better differentiated than tumors found with the first two biopsies. The authors concluded that repeating one biopsy was justified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/194\">",
"     194",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, 272 men in the screening arm of the ERSPC, Rotterdam had a PSA &ge;4.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and a negative biopsy and underwent repeat screening four years later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/195\">",
"     195",
"    </a>",
"    ]. In 217 of the men with a repeat PSA &ge;3.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    a biopsy was performed; prostate cancer was found in 18 (positive predictive value 8.3 percent). The majority (88.5 percent) of cancers detected during the second round of screening were organ confined, and the authors concluded that there was no need for immediate repeat biopsies in men with a PSA &ge;4.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and a negative initial biopsy.",
"   </p>",
"   <p>",
"    Another analysis of the ERSPC, Rotterdam data evaluated factors associated with having cancer detected during the second round of screening among men with a previous negative biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/196\">",
"     196",
"    </a>",
"    ]. Having a previous negative biopsy was the only factor significantly associated with biopsy outcome in the second round of screening. Among 459 men with a previous negative biopsy who underwent a second biopsy because their PSA level was still elevated on the second round of screening, only 48 cancers were detected (positive predictive value 10.5 percent). In comparison, 149 cancers were diagnosed in men with elevated PSA levels who had not been previously biopsied (positive predictive value 25.6 percent). After adjusting for the previous negative biopsy in multivariate models, investigators did not find that either total PSA level (all were above 3.0",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    or PSA velocity significantly predicted finding cancer on the second biopsy.",
"   </p>",
"   <p>",
"    We suggest that men with negative extended biopsies (biopsies performed using an extended protocol as opposed to just sextant biopsies) be managed similarly to men who have not previously undergone screening. That is, when screening is next routinely considered, men should again make an informed decision about testing; if the decision is made to screen, the same criteria used for the initial biopsy referral should again be applied. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/20/14666?source=see_link\">",
"     \"Prostate biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Stopping screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for prostate cancer is unlikely to benefit men with less than a 10-year life expectancy given the generally indolent course of the disease. While most agree with stopping screening of men who develop substantial comorbidities, applying an upper age limit to screening has less of a consensus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Actuarial tables suggest that among men in average health, only those ages 75 and younger have a 10-year life expectancy, and guidelines recommend against screening older men.",
"     </li>",
"     <li>",
"      An analysis of data from the Baltimore Longitudinal Aging Study found that discontinuing PSA testing at age 65 for men with PSA levels 0.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or less would still identify all cancers that would have been detected by age 75 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/197\">",
"       197",
"      </a>",
"      ]. If screening were discontinued for men with PSA levels of 1.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or less at age 65, then 94 percent of the cancers would still be detected.",
"     </li>",
"     <li>",
"      A case-control study from a population-based cohort in Sweden estimated that a PSA level &le;1",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      at age 60 was associated with an extremely low risk of prostate cancer metastasis (0.5 percent) or death from prostate cancer (0.2 percent) by age 85 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/198\">",
"       198",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A population-based cohort study using SEER-Medicare linked data evaluated outcomes of 89,877 older men (median age 78) diagnosed with clinically localized prostate cancer between 1992 and 2002 who were managed without attempted curative therapy. The 10-year prostate cancer specific mortality ranged from 8.3 percent (95% CI 42-12.8 percent) for men with well-differentiated cancers to 25.6 percent (CI 23.7-28.3 percent) for men with poorly-differentiated cancers. Approximately 60 percent of all subjects died from competing causes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/199\">",
"       199",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another SEER-Medicare analysis highlighted the importance of considering comorbidity. Among men with localized prostate cancer aged 75 and older, the 10-year prostate cancer mortality without attempted curative therapy was only 5.0 percent (CI 2.5-8.7 percent) for those with moderately-differentiated cancers and two or more comorbidities. The 10-year prostate cancer mortality was 18.8 percent (CI 9.3-36.8 percent) for men with poorly-differentiated cancers and two or more comorbidities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/200\">",
"       200",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A decision analysis using Medicare data found that aggressively treating men age 70 and older could actually decrease the quality adjusted life expectancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/201\">",
"       201",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, another decision model, using results from the Scandinavian randomized trial of radical prostatectomy versus watchful waiting and case series utilizing three-dimensional conformal external beam radiation, concluded that many healthy men in their 70s or 80s with at least moderate-grade disease would benefit from aggressive therapy. However, subsequent results from the Scandinavian trial suggest that mortality benefits from radical prostatectomy may be limited to men younger than age 65.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Currently, clinical trial data are insufficient to resolve this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Cancer Society (ACS) emphasizes the need for involving men in the decision whether to screen for prostate cancer. Men need to have sufficient information regarding the risks and benefits of screening and treatment to make an informed and shared decision; providing them with a decision aid may facilitate the decision-making process [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/44\">",
"       44",
"      </a>",
"      ]. For men who decide to be screened, the ACS recommends PSA testing with or without DRE for average-risk men beginning at 50 years of age. Screening should not be offered to men with a life expectancy less than 10 years. Men whose initial PSA level is greater than or equal to 2.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      should undergo annual testing; men with a lower initial level can be tested every two years. The guidelines also recommend beginning screening discussions at age 40 to 45 in patients at high-risk of developing prostate cancer (eg, black men and men with a first-degree relative with prostate cancer diagnosed before age 65). The guideline also recommends keeping the biopsy referral threshold at 4.0",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      However, for men with PSA levels from 2.5 to 4.0",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      the guideline encourages individualized decision making and assessment (",
"      <a class=\"external\" href=\"file://deb.uthscsa.edu/URORiskCalc/Pages/uroriskcalc.jsp\">",
"       file://deb.uthscsa.edu/URORiskCalc/Pages/uroriskcalc.jsp",
"      </a>",
"      ), which can include age, race, family history, digital rectal examination findings, previous biopsy results, and use of five alpha-reductase inhibitors.",
"     </li>",
"     <li>",
"      The American Urological Association continues to recommend informing men about the risks and benefits of prostate cancer screening and treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/169\">",
"       169",
"      </a>",
"      ]. Screening should be performed annually with both PSA and DRE; however, the guideline now recommends that average-risk men consider obtaining a baseline PSA at age 40 if their life expectancy is greater than 10 years. The decision regarding the age to stop screening should be individualized based on presence of comorbidities and family history of longevity. Furthermore, the AUA no longer recommends a single threshold value of PSA for biopsy referral. Instead, biopsy detections should consider multiple factors, including free and total PSA, PSA velocity, DRE findings, age,",
"      <span class=\"nowrap\">",
"       race/ethnicity,",
"      </span>",
"      family history, previous biopsy results, and comorbidities.",
"     </li>",
"     <li>",
"      The United States Preventive Services Task Force (USPSTF) updated its recommendations in 2012 to recommend that men not be screened for prostate cancer, concluding that there is moderate certainty that the benefits of such screening do not outweigh the harms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/202\">",
"       202",
"      </a>",
"      ]. The USPSTF did advise that men requesting screening be supported in making an informed decision. The USPSTF clinical practice guideline for screening for prostate cancer, as well as other USPSTF guidelines, can be accessed through the website for the",
"      <a class=\"external\" href=\"file://www.ahrq.gov/clinic/uspstfix.htm\">",
"       Agency for Healthcare Research and Quality",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The Canadian Task Force on Preventive Health Care recommends against screening for prostate cancer with PSA or TRUS and states that there is insufficient evidence to recommend for or against screening with DRE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/203\">",
"       203",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The United Kingdom National Screening Committee does not recommend screening for prostate cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/204\">",
"       204",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Australian Cancer Council states that the evidence does not support population-based screening and recommends a patient-centered approach that individualizes the decision [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/205\">",
"       205",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The European Society for Medical Oncology (ESMO) recommends against population based screening and in favor of an individualized approach using shared decision making [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/206\">",
"       206",
"      </a>",
"      ]. ESMO further states that there is inconsistent evidence on screening men younger than 50 and between 70 and 75 years of age, and evidence that the harms of screening outweigh the benefits for men over age 75.",
"     </li>",
"     <li>",
"      The American College of Physicians (ACP) recommendation states that \"Rather than screening all men for prostate cancer as a matter of routine, physicians should describe the potential benefits and known harms of screening, diagnosis, and treatment; listen to the patient's concerns; and then individualize the decision to screen\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/8/42122/abstract/168\">",
"       168",
"      </a>",
"      ]. The ACP also suggests that men between the ages of 50 to 69 years are most likely to benefit from screening. Black men and men with a positive family history of prostate cancer should be informed of their higher lifetime risk, although the available evidence does not suggest that they need to be treated differently from men at average risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/27/32176?source=see_link\">",
"       \"Patient information: Prostate cancer screening (PSA tests) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/55/38770?source=see_link\">",
"       \"Patient information: Prostate cancer screening (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although screening for prostate cancer with PSA can reduce mortality from prostate cancer, the absolute risk reduction is very small. Given limitations in the design and reporting of the randomized trials, there remain important concerns about whether the benefits of screening outweigh the potential harms to quality of life, including the substantial risks for overdiagnosis and treatment complications. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Approach to screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because individual patient preferences for specific health outcomes are a deciding factor in determining whether to screen for prostate cancer, men who are potential candidates for screening should be engaged in discussions or decision-making processes that inform them and evoke these preferences:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Discussions should present men with information on the risks and benefits of screening, such as those in the summary points suggested by the American Cancer Society that are discussed above. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Informed decision making'",
"      </a>",
"      above.) Using existing written or video decision aids may help ensure that patients receive consistent, complete, and objective information and may optimize the time spent discussing screening during a clinic visit.",
"     </li>",
"     <li>",
"      Health care providers should periodically discuss prostate cancer screening with men who are expected to live at least 10 years and are old enough to be at significant risk for prostate cancer. We suggest that discussions begin at age 50 in average risk white men and at age 40 to 45 in black men, men with a positive family history, and men who are known or likely to have the BRCA1 mutation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Men who are at increased risk of prostate cancer because of race or family history may be more likely to benefit from screening. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Age to begin screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a decision is made to screen, we suggest that screening be performed with prostate specific antigen (PSA) tests at intervals ranging from every two to four years (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest not performing digital rectal examination as part of screening (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Frequency and method of screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a decision is made to screen, we suggest that screening be performed until comorbidities or age (75 years) limit life expectancy to less than 10 years or the patient decides against further screening (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Stopping screening at age 65 may be appropriate if the PSA level is less than 1.0",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Stopping screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Men with an abnormal DRE (if performed) or PSA level above 7",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      should be referred for transrectal ultrasound-guided prostate biopsy without further testing. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Referrals for biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that men with a PSA level between 3",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      and 7",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      undergo repeat testing several weeks later (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Prior to repeat PSA testing, men should abstain from ejaculation and bike riding for at least 48 hours. Men with prostatitis should be treated with antibiotics before retesting. Men with a repeat PSA level above 3",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      should be referred for transrectal ultrasound-guided prostate biopsy. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Referrals for biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not considering PSA velocity in deciding which men should be referred for biopsy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'PSA velocity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that men with negative extended biopsies (biopsies performed using an extended protocol as opposed to just sextant biopsies) be managed similarly to men who have not previously undergone screening (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). That is, when screening is next routinely considered, men should again make an informed decision about testing; if the decision is made to screen, the same criteria used for the initial biopsy referral should again be applied. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Repeat biopsies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/2\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     Ries, LAG, Melbert, D, Krapcho, M, et al (Eds). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute, Bethesda, MD 2007. Available at: file://seer.cancer.gov/csr/1975_2004/ (Accessed on October 16, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/4\">",
"      Dorr VJ, Williamson SK, Stephens RL. An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch Intern Med 1993; 153:2529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/5\">",
"      Mettlin C, Jones G, Averette H, et al. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin 1993; 43:42.",
"     </a>",
"    </li>",
"    <li>",
"     American Urological Association. Early detection of prostate cancer and use of transrectal ultrasound. In: American Urological Association 1992 Policy Statement Book, Williams &amp; Wilkins, Baltimore 1992.",
"    </li>",
"    <li>",
"     LAG, Eisner, MP, Kosary, CL, et al. SEER Cancer Statistics Review, 1973-1999, National Cancer Institute, Bethesda, MD 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/8\">",
"      Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet 1994; 343:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/9\">",
"      Lu-Yao GL, Friedman M, Yao SL. Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing. J Urol 1997; 157:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/10\">",
"      Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273:548.",
"     </a>",
"    </li>",
"    <li>",
"     Stanford, JL, Stephenson, RA, Coyle, LM, et al. Prostate Cancer Trends 1973-1995, Publication no. 99-4543, SEER Program, National Cancer Institute, Bethesda, MD 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/12\">",
"      Brett AS, Ablin RJ. Prostate-cancer screening--what the U.S. Preventive Services Task Force left out. N Engl J Med 2011; 365:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/13\">",
"      Schr&ouml;der FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/14\">",
"      Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/15\">",
"      Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/16\">",
"      Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/17\">",
"      Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/18\">",
"      Whittemore AS, Cirillo PM, Feldman D, Cohn BA. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J Urol 2005; 174:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/19\">",
"      Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/20\">",
"      Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 1997; 24:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/21\">",
"      Yuan JJ, Coplen DE, Petros JA, et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 1992; 147:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/22\">",
"      Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/23\">",
"      Chybowski FM, Bergstralh EJ, Oesterling JE. The effect of digital rectal examination on the serum prostate specific antigen concentration: results of a randomized study. J Urol 1992; 148:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/24\">",
"      Effect of digital rectal examination on serum prostate-specific antigen in a primary care setting. The Internal Medicine Clinic Research Consortium. Arch Intern Med 1995; 155:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/25\">",
"      Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology 1997; 50:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/26\">",
"      Tchetgen MB, Song JT, Strawderman M, et al. Ejaculation increases the serum prostate-specific antigen concentration. Urology 1996; 47:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/27\">",
"      Kawakami J, Siemens DR, Nickel JC. Prostatitis and prostate cancer: implications for prostate cancer screening. Urology 2004; 64:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/28\">",
"      Simardi LH, Tobias-MacHado M, Kappaz GT, et al. Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study. Urology 2004; 64:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/29\">",
"      Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993; 22:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/30\">",
"      Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004; 63:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/31\">",
"      Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998; 52:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/32\">",
"      Etzioni RD, Howlader N, Shaw PA, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 2005; 174:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/33\">",
"      Punglia RS, D'Amico AV, Catalona WJ, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/34\">",
"      Stroumbakis N, Cookson MS, Reuter VE, Fair WR. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology 1997; 49:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/35\">",
"      Ellis WJ, Brawer MK. Repeat prostate needle biopsy: who needs it? J Urol 1995; 153:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/36\">",
"      Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998; 159:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/37\">",
"      Eichler K, Hempel S, Wilby J, et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 175:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/38\">",
"      McNaughton Collins M, Ransohoff DF, Barry MJ. Early detection of prostate cancer. Serendipity strikes again. JAMA 1997; 278:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/39\">",
"      Carroll P, Coley C, McLeod D, et al. Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer. Urology 2001; 57:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/40\">",
"      Brawer MK, Chetner MP, Beatie J, et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/41\">",
"      Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/42\">",
"      Crawford ED, DeAntoni EP, Etzioni R, et al. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 1996; 47:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/43\">",
"      Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67:2949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/44\">",
"      Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/45\">",
"      Meigs JB, Barry MJ, Oesterling JE, Jacobsen SJ. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer. J Gen Intern Med 1996; 11:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/46\">",
"      Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/47\">",
"      Schr&ouml;der FH, van der Cruijsen-Koeter I, de Koning HJ, et al. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/48\">",
"      Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Ann Intern Med 1997; 126:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/49\">",
"      Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level &lt; or =4.0 ng per milliliter. N Engl J Med 2004; 350:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/50\">",
"      Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/51\">",
"      Babaian RJ, Johnston DA, Naccarato W, et al. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol 2001; 165:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/52\">",
"      Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology 2005; 65:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/53\">",
"      Porter MP, Stanford JL, Lange PH. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening. Prostate 2006; 66:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/54\">",
"      Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/55\">",
"      Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 2005; 97:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/56\">",
"      Carter HB. Prostate cancers in men with low PSA levels--must we find them? N Engl J Med 2004; 350:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/57\">",
"      Stamey TA, Johnstone IM, McNeal JE, et al. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol 2002; 167:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/58\">",
"      Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/59\">",
"      Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996; 276:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/60\">",
"      Grubb RL 3rd, Pinsky PF, Greenlee RT, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008; 102:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/61\">",
"      Postma R, Schr&ouml;der FH, van Leenders GJ, et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007; 52:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/62\">",
"      Brawer MK, Beatie J, Wener MH, et al. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol 1993; 150:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/63\">",
"      Stamey TA, Caldwell M, McNeal JE, et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/64\">",
"      Stamey TA. The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA. BJU Int 2004; 94:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/65\">",
"      Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/66\">",
"      Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol 1999; 162:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/67\">",
"      Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/68\">",
"      Nixon RG, Wener MH, Smith KM, et al. Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol 1997; 157:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/69\">",
"      Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001; 344:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/70\">",
"      Cher ML, Carroll PR. Screening for prostate cancer. West J Med 1995; 162:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/71\">",
"      Raaijmakers R, Wildhagen MF, Ito K, et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 2004; 63:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/72\">",
"      Vickers AJ, Wolters T, Savage CJ, et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol 2009; 56:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/73\">",
"      Roobol MJ, Kranse R, de Koning HJ, Schr&ouml;der FH. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology 2004; 63:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/74\">",
"      Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/75\">",
"      Vickers AJ, Till C, Tangen CM, et al. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011; 103:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/76\">",
"      Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/77\">",
"      Etzioni RD, Ankerst DP, Weiss NS, et al. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst 2007; 99:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/78\">",
"      Pinsky PF, Andriole G, Crawford ED, et al. Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer 2007; 109:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/79\">",
"      Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/80\">",
"      Benson MC, Whang IS, Olsson CA, et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/81\">",
"      Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/82\">",
"      Stephan C, Stroebel G, Heinau M, et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of &lt; 4 ng/mL. Cancer 2005; 104:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/83\">",
"      Horninger W, Reissigl A, Klocker H, et al. Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. Prostate 1998; 37:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/84\">",
"      Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/85\">",
"      Lee R, Localio AR, Armstrong K, et al. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 2006; 67:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/86\">",
"      Hoffman RM, Clanon DL, Littenberg B, et al. Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. J Gen Intern Med 2000; 15:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/87\">",
"      Brawer MK, Meyer GE, Letran JL, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/88\">",
"      Partin AW, Brawer MK, Bartsch G, et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003; 170:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/89\">",
"      Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011; 185:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/90\">",
"      Guazzoni G, Nava L, Lazzeri M, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011; 60:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/91\">",
"      Roobol MJ. Prostate cancer biomarkers to improve risk stratification: is our knowledge of prostate cancer sufficient to spare prostate biopsies safely? Eur Urol 2011; 60:223.",
"     </a>",
"    </li>",
"    <li>",
"     McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guidelines, AHCPR Publication no. 94-0582, Agency for Health Care Policy and Research; U.S. Department of Health and Human Services, Rockville, MD, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/93\">",
"      Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/94\">",
"      Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/95\">",
"      Moul JW, Sesterhenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 1995; 274:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/96\">",
"      Morgan TO, Jacobsen SJ, McCarthy WF, et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/97\">",
"      Powell IJ, Banerjee M, Novallo M, et al. Should the age specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years? J Urol 2000; 163:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/98\">",
"      Oesterling JE, Kumamoto Y, Tsukamoto T, et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 1995; 75:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/99\">",
"      Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004; 10:3943.",
"     </a>",
"    </li>",
"    <li>",
"     Epstein JI. Pathology of prostatic neoplasia. In: Campbell's Urology, 8th ed, Walsh PC (Ed), Saunders, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/101\">",
"      Krahn MD, Mahoney JE, Eckman MH, et al. Screening for prostate cancer. A decision analytic view. JAMA 1994; 272:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/102\">",
"      Chodak GW, Keller P, Schoenberg HW. Assessment of screening for prostate cancer using the digital rectal examination. J Urol 1989; 141:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/103\">",
"      Smith DS, Catalona WJ. Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 1995; 45:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/104\">",
"      Hoogendam A, Buntinx F, de Vet HC. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Fam Pract 1999; 16:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/105\">",
"      Pedersen KV, Carlsson P, Varenhorst E, et al. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ 1990; 300:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/106\">",
"      Richie JP, Catalona WJ, Ahmann FR, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993; 42:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/107\">",
"      Gustafsson O, Norming U, Almg&aring;rd LE, et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men. J Urol 1992; 148:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/108\">",
"      Yamamoto T, Ito K, Ohi M, et al. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less. Urology 2001; 58:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/109\">",
"      Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection. CA Cancer J Clin 2001; 51:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/110\">",
"      Bretton PR. Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study. South Med J 1994; 87:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/111\">",
"      Muschenheim F, Omarbasha B, Kardjian PM, Mondou EN. Screening for carcinoma of the prostate with prostate specific antigen. Ann Clin Lab Sci 1991; 21:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/112\">",
"      Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009; 6:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/113\">",
"      Vlaeminck-Guillem V, Ruffion A, Andr&eacute; J, et al. Urinary prostate cancer 3 test: toward the age of reason? Urology 2010; 75:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/114\">",
"      Roobol MJ, Schr&ouml;der FH, van Leeuwen P, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010; 58:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/115\">",
"      Kerkhof M, Roobol MJ, Cuzick J, et al. Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam). Int J Cancer 2010; 127:2639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/116\">",
"      Schr&ouml;der FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/117\">",
"      Roobol MJ, Kerkhof M, Schr&ouml;der FH, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009; 56:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/118\">",
"      Loeb S, Vonesh EF, Metter EJ, et al. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol 2011; 29:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/119\">",
"      Barry MJ. Screening for prostate cancer--the controversy that refuses to die. N Engl J Med 2009; 360:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/120\">",
"      Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 2000; 92:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/121\">",
"      Hugosson J, Carlsson S, Aus G, et al. Mortality results from the G&ouml;teborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/122\">",
"      Bill-Axelson A, Holmberg L, Fil&eacute;n F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/123\">",
"      Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/124\">",
"      Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010; 341:c4543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/125\">",
"      Ilic D, O'Connor D, Green S, Wilt TJ. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 2011; 107:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/126\">",
"      Chou R, LeFevre ML. Prostate cancer screening--the evidence, the recommendations, and the clinical implications. JAMA 2011; 306:2721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/127\">",
"      Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367:203.",
"     </a>",
"    </li>",
"    <li>",
"     LAG, Eisner, MP, Kosary, CL, et al. SEER Cancer Statistics Review, 1973-1999. National Cancer Institute, Bethesda, MD, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/129\">",
"      Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/130\">",
"      Roberts RO, Bergstralh EJ, Katusic SK, et al. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol 1999; 161:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/131\">",
"      Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008; 9:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/132\">",
"      Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000; 355:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/133\">",
"      Lu-Yao G, Albertsen PC, Stanford JL, et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002; 325:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/134\">",
"      Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008; 19:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/135\">",
"      Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012; 367:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/136\">",
"      Sox HC. Quality of life and guidelines for PSA screening. N Engl J Med 2012; 367:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/137\">",
"      Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med 2013; 158:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/138\">",
"      Concato J. Probability, uncertainty, and prostate cancer. Ann Intern Med 2013; 158:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/139\">",
"      Rietbergen JB, Kruger AE, Kranse R, Schr&ouml;der FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology 1997; 49:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/140\">",
"      Loeb S, Carter HB, Berndt SI, et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/141\">",
"      Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183:963.",
"     </a>",
"    </li>",
"    <li>",
"     AUA/SUNA  white paper on the incidence, prevention and treatment of complications related to prostate needle biopsy. www.auanet.org/content/health-policy/quality/pdf/AUA-SUNA-PNBWhitePaper.pdf (Accessed on November 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/143\">",
"      Gallina A, Suardi N, Montorsi F, et al. Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men. Int J Cancer 2008; 123:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/144\">",
"      Boniol M, Boyle P, Autier P, et al. Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme. BJU Int 2012; 110:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/145\">",
"      Rosario DJ, Lane JA, Metcalfe C, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ 2012; 344:d7894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/146\">",
"      Loeb S, van den Heuvel S, Zhu X, et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012; 61:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/147\">",
"      Essink-Bot ML, de Koning HJ, Nijs HG, et al. Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 1998; 90:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/148\">",
"      McNaughton-Collins M, Fowler FJ Jr, Caubet JF, et al. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. Am J Med 2004; 117:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/149\">",
"      Fowler FJ Jr, Barry MJ, Walker-Corkery B, et al. The impact of a suspicious prostate biopsy on patients' psychological, socio-behavioral, and medical care outcomes. J Gen Intern Med 2006; 21:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/150\">",
"      Klotz LH. PSAdynia and other PSA-related syndromes: a new epidemic--a case history and taxonomy. Urology 1997; 50:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/151\">",
"      Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/152\">",
"      Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977; 20:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/153\">",
"      Sakr WA, Grignon DJ, Haas GP, et al. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996; 30:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/154\">",
"      Haas GP, Sakr WA. Epidemiology of prostate cancer. CA Cancer J Clin 1997; 47:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/155\">",
"      Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/156\">",
"      Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009; 101:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/157\">",
"      Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/158\">",
"      Pashayan N, Duffy SW, Pharoah P, et al. Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer 2009; 100:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/159\">",
"      Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002; 346:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/160\">",
"      Lu-Yao GL, Albertsen P, Warren J, Yao SL. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy--a population-based study. Urology 1999; 54:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/161\">",
"      Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/162\">",
"      Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/163\">",
"      Hamilton AS, Stanford JL, Gilliland FD, et al. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/164\">",
"      McNaughton-Collins MF, Barry MJ. One man at a time--resolving the PSA controversy. N Engl J Med 2011; 365:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/165\">",
"      Schr&ouml;der FH. Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening. N Engl J Med 2011; 365:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/166\">",
"      Volk RJ, Wolf AM. Grading the new US Preventive Services Task Force prostate cancer screening recommendation. JAMA 2011; 306:2715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/167\">",
"      U.S. Preventive Services Task Force. Screening for prostate cancer: recommendation and rationale. Ann Intern Med 2002; 137:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/168\">",
"      Screening for prostate cancer. American College of Physicians. Ann Intern Med 1997; 126:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/169\">",
"      Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009; 182:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/170\">",
"      Feightner JW. Recommendations on secondary prevention of prostate cancer from the Canadian Task Force on the Periodic Health Examination. Can J Oncol 1994; 4 Suppl 1:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/171\">",
"      Dunn AS, Shridharani KV, Lou W, et al. Physician-patient discussions of controversial cancer screening tests. Am J Prev Med 2001; 20:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/172\">",
"      Barry MJ. Health decision aids to facilitate shared decision making in office practice. Ann Intern Med 2002; 136:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/173\">",
"      Hoffman RM. Clinical practice. Screening for prostate cancer. N Engl J Med 2011; 365:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/174\">",
"      Frosch DL, Kaplan RM, Felitti V. The evaluation of two methods to facilitate shared decision making for men considering the prostate-specific antigen test. J Gen Intern Med 2001; 16:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/175\">",
"      Flood AB, Wennberg JE, Nease RF Jr, et al. The importance of patient preference in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team. J Gen Intern Med 1996; 11:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/176\">",
"      Volk RJ, Cass AR, Spann SJ. A randomized controlled trial of shared decision making for prostate cancer screening. Arch Fam Med 1999; 8:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/177\">",
"      Wolf AM, Nasser JF, Wolf AM, Schorling JB. The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med 1996; 156:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/178\">",
"      Davison BJ, Kirk P, Degner LF, Hassard TH. Information and patient participation in screening for prostate cancer. Patient Educ Couns 1999; 37:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/179\">",
"      Schapira MM, VanRuiswyk J. The effect of an illustrated pamphlet decision-aid on the use of prostate cancer screening tests. J Fam Pract 2000; 49:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/180\">",
"      Wilt TJ, Paul J, Murdoch M, et al. Educating men about prostate cancer screening. A randomized trial of a mailed pamphlet. Eff Clin Pract 2001; 4:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/181\">",
"      Partin MR, Nelson D, Radosevich D, et al. Randomized trial examining the effect of two prostate cancer screening educational interventions on patient knowledge, preferences, and behaviors. J Gen Intern Med 2004; 19:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/182\">",
"      Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004; 22:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/183\">",
"      Mitra AV, Bancroft EK, Barbachano Y, et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int 2011; 107:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/184\">",
"      Roobol MJ, Grenabo A, Schr&ouml;der FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst 2007; 99:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/185\">",
"      Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000; 284:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/186\">",
"      Crawford ED, Pinsky PF, Chia D, et al. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol 2006; 175:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/187\">",
"      Schr&ouml;der FH, Raaijmakers R, Postma R, et al. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. J Urol 2005; 174:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/188\">",
"      Candas B, Labrie F, Gomez JL, et al. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. J Urol 2006; 175:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/189\">",
"      Kundu SD, Grubb RL, Roehl KA, et al. Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. J Urol 2005; 173:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/190\">",
"      Prestigiacomo AF, Stamey TA. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers. J Urol 1996; 155:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/191\">",
"      Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003; 289:2695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/192\">",
"      Fleshner NE, O'Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 1997; 158:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/193\">",
"      Djavan B, Zlotta A, Remzi M, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000; 163:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/194\">",
"      Djavan B, Ravery V, Zlotta A, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 2001; 166:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/195\">",
"      Roobol MJ, van der Cruijsen IW, Schr&ouml;der FH. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam). Urology 2004; 63:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/196\">",
"      Roobol MJ, Schr&ouml;der FH, Kranse R, ERSPC, Rotterdam. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam). Prostate 2006; 66:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/197\">",
"      Carter HB, Landis PK, Metter EJ, et al. Prostate-specific antigen testing of older men. J Natl Cancer Inst 1999; 91:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/198\">",
"      Vickers AJ, Cronin AM, Bj&ouml;rk T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010; 341:c4521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/199\">",
"      Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/200\">",
"      Albertsen PC, Moore DF, Shih W, et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011; 29:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/201\">",
"      Fleming C, Wasson JH, Albertsen PC, et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA 1993; 269:2650.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.uspreventiveservicestaskforce.org/prostatecancerscreening/prostatefinalrs.htm (Accessed on May 21, 2012).",
"    </li>",
"    <li>",
"     www.ctfphc.org/index.html (Accessed on July 26, 2006).",
"    </li>",
"    <li>",
"     www.screening.nhs.uk/prostatecancer (Accessed on December 20, 2010).",
"    </li>",
"    <li>",
"     www.cancer.org.au/File/PolicyPublications/Position_statements/PS_prostate_cancer_screening_updated_June_2010.pdf (Accessed on January 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/8/42122/abstract/206\">",
"      Horwich A, Hugosson J, de Reijke T, et al. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 2013.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7567 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42122=[""].join("\n");
var outline_f41_8_42122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROSTATE SPECIFIC ANTIGEN (PSA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Measuring PSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Test performance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Sensitivity and specificity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Positive predictive value",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7597682\">",
"      - Negative predictive value",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Effect of lowering PSA cutoffs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Serial PSA measurements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Secular trends in the utility of PSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Improving the accuracy of PSA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - PSA velocity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - PSA density",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Free PSA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Complexed PSA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2782134\">",
"      - [-2]ProPSA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Age-specific reference ranges",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Race-specific reference ranges",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIGITAL RECTAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Test performance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Sensitivity and specificity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Positive predictive value",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COMBINING PSA AND DRE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OTHER TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H988952102\">",
"      PCA3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Transrectal ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      EFFECTIVENESS OF PROSTATE CANCER SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Evidence from randomized trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Evidence from observational studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Evidence from modeling studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      HARM FROM SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Risks of biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Overdiagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Risks of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      APPROACH TO SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Informed decision making",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Age to begin screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Frequency and method of screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Referrals for biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Repeat biopsies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Stopping screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7567\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7567|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/2/6190\" title=\"figure 1\">",
"      Prostate ca incidence over time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/14/14574\" title=\"figure 2\">",
"      Rate of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7567|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/61/5083\" title=\"table 1\">",
"      Causes of benign PSA elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/21/40283\" title=\"table 2\">",
"      Decision aids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4776?source=related_link\">",
"      Acute bacterial prostatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=related_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36101?source=related_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21930?source=related_link\">",
"      Initial management of regionally localized intermediate and high risk prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/55/38770?source=related_link\">",
"      Patient information: Prostate cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/27/32176?source=related_link\">",
"      Patient information: Prostate cancer screening (PSA tests) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/20/14666?source=related_link\">",
"      Prostate biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24313?source=related_link\">",
"      Radical prostatectomy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_8_42123="Moderate schedule";
var content_f41_8_42123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Aeroallergen subcutaneous immunotherapy (SCIT) - Example of schedule for moderately sensitive patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Concentration: 1:100 v/v dilution of maintenance vial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.05 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.10 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.20 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.04 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.07 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Concentration: 1:10 v/v",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.10 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.20 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.30 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.50 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.70 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Maintenance concentration: 1:1 v/v",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.10 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.15 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.20 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.30 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.40 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.50 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.40 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.50 mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     v/v: volume/volume.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42123=[""].join("\n");
var outline_f41_8_42123=null;
var title_f41_8_42124="Factors causing nocturia";
var content_f41_8_42124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors potentially causative of nocturia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Small volume bladder voids",
"       </td>",
"       <td>",
"        Urgency, sometimes with urge incontinence, urinary frequency (&gt;8 voids/24 hours), and/or nocturia.",
"       </td>",
"       <td>",
"        Daytime voids &ge; 8, urgency, nocturia, and urge incontinence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign prostatic hyperplasia (BPH) or bladder outlet obstruction",
"       </td>",
"       <td>",
"        BPH: AUA-7 SI &gt;8 and peak uroflow between 4 and 15 ml/sec; BOO: evidence of obstruction, including peak uroflow less than 15 ml/sec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract infection",
"       </td>",
"       <td>",
"        Leukocyte esterase on U/A; presence of white blood cells &gt;5 HPF on microscopic examination; &gt;1000 colony forming units by culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low bladder capacity",
"       </td>",
"       <td>",
"        Cystometric capacity less than 150 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Increased urine output at night",
"       </td>",
"       <td>",
"        Nocturnal polyuria",
"       </td>",
"       <td>",
"        35 percent or more of 24-hour urine output occurring during sleep hours, may be related to loss of diurnal variation or deficiency for arginine vasopressin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral edema (without heart failure)",
"       </td>",
"       <td>",
"        Presence of pitting edema 10 cm above ankle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congestive heart failure (HF)",
"       </td>",
"       <td>",
"        echocardiographic evidence of a LVEF &lt;35 percent; presence of S3; bilateral lung crackles; Use of an ACEI for HF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor control of diabetes mellitus",
"       </td>",
"       <td>",
"        Random glucose &gt;200 mg/dl (11.1 mmol/l); glucosuria on urine dipstick",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excessive fluid intake throughout day or large fluid intake immediately prior to bedtime",
"       </td>",
"       <td>",
"        Analysis of self-reported intake or recorded voiding diary or fluid intake record",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intake of diuretic substances",
"       </td>",
"       <td>",
"        Analysis of self-reported intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Sleep related disorders",
"       </td>",
"       <td>",
"        Difficulty with sleep maintenance",
"       </td>",
"       <td>",
"        Self-reported sleep latency of &gt;30 minutes following first awakening for nocturia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sleep apnea",
"       </td>",
"       <td>",
"        Daytime sleepiness, loud snoring, witnessed breathing interruptions, or awakenings due to gasping or choking in the presence of at least 5 obstructive respiratory events per hour of sleep*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Restless leg syndrome or periodic limb movements",
"       </td>",
"       <td>",
"        History, partner report, or nighttime sleep study",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unknown mechanism",
"       </td>",
"       <td>",
"        Hypertension",
"       </td>",
"       <td>",
"        &gt;140/90 mm Hg supine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AUA SI: American Urological Association Symptom Index; U/A: urinalysis; HPF: high powered field; ACE-I: angiotensin-converting enzyme inhibitors; LVEF: left-ventricular ejection fraction.",
"     <br>",
"      * Epstein, LJ, Kristo, D, Strollo, PJ, et al. Clinical guidelines for the evaluation, management, and long-term treatment of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5:263.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42124=[""].join("\n");
var outline_f41_8_42124=null;
var title_f41_8_42125="Vitamin C and CHD";
var content_f41_8_42125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Role of ascorbic acid (vitamin C) in coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 324px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42125=[""].join("\n");
var outline_f41_8_42125=null;
var title_f41_8_42126="Electrolyte concentrations";
var content_f41_8_42126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal plasma electrolyte concentrations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 197px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The values for calcium and magnesium include only the ionized (unbound) form of these ions. \"Other\" anions include sulfate and organic anions such as lactate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42126=[""].join("\n");
var outline_f41_8_42126=null;
var title_f41_8_42127="ICE PMBV";
var content_f41_8_42127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    This two panel figure shows a balloon inflation (inoue catheter) by both ICE visualization and fluoroscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Ice image shows the mitral valve and the fully inflated balloon. The fluoroscopic image shows the indented mid section of the valve from the fused commissures immediately before full inflation splits the scar tissue and relieves the obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_8_42127=[""].join("\n");
var outline_f41_8_42127=null;
